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Abstract 
Autonomic dysfunction is a common presentation of various neurological disorders and has a 
heterogeneous aetiology and pathophysiology. PoTS is a very common form of orthostatic 
intolerance characterized by excessive increases in heart rate during orthostatic stress 
without orthostatic hypotension and is often associated with the Joint Hypermobility 
Syndrome (JHS); the most common heritable disorder of connective tissue. However, 
information is still limited in PoTS with regards to the clinical presentation and quality of life, 
pathophysiology, the responses to treatment and possible genetic contributions.  
 
As part of this thesis a novel autonomic function scoring scale was generated and validated 
to quantify the degree of autonomic impairment (CAF score), which was able to differentiate 
patients with different autonomic disorders and quantify the degree of autonomic overactivity 
in patients with PoTS. An autonomic and quality of life self-administered questionnaire 
(AQQoL) was also developed in order to assess a range of autonomic symptoms, allied 
features, familial autonomic dysfunction and the relative quality of life in a large cohort of 
patients with autonomic disorders. This instrument was found to be helpful in detecting 
autonomic, non-cardiovascular and quality of life impairments in patients with autonomic 
disorders and could inform future longitudinal studies in patients with a wide range of 
autonomic disorders.  
 
PoTS might be a genetic disorder with a likely multifactorial and polygenic pathophysiology 
and possible variable expressivity. Using the AQQoL and further investigations 21 families 
with PoTS and JHS were described for the first time. In order to further understand the 
pathophysiology of PoTS and JHS, peripheral small nerve fibre function and morphology, 
using the skin biopsy technique, were evaluated. A subgroup of patients with PoTS and JHS 
have an underlying small fibre neuropathy and associated abnormalities of Collagen IV in 
basement membranes and blood vessels in the skin indicating that multiple 
pathophysiological mechanisms could coexist in the same patients and that the skin biopsy is 
a valuable tool to differentiate PoTS sub-groups. 
 
Diagnosing PoTS can be challenging and tests, in addition to the traditional orthostatic 
stressors, such as liquid meal challenge, modified exercise and heat challenge tests, can be 
of value in the assessment of these patients. In particular, the liquid meal challenge test is 
also helpful in determining whether drugs such as the somatostatin analogue, Octreotide, 
can reduce postural tachycardia and symptoms of orthostatic intolerance pre- and post-
prandially. Similarly, for the first time, the beneficial effect of 50 mcg of Octreotide on 
orthostatic hemodynamic responses before and after food ingestion in PoTS was shown.  
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PoTS is a complex multi-system disorder that may cause significant autonomic morbidity and 
impairment of quality of life. The pathophysiology is heterogeneous and in our patient cohort 
is likely to be linked to connective tissue disorders, such as JHS and genetic factors. A more 
extensive autonomic assessment, including the evaluation of hemodynamic responses to 
daily stimuli, may be important for establishing definitive diagnostic criteria for PoTS. The 
management of these patients needs a multi-step pharmacological approach and in the most 
severe cases requires specific targeting, with medications such as Octreotide for example, 
which might be beneficial in reducing postural tachycardia and orthostatic intolerance.  
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1 Chapter 1. Introduction 
 
The autonomic nervous system, through the sympathetic and parasympathetic neural pathways, 
plays a critical role in the maintenance of arterial blood pressure and local blood flow to vital 
organs, as well as other key physiological processes, such as temperature regulation and 
gastrointestinal function. Autonomic dysfunction is a common presentation of various 
neurological disorders, which significantly impacts quality of life and has a heterogeneous 
aetiology and pathophysiology. For example, in Postural Tachycardia Syndrome (PoTS) 
patients, orthostatic intolerance, the inability to withstand the upright posture, is associated with 
excessive increases of heart rate without orthostatic hypotension (OH) during standing 
(Schondorf & Low, 1993; Mathias et al., 2012), whereas, in Autonomic Failure syndromes [such 
as Pure Autonomic Failure (PAF), Multiple System Atrophy (MSA), Parkinson's Disease with 
autonomic failure (PD+AF) and Dementia with Lewy Body Disease (DLB)] symptoms of 
orthostatic intolerance are most commonly associated with a broader autonomic dysfunction and 
excessive decreases in blood pressure and OH, which is defined as a >20mmHg systolic and/or 
>10mmHg diastolic decline in blood pressure within 3 min of standing (Lahrmann et al., 
2006). Furthermore, autonomic dysfunction can be classed as intermittent, as in autonomic 
(neurally) mediated syncope (AMS) (fainting), PoTS and Hyperhidrosis, or chronic, as in 
primary chronic autonomic failure, such as PAF without an associated neurological disorder, 
MSA with central neurological degeneration, PD+AF, or autonomic failure associated with 
diffuse Lewy body disease or dementia with Lewy Bodies (DLB). Autonomic dysfunction may 
also occur secondary to non-autonomic conditions, such as in diabetic autonomic neuropathy 
and amyloidosis. 
 
PoTS is the most common form of orthostatic intolerance and is a complex syndrome arising 
from an interrelationship of autonomic, biochemical, genetic and environmental factors. PoTS 
aetiology includes: a limited autonomic neuropathy (probably with an autoimmune basis), 
physical deconditioning, relative chronic hypovolemia, hyperadrenergic tone, impaired 
cerebral autoregulation and genetic mutations (Mathias et al., 2012). There are several 
different subgroups of patients that may result in subtle clinical differences and divergent 
responses to treatment. PoTS is often associated with the joint hypermobility syndrome 
(Gazit et al., 2003), which is the most common heritable disorder of connective tissue, 
characterized by joint laxity and causes articular dislocations, subluxations and arthralgia and 
is believed to be indistinguishable from, if not identical, to the Ehlers-Danlos Syndrome 
hypermobility type (formerly EDS type III). Patients with PoTS and EDS III often have a multi-
system involvement and need a prolonged and multi-step treatment approach. AMS refers to 
a transient loss of consciousness resulting from temporary inadequate cerebral perfusion. 
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There is a female predominance in AMS and it may present at any age, but patients are 
often young (<40 years of age) with an increased incidence during the teenage years. The 
onset of syncope can be gradual with ample warning signs or it can happen quite abruptly. 
Hyperhidrosis is defined as excessive sweating beyond what is required to regulate core 
(internal) temperature. It may occur in isolation with no apparent cause and is thus termed 
primary or essential or it may be associated with infection, malignancy, neurologic, endocrine 
and other system disorders and classified as secondary (Naumann, 2013). 
 
MSA is a sporadic multi-system progressive disorder characterized by autonomic failure, OH, 
neurogenic bladder/erectile dysfunction, cerebellar ataxia, corticospinal dysfunction and 
parkinsonism that may be poorly responsive to levodopa (Gilman et al., 2008). PD is 
characterized clinically by akinesia, muscular rigidity and resting tremor and pathologically by 
a more restricted neuropathology, with neuronal loss and Lewy bodies in pigmented nuclei of 
the substantia nigra (Gelb et al., 1999; Brooks, 2012). Several authors have reported 
abnormalities of the autonomic nervous system and resultant cardiovascular, sudomotor, 
gastrointestinal and bladder dysfunction in PD patients (Asahina et al., 2012). In particular, 
autonomic involvement with mild OH commonly occurs in PD and occasionally severe OH 
can occur (Velseboer et al., 2011). PAF is an uncommon sporadic disorder, characterized by 
autonomic failure without other neurological deficits and histopathologically by cell loss in 
intermediolateral columns and sympathetic ganglia (1996). 
 
The complexity of pathological conditions affecting the autonomic nervous system requires 
an accurate approach to evaluate the multi-system involvement, the site of the lesion and the 
relative quality of life in these patients. The evaluation and accurate diagnosis of the cause of 
autonomic dysfunction and the associated symptoms are necessary in order to plan the most 
effective treatment strategies. Autonomic cardiovascular screening tests were originally 
designed as a key diagnostic approach in patients with autonomic disorders in order to 
provide information regarding the presence of orthostatic hypotension; a cardinal feature in 
patients with widespread autonomic failure. More recently, similar tests have been used to 
provide vital information on postural tachycardia and/or a tendency to AMS as key features 
observed in intermittent autonomic disorders (e.g., PoTS or Syncope), as well as the 
determination of autonomic ‘overactivity’, as observed in patients with baroreflex failure or 
PoTS. Cardiovascular autonomic function screening tests are often accompanied by the use 
of a severity score or scale in order to provide an overall quantitative score of autonomic 
dysfunction not only to detect impairments but also to track changes in autonomic function in 
response to treatment and/or for use in prospective controlled therapeutic trials (Low, 1993). 
Previous autonomic scoring systems were directed at grading the autonomic impairment in 
Page 21 
 
patients with widespread autonomic failure and were of little use in patients without damage 
to the autonomic nervous system but with intermittent autonomic dysfunction because they 
only scored for indications of autonomic failure, or underactivity, and not exaggerated or 
overactivity (Low, 1993). Therefore, aim #1 of this thesis was to develop a quantitative 
severity score from our cardiovascular autonomic function screening tests for patients with 
different degrees of autonomic impairment (e.g., autonomic failure and intermittent 
autonomic disorders). 
 
Autonomic function screening tests are commonly used to interrogate the integrity of 
cardiovascular autonomic function in patients where orthostatic intolerance and/or other 
features of impaired blood pressure control present (Mathias C.J., 2013). Information is still 
limited on the assessment of autonomic symptoms and quality of life however. Furthermore, 
although orthostatic intolerance is the hallmark of patients with intermittent autonomic 
dysfunction, such as PoTS or AMS, and OH is the hallmark of Autonomic Failure, patients 
may experience other symptoms of autonomic dysfunction as well, including upper 
gastrointestinal tract symptoms, bowel and bladder dysfunction, and secretomotor 
dysfunction. Therefore, assessing the various types of autonomic symptoms and their 
intensity is essential when studying patients with autonomic disorders. Moreover, patients 
with autonomic dysfunction can often present with allied features that need to be carefully 
investigated. For example, assessing the skeletal muscle features is a key component in 
PoTS patients with suspected joint hypermobility. Clinical observations suggest that 
autonomic and allied features in autonomic disorders affect quality of life considerably; 
however, to our knowledge, no data have systematically investigated the importance of 
quality of life with regards to autonomic and allied features in a range of intermittent and 
chronic autonomic disorders. Therefore aim #2 of this thesis is to design and validate a self 
completed questionnaire that assesses a range of autonomic domain symptoms, quality of 
life and allied non-autonomic features in a large cohort of autonomic disorders and evaluate 
the prevalence of autonomic symptoms and the relative quality of life in a cross-sectional 
study of various autonomic disorders in patients with intermittent (primary Hyperhidrosis, 
AMS, PoTS), primary autonomic failure (MSA, PD, PAF) and autonomic peripheral 
neuropathy (diabetic autonomic neuropathy, amyloidosis) and normal healthy controls. 
 
Recent advances in clinical research of autonomic disorders has indicated that a variety of 
disorders have a strong familial component. A positive family history is often present in 
patients with essential or primary Hyperhidrosis, which likely has an autosomal dominant 
inheritance with incomplete penetrance (Strutton et al., 2004), and in patients with AMS 
(Mathias et al., 1998; Mathias et al., 2000; Newton et al., 2003; Newton et al., 2005; 
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Holmegard et al., 2013). PoTS is commonly associated with EDS III, which is an inheritable 
disorder of the connective tissue. This raises the possibility of a genetic component in those 
developing PoTS, either with or without EDS III. Therefore, aim #3 of this thesis is to 
evaluate the prevalence of familial autonomic dysfunction in patients with intermittent 
(primary Hyperhidrosis, AMS, PoTS) and evaluate the clinical features and the autonomic 
dysfunction and allied features in families with PoTS and EDS III. 
 
Diagnosing PoTS remains a challenge in some patients, likely due to the intermittent nature 
of the syndrome, the multi-system involvement and the heterogeneous presentation and 
pathophysiology (Mathias et al., 2012). According to current diagnostic criteria, PoTS is 
diagnosed when sustained excessive tachycardia is noted during a head up tilt (HUT) or 
standing test, accompanied by orthostatic symptoms (Freeman et al., 2011). However in our 
clinical practice, we have encountered patients with chronic orthostatic symptoms who do not 
meet the criteria of excessive tachycardia on HUT or standing but who present with 
exacerbation and worsening of the postural tachycardia in response to daily life stimuli, 
including, food ingestion, physical exercise and heat challenge (Mathias et al., 2012). The 
liquid meal challenge and modified exercise tests are well established additional autonomic 
function assessments in the diagnosis of post-prandial hypotension and exercise-induced 
hypotension, respectively, mainly in patients with chronic autonomic failure (Smith & Mathias, 
1995; Smith et al., 1995b; Puvi-Rajasingham & Mathias, 1996; Puvi-Rajasingham et al., 
1997b, 1998) and can provide key information about symptoms and diagnosis in relation to 
these daily activities and inform the management of these patients. Whether these stimuli 
unmask a PoTS diagnosis and/or exacerbates PoTS symptoms/features, and the 
mechanisms underlying such changes, if they are present, remain poorly understood 
however and have not been well described as yet. Therefore, aim #4 of this thesis is to 
evaluate the cardiovascular responses to food, exercise and heat stimuli in the assessment 
of PoTS patients. 
The etiology and pathophysiology in patients with PoTS is extremely heterogeneous. For 
example, it has been described that about ~50% of PoTS patients may be post-infectious 
suggesting an immune-mediated limited autonomic neuropathy (Schondorf & Low, 1993) 
suggesting that a limited peripheral autonomic neuropathy might be one of the subtypes of 
PoTS. Proposed pathophysiological mechanisms also include relative chronic hypovolemia, 
hyperadrenergic tone, impaired cerebral autoregulation and genetic mutations and physical 
deconditioning (Mathias et al., 2012). In addition, PoTS is often associated with the joint 
hypermobility syndrome (JHS), which is the most common heritable disorder of connective 
tissue, characterized by joint laxity and believed to be indistinguishable from, if not identical, 
to EDS III (Tinkle et al., 2009). Currently, there is no molecular diagnostic testing of JHS/EDS 
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III and the diagnosis is based on clinical evaluation and history. The connective tissue 
dysfunction may result in abnormalities of the basement membrane and the vessel bed. 
Patients with PoTS and EDS III often also experience cold and heat intolerance, which can 
be detected by thermal thresholds assessment. Skin biopsy morphology findings can also 
help to distinguish patients with PoTS and an underlying limited autonomic neuropathy 
(Neuropathic PoTS) from PoTS patients with and without EDS III. Therefore aim #5 of this 
thesis is to evaluate autonomic function and peripheral small fibre morphology with a focus 
on post-ganglionic and collagen involvement in PoTS using a combination of function and 
morphology studies (punch skin biopsy technique) in order to differentiate PoTS subgroups 
and to further understand the underlying pathophysiology. 
 
PoTS patients respond differently to current treatment approaches. Fludrocortisone and 
midodrine are particularly successful in reducing symptoms in some PoTS patients, while 
others need drugs such as the cardio-selective beta-blockers (Bisoprolol) or the selective 
sinus node blocker, ivabradine combination (Freitas et al., 2000; Raj et al., 2005b; Raj et al., 
2009; McDonald et al., 2011; Mathias et al., 2012). Some patients are still resistant to these 
first and second lines of pharmacotherapy and need a prolonged and multi-step approach. 
Octreotide, a somatostatin analogue, is effective in preventing the release of pancreatic and 
gut hormones in response to various stimuli, including food and alcohol ingestion and has 
been effectively used in the treatment of autonomic failure patients with post-prandial 
hypotension (Alam et al., 1995; Chaudhuri et al., 1995; Smith et al., 1995a). Patients with 
PoTS often present with splanchnic hypervolemia (Tani et al., 2000; Stewart et al., 2005) and 
marked post-prandial orthostatic intolerance features. Octreotide may be beneficial in 
improving orthostatic intolerance and PoTS features (Hoeldtke et al., 2006, 2007; Kanjwal et 
al., 2012) but its role in reducing orthostatic tachycardia in the fasted state and also after 
food ingestion has not been thoroughly investigated however. Therefore, aim #6 of this thesis 
is to evaluate the pre and post-prandial cardiovascular autonomic function responses to the 
acute use of Octreotide in PoTS patients resistant to current medications.  
 
In conclusion, this project will examine autonomic symptoms and function in PoTS, as well as 
other autonomic disorders, using novel and standard methodologies in order to further 
understand the pathophysiology of autonomic disorders, with a particular emphasis on PoTS. 
This overall goal will be achieved by assessing autonomic dysfunction and its symptoms, 
quantifying their severity, defining the type of dysfunction (autonomic cardiovascular, 
peripheral small fibre and collagen involvement) in PoTS patients. 
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2 Chapter Two: Literature Review 
 
2.1 Introduction: the autonomic nervous system 
 
The autonomic nervous system has cranio-sacral parasympathetic and thoraco-lumbar 
sympathetic neural pathways (Figure 2.1) and supplies every organ in the body (Janig, 
2002). The system influences target organ function locally, has many central connections 
(e.g., the brainstem and hypothalamus), and integrates the control of vital functions, such as 
arterial blood pressure and body temperature. Key central components of the autonomic 
nervous system for (1) the control of blood pressure include the nucleus of the tractus 
solitarius in the dorsomedial medulla, the nucleus ambiguous, caudal and rostral 
ventrolateral medulla, and the paraventricular and supraoptic nuclei of the hypothalamus 
(Dampney et al., 2002; Buijs et al., 2003), and (2) for the control of body temperature include 
the preoptic region in and near the rostral hypothalamus (Boulant, 2000). Specific 
neurotransmitters in each neural pathway influence ganglionic and postganglionic nerve 
activity (Figure 2.2). A lesion at any parts of the neural axis; in the brain, spinal cord, or the 
peripheral nervous system, can result in abnormal function or autonomic dysfunction of 
varying severity depending on the lesion and often involves various systems (Mathias, 
1998).  
 
Figure 2.1. Scheme outlining details of the cranio-sacral parasympathetic and thoraco-lumbar 
sympathetic outflow to various target organs. (From Schmidt and Thews, 1987). 
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2.2 Physiology of the upright posture and blood pressure control 
 
Orthostasis poses a major problem to the circulation, and perfusion of the brain in particular, 
due to the vertical displacement of blood below the heart. A series of cardiovascular 
regulatory mechanisms are activated to maintain blood pressure and organ perfusion within 
appropriate limits (Figure 2.3). These complex mechanisms can fail leading to inappropriate 
blood flow distribution, e.g., venous pooling, and/or syncope (fainting), particularly in 
autonomic disorders. 
 
Target Organs 
 
Figure 2.2 Outline of the major neurotransmitters at autonomic ganglia and postganglionic 
sites on target organs supplied by the sympathetic and parasympathetic efferent pathways. 
The acetylcholine receptor at all ganglia is of the nicotinic subtype. However, acetylcholine 
receptors at postganglionic parasympathetic and sympathetic cholinergic sites are of the 
muscarinic subtype. ACh, acetylcholine; Adr, adrenaline; NA, noradrenaline. (From Mathias, 
1998). 
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 Figure 2.3. The physiology of the upright posture. The hydrostatic effect of orthostasis reduces venous return and cardiac output 
and requires the integrity of blood pressure regulatory mechanisms, including, neurovascular reflexes and humoral mechanisms in
order to maintain blood pressure at an appropriate level for perfusion of vital organs.  
Page 28 
 
2.2.1 Effect of gravity on cardiovascular hemodynamics: a time dependent process. 
 
a) The initial phase: venous pooling  
Upon assumption of the upright posture gravity pulls ~500-1000 ml of blood from the upper to 
the lower body, primarily the lower abdomen, buttocks and legs. Up to 50 % of this total shift 
of blood occurs within the first 10 seconds, this process is also called venous pooling. The 
amount of blood shifted to the lower body in this early phase mainly depends on venous 
compliance and the ability of venous vessels to constrict (Hainsworth, 1986). Capacitance 
vessels contribute to reducing venous pooling. Muscle veins in the lower limbs respond 
minimally to neural stimuli due to poor sympathetic innervation and little to no smooth 
muscle. Therefore, their capacity of reducing the gravitational shift of blood is nominal. In 
contrast, both arteries and veins in the splanchnic area are densely innervated (the density of 
sympathetic innervation is particularly greater in mesenteric veins than arteries) reflecting the 
crucial role of splanchnic vascular capacitance regulation during the upright posture (Birch et 
al., 2008) (Figure 2.4). The splanchnic circulation is one of the largest vascular beds in the 
body receiving ~ 25-30% of cardiac output at rest (Donald & Shepherd, 1980) and veins in 
the splanchnic region are the major site for blood storage (capacitance) containing up to 30% 
of the total circulating blood volume (Greenway, 1983). Hence, the splanchnic circulation has 
a major role in cardiovascular homeostasis, influencing systemic arterial pressure via 
widespread contraction of arteries, or due to passive discharge of stored blood in the central 
circulation and the ability of rapidly mobilizing large quantities of blood from this vascular 
bed.  
 
2.2.2 The late phase: transcapillary filtration 
Venous pooling is associated with an increase of the capillary transmural pressure in the 
lower body which produces continued net filtration into the tissue spaces (Lundvall et al., 
1996). Transcapillary filtration occurs within 20-30 minutes after assumption of the upright 
posture leading to a substantial loss of plasma volume from the blood into the tissues and a 
subsequent hemoconcentrantion (Jacob et al., 2005).  
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Figure 2.4 a, b Confocal images of transverse sections of human mesenteric arteries 
and veins. Perivascular nerves stained for PGP9.5 (green) can be seen. In the artery, 
nerves are located at the adventitial (A)/medial (M) border (arrowheads). Note the well-
defined external elastic lamina. In the vein, nerves are distributed throughout the 
media. L = Lumen. c–f Confocal images of whole-mount preparations of human 
mesenteric arteries and veins. The longitudinal axis of the vessels is from top to 
bottom and the nerve bundles are orientated longitudinally. Immunostaining for 
PGP9.5 (c, d) and TH (e, f). Scale bars = 100 μm (a, b), 50 μm (c–f). (From Birch et al,. 
2008). 
 
 
2.2.3 Role of neurovascular reflexes in blood pressure control 
Arterial baroreceptors located in the carotid sinus and aortic arch tonically inhibit the 
vasomotor centers in the brainstem. The assumption of the upright posture in particular 
results in a decrease of blood pressure which removes this tonic inhibition leading to a 
decrease in vagal outflow and an increase in sympathetic activity and a consequent increase 
in total peripheral resistance via vasoconstriction and tachycardia (Pilowsky & Goodchild, 
2002; Dampney et al., 2003)  (Figure 2.3). These are the most important mechanisms for 
moment-to-moment and long term control of arterial blood pressure (Thrasher, 2006), and 
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they buffer acute fluctuations of arterial blood pressure that occur during changes in posture, 
exercise, emotional stress and many other conditions.  
 
2.2.4 Role of skeletal muscle pump 
Contractions of skeletal muscles pump blood back to the heart. Venous valves ensure that 
blood only travels in the direction of the heart. In addition, the increase in hydrostatic 
pressure in the muscle tissue opposes the high capillary pressure and reduces the rate of 
capillary filtration. Both actions limit venous pooling, thus improving venous return and 
increasing cardiac output.  Leg crossing and contraction of leg and abdominal muscles have 
been shown to be beneficial for combating orthostatic intolerance as these maneuvers 
translocate venous blood pooled below the diaphragm to the chest and thereby partially 
restore cardiac filling pressure, stroke volume and cardiac output (Claydon & Hainsworth, 
2005; Miller et al., 2005). 
 
2.2.5 Humoral responses to Orthostasis 
In addition to cardiovascular responses, the upright posture also activates neurohormonal 
mechanisms (catecholamines, renin-angiotensin system and vasopressin) which also induce 
vasoconstriction and retain water. Plasma noradrenaline is predominantly released at post-
ganglionic sympathetic nerve terminals, whereas, changes in plasma adrenaline are largely 
determined by adrenal output. Noradrenaline, and to a lesser extent adrenaline, rise on 
postural change in order to support increases in vasoconstriction and peripheral resistance 
(Mathias, 2013).  
 
Renin is released from the renal arterioles in response to volume and pressure changes and 
transforms angiotensinogen, generated in the liver, to angiotensin I, which is catalyzed to 
angiotensin II (AngII), by endothelium-bound converting enzyme (ACE). AngII modulates 
blood pressure through vasoconstriction, in particular it constricts peripheral vessels by 
increasing sympathetic activity and via direct effects (Guyton, 1981), and sodium retention. 
Angiotensin also has actions in the brain and stimulates the secretion of aldosterone from the 
adrenal cortex. Aldosterone promotes the re-absorption of sodium and water in the kidney 
and serves to retain plasma volume. Increases in renin release occur on standing (Wieling, 
1993; Laszlo et al., 2001). Vasopressin (VP), is a potent vasoconstrictor and is  released 
from the pituitary gland in response to changes in blood osmolarity and baroreflex activity 
(Robertson, 2001). VP has physiological effects at multiple sites, including the splanchnic 
vasculature and the central nervous system, causing elevations in sympathetic nerve activity 
and and peripheral resistance. 
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2.2.6 Hemodynamic changes to head-up tilting (HUT) and Standing tests 
In normal subjects during HUT there is only a transient reduction in systolic, mean and 
diastolic blood pressure followed by recovery within ~1 minute (Imholz et al., 1990). This 
orthostatic drop in arterial and cardiac filling pressures is perceived by the carotid sinus and 
aortic arch baroreceptors producing an increase in heart rate and vasoconstriction. The 
gradual increase in diastolic blood pressure on tilt can be related to the rise in peripheral 
vascular resistance, whereas the change in systolic blood pressure is only small. Therefore 
in normal subjects, head-up tilt or standing results in minimal changes in blood pressure. 
 
The standing test is an active change in posture which evokes initial cardiovascular 
responses that differ slightly from the response to a passive HUT. There is an immediate rise 
in heart rate upon standing as a result of abrupt inhibition of vagal activity (Borst et al., 1982; 
Wieling et al., 1991). The latter may be due to a central motor signals from brainstem 
cardiovascular centres and feedback from contracting muscles and activation of 
mechanoreceptors (Goodwin et al., 1972; Hollander & Bouman, 1975; Critchley et al., 2000). 
The rise in heart rate is associated with an increase cardiac output as stoke volume remains 
the same. The transient fall in blood pressure in the first phase of a standing challenge is 
therefore chiefly explained by a pronounced fall in systemic vascular resistance, which is 
typically not found on HUT (Sprangers et al., 1991; Tanaka et al., 1996; Wieling et al., 2007).  
 
2.3 Classification of autonomic dysfunction 
 
Autonomic disorders may be classified in a variety of ways, for example, according to the 
distribution or degree of autonomic impairment, the aetiology, and/or the chronic or 
intermittent nature of the disorder (Mathias, 1995). Damage of the autonomic nervous 
system can cause irreversible abnormalities and as a result induce significant impairments to 
blood pressure control while upright. Patients with a permanent loss of baroreflex function 
often have orthostatic hypotension as a hallmark of cardiovascular autonomic dysfunction, 
e.g., chronic autonomic failure, and a range of remarkable clinical characteristics (Mathias et 
al., 2013a). This contrasts with intermittent autonomic dysfunction, such as AMS and PoTS 
where the orthostatic intolerance, which is common and even more pronounced than in 
patients with autonomic failure, is not due to widespread damage or failure of the autonomic 
nervous system or of the baroreflex systems.  
 
Considering the distribution of autonomic nervous system impairment, autonomic 
dysfunction can be divided into localized and generalized autonomic disorders. Localized 
disorders affect a specific organ or region of the body but they may also be part of a 
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generalized disorder, such as gustatory sweating in diabetes mellitus. Generalized disorders 
often affect a variety of systems, such as those involved in blood pressure control and 
thermoregulation.  Autonomic disorders are also classified based on their aetiology, such as 
primary disorders when the cause is unclear, and secondary when they are associated with 
a specific disease or its complications (Table 2.1, 2.2). Drugs are a common cause of 
autonomic dysfunction, either because of their pharmacological effects or because of 
autonomic nerve damage.  
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Table 2.1 Outline classification of autonomic disorders (from Mathias (2010)). 
 
 
Primary
Acute/subacute dysautonomias
• Pure pan-dysautonomia
• Pan-dysautonomia with neurological features
• Pure cholinergic dysautonomia
Chronic autonomic failure syndromes
• Pure autonomic failure
• Multiple system atrophy (Shy–Drager syndrome)
• Parkinson’s disease with autonomic failure
• Lewy body disease
Secondary
Congenital
• Nerve growth factor deficiency
Hereditary
• Autosomal dominant trait
• Familial amyloid neuropathy
Autosomal recessive trait
• Familial dysautonomia — Riley–Day syndrome
• Dopamine-beta-hydroxylase defi ciency
Metabolic diseases
• Diabetes mellitus
• Chronic renal failure
• Chronic liver disease
• Alcohol-induced
Infl ammatory
• Guillain–Barré syndrome
• Transverse myelitis
Infections
• Bacterial— tetanus
• Viral— HIV infection
Neoplasia
• Brain tumours — especially of third ventricle or posterior fossa
• Paraneoplastic — especially adenocarcinoma of lung and pancreas
Surgery
• Vagotomy and drainage procedures — ‘dumping syndrome’
Trauma
• Cervical and high thoracic spinal cord transection
Drugs, chemical toxins
• By direct effects
• By causing a neuropathy
Autonomic (neurally) mediated syncope
• Vasovagal syncope
• Carotid sinus hypersensitivity
• Situational syncope
Postural tachycardia syndrome
Initial orthostatic hypotension
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Table 2.2 Classification based on natural history and intervention 
• Fixed and irreversable- pure autonomic failure, spinal cord injury
• Progressive and irreversable - multiple system atrophy
• Progressive but stoppable- familial amyloid polyneuropathy, diabetes mellitus
• Reversible- immuno mediated autonomic neuropathies 
 
 
 
2.4 The Postural Tachycardia Syndrome (PoTS) 
 
PoTS is the most common form of orthostatic intolerance characterized by excessive 
increases in heart rate (HR) during orthostatic stress without OH (Schondorf & Low, 1993; 
Mathias et al., 2012). The principal feature of PoTS is orthostatic intolerance, defined as the 
provocation of symptoms on orthostasis that are relieved by recumbence (Mathias et al., 
2012). HUT and standing tests are crucial diagnostic procedures used to identify the 
syndrome (Figure 2.5). The hallmark criterion of PoTS is an increase in HR by >30 beats/min 
or a maximum HR of >120 bpm within 10 minutes of assumption of the upright posture.  The 
method of achieving the upright posture is not specified however and HUT and standing tests 
have different hemodynamic responses, potentially influencing the diagnosis of PoTS.  
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Figure 2.5.  Blood pressure and heart rate profiles obtained while supine and during 
head-up tilt. a | Profile of a healthy individual. b | Profile from a patient with PoTS. The 
vertical dashed line indicates the onset of postural change (head-up tilt). Excessive 
tachycardia is observed after the onset of head-up tilt in the patient with PoTS. 
Abbreviation: PoTS, postural tachycardia syndrome. (From Mathias et al., 2012). 
 
 
 
2.5 Clinical presentation of PoTS 
 
PoTS patients present with symptoms of orthostatic intolerance including lightheadness, 
dizziness, postural palpitations and with either syncope or presyncope (Mathias et al., 2012). 
Additional frequent clinical features include fatigue, headache and a multi-visceral 
involvement (Mathias et al., 2012). Although orthostatic intolerance is the hallmark of patients 
with intermittent autonomic dysfunction, such as PoTS or AMS, patients may experience 
other symptoms of autonomic dysfunction as well, including upper gastrointestinal tract 
symptoms, bowel and bladder dysfunction, and secretomotor dysfunction. Therefore, 
assessing the various types of autonomic symptoms and their intensity is essential when 
studying patients with autonomic disorders. PoTS patients can often present with allied 
features that also need to be carefully investigated. PoTS is often associated with the joint 
hypermobility syndrome and assessing skeletal muscle features is a key component in these 
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patients. The overlap with different disorders, including the Chronic fatigue syndrome, will be 
discussed in the section below. Clinical observations suggest that these autonomic and allied 
features affect quality of life considerably and measures of autonomic symptoms and quality 
of life are increasingly being recognized as important outcome measures for clinical trials in 
autonomic disorders, particularly in patients with neurodegenerative disorders such as MSA 
(Wenning et al., 2004; Damon-Perriere et al., 2012; Kaufmann et al., 2012; Meissner et al., 
2012) and PD (Visser et al., 2004; Wenning et al., 2004; Chaudhuri et al., 2006). However, to 
our knowledge, no data have systematically investigated the importance of quality of life in a 
range of chronic and  intermittent autonomic disorders, and in particular PoTS patients, who 
often present with severe disability and multi-system involvement (Mathias et al., 2012). 
Indeed, there are no multi-domain symptom assessment tools that also assess the impact on 
quality of life for each autonomic domain. Therefore, there is a need for a self-completed 
questionnaire that at the same time assesses autonomic symptoms and the impact on daily 
life in a range of autonomic and allied domains in a broad spectrum of autonomic disorders.  
 
Patients with PoTS, AMS and Hyperhidrosis can present with non-autonomic allied features, 
such as musculoskeletal involvement and small fibre dysfunction (Mathias et al., 2013a). 
Assessing these allied features is crucial in terms of diagnosis, prognosis and management 
of these patients. Also for young adults, musculoskeletal impairment is a major cause of 
activity limitation and a key component which needs to be taken in account into the overall 
evaluation of quality of life in patients with chronic conditions (Verbrugge & Patrick, 1995). 
Autonomic questionnaires currently available focus on either peripheral involvement of the 
autonomic nervous system or have been designed mainly for patients with chronic primary 
autonomic failure, and therefore may not be sufficient to accurately assess musculoskeletal 
impairments and the degree of chronic fatigue and/or sleep problems which can occur in 
patients with PoTS and intermittent autonomic disorders (Hoad et al., 2008; Bagai et al., 
2013).  
 
2.6 Diagnosis of PoTS 
 
HUT and standing tests are crucial diagnostic procedures used to identify PoTS and both are 
often included in orthostatic tolerance evaluations. The method of achieving the upright 
posture is not specified for the diagnosis of PoTS however, and HUT and standing tests have 
different hemodynamic responses. Furthermore, there are a number of factors that 
exacerbate orthostatic intolerance. Some patients do not meet the PoTS criteria on HUT or 
standing, but they present with the hallmark exacerbation of orthostatic tachycardia and 
symptoms in response to various daily events, such as food ingestion, exercise and heat 
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challenge. Assessing the hemodynamic responses to these daily life stimuli could be crucial 
in accurately diagnosing PoTS (Table 2.3) but this has yet to be thoroughly investigated  
 
Table 2.3 Cardiovascular Autonomic Investigations for PoTS  
(adapted from Mathias et al., (2012)) 
• Head-up tilt (at an angle of 60° for 10 min)
• Standing
• Pressor stimuli (to determine sympathetic vasoconstrictor function): 
isometric exercise, cutaneous cold, Valsalva maneuver and mental 
arithmetic
• Heart rate responses (to determine cardiac parasympathetic 
responsiveness) to: deep breathing, the Valsalva maneuver, 
hyperventilation, standing and head-up tilt
• Plasma norepinephrine and epinephrine levels: supine, and during 
head-up tilt or standing
• 24-h ambulatory blood pressure and heart rate profile using the 
London Autonomic Units protocol
• Prolonged head-up tilt (at an angle of 60° for up to 60 min)
• Liquid meal challenge to determine preprandial and postprandial 
cardiovascular autonomic responses to the transition from supine to 
head-up tilt or standing
• Modified, graded exercise, to determine the cardiovascular autonomic 
responses while exercising in a supine position, and to compare these 
responses with before and after this exercise and while standing
Autonomic screening tests
Additional tests
Investigations for PoTS
 
 
2.7 Associated features of PoTS: the Joint Hypermobility Syndrome (JHS) 
 
PoTS is often associated with the JHS, which is the most common heritable disorder of 
connective tissue, characterized by joint laxity (Grahame et al., 2000). It causes articular 
dislocations, subluxations and arthralgia. Currently, the clinical criteria established to 
diagnose and distinguish JHS and EDS III are non specific (Remvig et al., 2007) and JHS is 
believed to be indistinguishable from, if not identical, to EDS III (Tinkle et al., 2009). There is 
no molecular diagnostic testing of JHS/EDS III and the diagnosis is based on clinical 
evaluation and history.  
 
According to the Brighton criteria (see Table 2.4, 2.5), an individual with JHS is diagnosed as 
having or having had a history of, generalized joint hypermobility (Figure 2.6) taking into 
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account the common finding that joint hypermobility decreases with age (Grahame et al., 
2000). Therefore, familial joint laxity, EDS hypermobility type, and Benign Joint Hypermobility 
Syndrome (BJHS) are thought to represent a phenotypic continuum whose symptoms are 
more often related to activity and age rather than the underlying genetic defect (Tofts et al., 
2009). The role of collagen pathology in the context of PoTS has not been investigated as 
yet however.  
 
 
 
 
A B 
C 
Figure 2.6 Joint hypermobility in a patient with PoTS and EDS type III.  
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Table 2.4 Beighton scoring criteria 
Joint Finding Points
Left little (fifth) finger passive dorsiflexion beyond 
90°
1
passive dorsiflexion <= 90° 0
Right little (fifth) finger passive dorsiflexion beyond 
90°
1
passive dorsiflexion <= 90° 0
Left thumb passive dorsiflexion to the 
flexor aspect of the forearm
1
cannot passively dorsiflex 
thumb to flexor aspect of the 
forearm
0
Right thumb passive dorsiflexion to the 
flexor aspect of the forearm
1
cannot passively dorsiflex 
thumb to flexor aspect of the 
forearm
0
Left elbow hyperextends beyonds 10° 1
extends ≤10 0
Right elbow hyperextends beyonds 10° 1
extends ≤10 0
Left knee hyperextends beyonds 10° 1
extends ≤10 0
Right knee hyperextends beyonds 10° 1
extends ≤10 0
Forward flexion of 
trunk with knees full 
extended
palms and hands can rest flat 
on the floor
1
palms and hands cannot rest 
flat on the floor
0
 
 
 
 
Table 2.5 The 1998 Brighton Criteria for a Diagnosis of Benign 
Joint Hypermobility Syndrome (from Grahame et al., (2000)). 
Major criteria
(1) Beighton score of  4/9
(2) Arthralgia for >3 months in >4 joints
Minor criteria
(1) Beighton score of 1–3
(2) Arthralgia in 1–3 joints
(3) History of joint dislocation
(4) Soft tissue lesions >3
(5) Marfan-like habitus
(6) Skin striae, hyperextensibility, or scarring
(7) Eye signs, lid laxity
(8) History of varicose veins, hernia, visceral prolapse
For a diagnosis to be made either
Both of the major criteria must be present
OR one major and two minor
OR four minor
AND other disorders of connective tissue need be excluded
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2.8 The complex pathophysiology of PoTS: a multi-system disorder 
 
PoTS is a complex syndrome arising from an interrelationship of autonomic, biochemical, 
genetic and environmental factors. There are several different subgroups of patients that 
may result in subtle clinical differences and divergent responses to treatment. PoTS 
aetiology includes: a limited autonomic neuropathy (probably with an autoimmune basis), 
physical deconditioning, relative chronic hypovolemia, hyperadrenergic tone, impaired 
cerebral autoregulation and genetic mutations (Mathias et al., 2012), which will be discussed 
in this section. The complexity of multi-system conditions such as PoTS requires an accurate 
approach to evaluate aetiology and pathophysiology, which in these patients remains 
extremely heterogeneous.  
 
2.8.1 Neural mechanisms 
PoTS is associated with regional autonomic denervation, usually in the lower limbs. This has 
been confirmed by a reduction in vascular resistance responses to orthostatic stress (Figure 
2.7) (Bush et al., 2000) and venous pooling (Figure 2.8) due to blunted arterial 
vasoconstriction (Stewart, 2002). Impaired noradrenaline release in response to 
physiological maneuvers and also to pharmacological stimuli, such as sodium nitroprusside 
and tyramine, also indicate autonomic denervation (Jacob et al., 2000). 
 
Figure 2.7 Change in vascular resistance, expressed as a percentage change 
form supine, at various stages of orthostasis in PoTS, Low orthostatic 
intolerance (lot)  and Control groups. *p<0.05 vs. control (Bush et al., 2000). 
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Figure 2.8. Peripheral vascular pooling in the lower limbs during head-up-tilt (a). An 
image of the same patient, showing that no pooling occurs while supine (b). 
 
It has also been described that about ~50% of PoTS patients may be post-infectious 
suggesting an immune-mediated limited autonomic neuropathy (Schondorf & Low, 1993). 
Noradrenaline spillover in the leg is reduced in some patients with PoTS and there is 
denervation supersensitivity of the lower extremity veins (Streeten & Scullard, 1996). The 
presence of sudomotor denervation has also been described in the distal lower extremities 
as well. Denervation results in an increase in vascular capacity manifested as increased 
venous pooling (Low et al., 1995) and a reduction in preload (Low et al., 1994). Based on this 
evidence, it appears that a limited peripheral autonomic neuropathy might be one of the 
subtypes of PoTS (Jacob et al., 2000). The possibility of peripheral small nerve fiber 
involvement in these patients has not been thoroughly investigated however. The skin biopsy 
technique has been widely used to quantify autonomic innervation in diabetic neuropathy 
(Atherton et al., 2007; Gibbons et al., 2010; Nolano et al., 2010; Giannoccaro et al., 2011; 
Narayanaswamy et al., 2012) although it is still underused in other autonomic disorders. A 
more specific quantification of autonomic nerve fibers is needed to allow the use of this 
technique in a broad group of autonomic disorder patients. The limited amount of skin biopsy 
analyses in PoTS have shown normal skin noradrenaline concentrations but with some 
morphologic abnormalities in somatic C fibers in three of the eight patients studied (Singer et 
al., 2004). No further studies have been performed in this patient group, which could help 
identify a possible neuropathic PoTS subgroup and help to better understand their 
pathophysiology. 
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2.8.2 Humoral factors 
Elevated plasma noradrenaline levels with raised systolic blood pressure during head-up tilt, 
an exaggerated pressor response to the Valsalva maneuver, and an increase in muscle 
sympathetic nerve activity have been described in some patients with PoTS (Jordan et al., 
2002), which suggests that this syndrome could have a hyperadrenergic basis underpinned 
by either neural or humoral mechanisms or a possible association with a mast cell activation 
(Figure 2.9) (Shibao et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Elevated levels of angiotensin II have also been reported in some PoTS patients who have 
low blood volumes which might contribute to the local blood flow dysregulation observed in 
A 
 
 
B 
 
 
Figure 2.9. Possible pathophysiology underlying the association between 
PoTS and Mast Cell Activation (MCA) and the Valsalva maneuver (VM) BP 
profile. Panel A. Positive feedback loop by which MCA releases vasoactive 
mediators and causes vasodilatation, subsequent sympathetic activation, 
central volume contraction, noradrenaline release and orthostatic 
intolerance (panel A). Panel B. Cardiovascular responses to the VM in 
normal controls and MCA+PoTS patients showing the exaggerated increase 
in BP during phase II late and phase IV (Shibao et al., 2005). 
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some patients with peripheral vasoconstriction and reduced nitric oxide bioavailability (Figure 
2.10) (Stewart et al., 2006a). 
 
Figure 2.10. PRA (plasma renin activity) and serum aldosterone and plasma Ang II (angiotensin 
II) concentrations in patients with PoTS and normal controls. PRA was significantly decreased 
and Ang II was increased in low-flow PoTS patients compared with controls. Calf blood flow 
was defined as follows: low-flow PoTS as PoTS patients with calf blood flow <1.2 ml•min
-1
•(100 
ml of tissue)
-1
, high-flow PoTS as PoTS patients with calf blood flow >4.0 ml•min
-1
•(100 ml of 
tissue)
-1
 and normal-flow as PoTS patients with calf blood flow ≥1.2 ml and ≤ 4.0 ml•min
-1
•(100 
ml of tissue)
-1
 (Stewart et al., 2006a). 
 
2.8.3 Decreased intravascular volume 
Hypovolemia commonly occurs in orthostatic intolerance, however, the underlying 
pathophysiological mechanisms are not fully understood. The renin-angiotensin system is a 
complex and powerful regulatory system for the conservation of salt and blood volume, and 
the preservation of an adequate blood pressure (Figure 2.11) (Montani, 2004). 
 
Reduced plasma renin activity has been documented in PoTS patients with hypovolemia and 
elevated plasma noradrenaline suggesting that PRA might be an important 
pathophysiological component of the syndrome of orthostatic intolerance (Jacob et al., 
1997a; Raj et al., 2005a). In patients with hypovolemia an increased plasma renin activity 
and aldosterone are expected as major compensatory mechanisms, however, this did not 
occur in patients described by Jacob et al (Jacob et al., 1997a) raising the possibility of 
abnormalities in the renin-aldosterone system in orthostatic intolerance which contribute to 
the pathophysiology of PoTS (Figure. 2.12). The cause of the inappropriately low levels of 
plasma renin activity and aldosterone in PoTS is not clear. The latter could be due to (1) 
impaired vascular function across the juxtaglomerular apparatus and/or (2) problems with 
sensor mechanisms at the level of the macula densa, or in the transmission of this signal to 
the juxtaglomerular apparatus, or in the response of the juxtaglomerular apparatus (Jackson, 
2001).  
Page 44 
 
Other mechanisms which have been suggested to contribute to changes in intravascular 
volume include a reduced responsiveness to renin–angiotensin–aldosterone or 
abnormalities in the renal control of fluid secretion. In addition to deficits in plasma volume, 
patients with PoTS also can have a significant reduction in red blood cell volume (Hoeldtke 
et al., 1995; Streeten et al., 2000; Raj et al., 2005a). A reduced cardiac size has also been 
proposed as a causative factor for PoTS (Fu et al., 2010). 
 
 
 
 
 
Figure 2.11. Schematic diagram showing the renin-angiotensin system and the major effects of 
Ang II on total peripheral resistance and extracellular fluid volume (Montani, 2004). 
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Figure 2.12. Proposed mechanism of the consequences of reduced plasma renin 
activity (PRA) in patients with orthostatic intolerance. AII, angiotensin II; Aldo, 
aldosterone; ECV, effective circulating volume; CO, Cardiac output; SNA, sympathetic 
nerve activity; BP, blood pressure; HR, heart rate; NE, noradrenaline. From Raj et al., 
(2005a). 
 
 
2.8.4 Other vascular mechanisms and the role of the splanchnic circulation 
In some PoTS patients, increased blood flow in the lower limbs and pelvis might result from 
inadequate peripheral (arterial) vasoconstriction and subsequent enhanced microvascular 
filtration (Stewart, 2003) (Figure 2.13). In these patients the vascular deficit while upright is 
thought to result primarily from blood pooling in the splanchnic vascular bed, which causes 
increased vasoconstriction in other vascular beds to counteract the splanchnic 
vasodilatation.  
 
In normal subjects, stimuli which result in sympathetic activation (pressor responses and 
head up tilting) cause vasoconstriction of the superior mesenteric artery (SMA) (Chaudhuri et 
al., 1991) while this response could not be elicited in patients with primary autonomic failure 
and likely impairment of the sympathetic splanchnic innervation (Chaudhuri et al., 1991; 
Chaudhuri et al., 1992). Impaired sympathetic splanchnic vasoconstriction is an important 
cause of orthostatic hypotension. Sympathetic neurons innervating the splanchnic regions 
are likely to be affected in patients with diabetes due to their susceptibility to glucose induced 
oxidative stress and it is well documented that an autonomic nervous system neuropathy, 
including orthostatic hypotension, are significant complications of diabetes (Semra et al., 
2006). In patients with diabetic autonomic neuropathy, abnormal splanchnic vascular 
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responses have been thought to be play a role in the pathogenesis of postural hypotension 
(Stevens et al., 1991). A marked increase in splanchnic blood volume has also been 
described in patients with postural syncope during orthostatic stress (Stewart et al., 2004), 
(Figure 2.14). Furthermore, additional vascular abnormalities, such as reductions in 
connective tissue proteins (such as collagen, fibrillin and tenascin), might have a role in 
peripheral pooling in patients with both PoTS and EDS type III and also need to be 
considered as one of the possible contributing factors in the pathophysiology of PoTS. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Filtration data from supine subjects. Arm data are shown in the upper panel; leg 
data are shown in lower panel. Control subjects are shown as triangles fitted to dotted line. 
Patients with PoTS are shown as crosses fitted to solid line. Microvascular filtration is 
expressed as the linear relation, e.g., the slope or the microvascular filtration coefficient, 
between limb filtration rate and cuff occlusion pressure. Filtration only occurs above a critical 
cuff occlusion pressure. There is a significantly increased rate of filtration in lower limbs of 
patients with PoTS compared with control subjects (Stewart, 2003). 
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Figure 2.14. Time course of impedance (top) and segmental volume changes (bottom) for 
individual segments in a representative control subject during upright tilt. Patients with 
postural faints had a greater increase in thoracic impedance and decrease in splanchnic 
impedance corresponding to a greater decrease in thoracic blood volume and increase in 
splanchnic blood volume during orthostatic stress compared with control subjects (Stewart et 
al., 2004). 
 
2.8.5 Physical deconditioning and association with Chronic Fatigue Syndrome (CFS) 
Many patients with PoTS fatigue readily, and a number of factors might underlie this feature.  
PoTS is strongly associated with cardiovascular deconditioning (Parsaik et al., 2012) and 
cardiovascular changes attributable to deconditioning are similar to those seen after 
prolonged bedrest and space flight. Whether deconditioning is a primary or secondary 
phenomenon remains unclear however. 
 
PoTS patients frequently report chronic fatigue and share clinical features with both chronic 
fatigue syndrome and fibromyalgia. Additionally, patients with chronic fatigue syndrome and 
fibromyalgia have symptoms of orthostatic intolerance (De Lorenzo et al., 1996; Timmers et 
al., 2002; Costigan et al., 2010; Hollingsworth et al., 2010; Frith et al., 2012; Lewis et al., 
2013). Also, all of these conditions are associated with marked deconditioning, raising the 
question that an intense therapeutic exercise and cardiovascular rehabilitation might be 
effective in all these conditions (Newton et al., 2011). There are several pieces of evidence 
that support the beneficial effects exercise training in PoTS (Winker et al., 2005a; Fu et al., 
2010; Fu et al., 2011). Exercise training has also been shown in a number of trials to 
improve symptoms and functionality in fibromyalgia (Richards & Scott, 2002). 
 
 
 
 
2.8.6 Familial PoTS and genetic mutations 
In the course of the evaluations of individuals with autonomic dysfunction it has become 
evident that a variety of autonomic disorders have a strong familial component. A positive 
family history is often present in patients with essential or primary Hyperhidrosis, which likely 
has an autosomal dominant inheritance with incomplete penetrance (Strutton et al., 2004), 
and in patients with AMS (Mathias et al., 1998; Mathias et al., 2000; Newton et al., 2003; 
Newton et al., 2005; Holmegard et al., 2013).  A specific neurohumoral abnormality has been 
reported in a single family of a PoTS patient.  A genetic mutation in the SLC6A2 gene was 
evident, which encodes the sodium-dependent noradrenaline transporter (see Figure 2.15). 
This mutation results in increased accumulation of noradrenaline in the synaptic cleft, and 
thus exacerbated heart rate responses (Robertson et al., 2001). This genetic mutation was 
Page 48 
 
reported in identical twins; although both possessed the same genotype, only one expressed 
the PoTS phenotype. No further families with such mutations have been reported to date. 
Genes encoding the β-1(Winker et al., 2005b) and β-2 (Jacob et al., 2006) adrenergic 
receptors, and endothelin-1 (Winker et al., 2005c) have also been associated with the 
development of PoTS. In particular, the bradycardia-promoting b1Gly49 polymorphism was 
underrepresented in idiopathic orthostatic intolerance subjects (Winker et al., 2005b). PoTS 
is commonly associated with EDS III, which is an inheritable disorder of the connective 
tissue. This raises the possibility of a genetic component in those developing PoTS, either 
with or without EDS III.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Schematic of 
noradrenaline neuronal release and 
uptake and selected receptor 
polymorphisms. Noradrenaline is 
released from vesicles in the 
neuron into the synaptic space, 
where it can interact with 
presynaptic and postsynaptic α- 
and β-adrenergic receptors. Eighty 
percent of the noradrenaline in the 
synaptic space is taken up by the 
noradrenaline transporter into the 
neuron, which releases it, and 
approximately 20% spills over into 
the circulation.  
The α2-adrenergic receptor inhibits 
noradrenaline release at 
presynaptic nerve endings through 
negative feedback. The presence of 
the dysfunctional α2CDel322-325 
receptor would therefore be 
Receptor  
Polymorphism
Effect in vitro Expected 
Effect in Vivo
α2c Del322-
325
Decreased 
functio
Increased 
nerepinephrine 
 release at 
synapse 
β1 Arg389 Increased 
function
Increased 
response at 
cardiomyocyte
β1Gly49 Increased 
down-
regulation
Decreased 
response at 
cardiomyocyte
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expected to result in an in vivo increased noradrenaline release at the synapse and impaired 
reuptake. 
The hyperfunctional β1Arg389 receptor would be expected to increase chronotropy at the 
myocyte. Therefore, the presence of these two receptor polymorphisms were hypothesised to 
be risk factors for Idiopathic orthostatic intolerance. The b149Gly receptor variant, which 
should lead to decreased function via down-regulation was hypothesised to be a protecting 
factor for Idiopathic orthostatic intolerance. 
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2.9 Treatment in PoTS  
 
The management of PoTS involves non-pharmacological (Table 2.6) and pharmacological  
(Table 2.7) approaches (Mathias et al., 2012). Patient education is the first and fundamental 
step of PoTS management. Patients should be informed about several measures to be 
introduced and other risk factors to be avoided (Table 2.5). Management needs to be 
individually tailored and even though the majority of patients will have a low blood pressure 
profile and would benefit from increased salt and fluid intake or even anti-hypotensive 
medications, some will not. The latter is related to patients with orthostatic tachycardia and 
normal to high blood pressure profiles (Mathias et al., 2012). Exercise is of particular 
importance in the long term management of these patients who often are deconditioned and 
will need a prolonged cardiovascular exercise training program to improve orthostatic 
intolerance symptoms. Deconditioning is even more prominent in patients with PoTS and 
EDS III who experience joint instability and muscle disuse due to pain. 
 
Table 2.6 Key Non Pharmacological measures in PoTS (from Mathias et al., (2012)) 
 
 
 
To be avoided
• Sudden head-up postural change 
(especially on waking)
• Prolonged recumbency 
• High enviromental temperatures (including 
hoth baths)  
• Large meals (especially of refined 
carbohydrate
• Alcohol
• Undue exertion
• Drugs with vasodepressor and/or 
vasodilatator properties (such as a diuretics, 
nitrates, and nifedipine)
To be introduced
• High salt intake (in patient who do not 
have hypertension)
• Water repletion (especially in the morning 
or waking)
• Small, frequent meals
• Judicious regular exercise (including 
swimming)
• Head-up-tilt at night
• Physical countermaneuvers to induce 
activation exercise 
To be considered
• Elastic stockings
• Abdominal binders
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2.9.1 PoTS patients with low supine blood pressure 
In patients with low supine blood pressure the treatment is aimed to increase blood volume 
mainly by increasing fluid and salt intake in combination with volume expander agents, such 
as Fludrocortisone (Freitas et al., 2000) or by enhancing sympathetic mediated 
vasoconstriction, such as midodrine (Gordon et al., 2000; Chen et al., 2011). This approach 
has the rationale of increasing blood pressure and having the desirable effect of reducing the 
compensatory tachycardia to the previously lower level of blood pressure. In some patients 
tachycardia is only slightly reduced by elevating blood pressure and a second line agent is 
needed to directly reduce the tachycardia, these include β blockers, including Propanolol 
(Gordon et al., 2000; Raj et al., 2009) and cardioselective agents, such as Bisoprolol (Freitas 
et al., 2000; Yusuf & Camm, 2005), and ivabradine (McDonald et al., 2011). The combined 
treatment with the cholinesterase inhibitor Pyridostigmine is aimed at prolonging the phasic 
effects of acetylcholine on the autonomic ganglia, leading to peripheral sympathetic 
vasoconstrictor output (and potentiating vagal effects) on standing (Raj et al., 2005b; Singer 
et al., 2006; Kanjwal et al., 2011). 
 
Table 2.7 Pharmacological treatment in PoTS (from Mathias et al., (2012)) 
 
Theraupetic strategy Drug class or mechanism of action Agent
Reducing salt loss and/or plasma volume expansion Mineralcorticoid Fludrocortisone
Vasoconstriction Sympathetic action on resistance vessels Midodrine
Ganglionic nicotinic receptor stimulation Anticholinesterase inhibitors Pyridostigmine
Preventing vasodilatation and tachycardia β adrenoreceptor blockers ideally 
cardioselective
Bisoprolol
Preventing postprandial tachycardia Peptide release inhibitors Somatostatin 
analogues
Octreotide
Directly reducing tachycadia Selective sinus node blockade Ivabradine
Lowering blood pressure if elevated and reducing 
tachycardia
Central sympatholytic Clonidine
 
 
2.9.2 PoTS patients with high blood pressure and tachycardia 
Patients with tachycardia and high blood pressure are often a difficult challenge in terms of 
management and the ideal approach is using a drug that lowers heart rate and possibly also 
reduces blood pressure if it is elevated. β-blockers, including Bisoprolol, and Propanolol, 
should be considered (Freitas et al., 2000; Yusuf & Camm, 2005). Alternative drugs, such as 
central sympatholytic agents like Clonidine, can be effective in reducing blood pressure, 
tachycardia and symptoms of orthostatic intolerance (Jacob et al., 1997b).  
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2.9.3 Treatment in Resistant PoTS patients 
PoTS patients respond differently to current treatment approaches and some patients are still 
resistant to first and second lines of pharmacotherapy and need a prolonged and multi-step 
approach. This subgroup of PoTS patients who are non-responsive to standard treatment 
and who often experience marked postprandial features, might benefit from subcutaneous 
octreotide in small doses of 25–50 μg, administered twice or three times daily before food 
ingestion (Hoeldtke et al., 2006). Octreotide, a somatostatin analogue, is effective in 
preventing the release of pancreatic and gut hormones in response to various stimuli, 
including food and alcohol ingestion and has been effectively used in the treatment of 
patients with post-prandial hypotension (Hoeldtke et al., 1986; Hoeldtke et al., 2007) (Figure 
2.16). Patients with PoTS often present with marked post-prandial features, and Octreotide 
may therefore be beneficial. This hypothesis has yet to be thoroughly investigated however. 
 
 
 
 
 
 
Figure 2.16. (a) Mean arterial blood pressure (MAP) before and after alcohol ingestion alone 
without octreotide (continuous line) and after pretreatment with octreotide (interrupted line), 
15, 30, 45 minutes (a15, a30, a45) after alcohol ingestion. Blood pressure falls after alcohol 
alone while supine, and to lower levels during head-up tilt (a45-At), unlike when ingested after 
pretreatment with octreotide. (b) Superior mesenteric artery blood flow (SMABF), and (c) 
superior mesenteric artery vascular resistance (SMAVR), before and after alcohol ingestion 
alone and after pretreatment with octreotide. The rise in SMABF after alcohol ingestion is 
prevented and superior mesenteric artery vascular resistance is much greater during 
octreotide. *p<0.05; **p<0.01. From Chaudhuri et al. (1995).  
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3 Chapter Three. General Methods 
 
3.1 Introduction 
This chapter provides a detailed description of the general methods used in the 
subsequent experimental chapters.  
 
3.2 .Participants 
Participants were recruited from the Autonomic Units at St Mary's Hospital and The 
National Hospital for Neurology and Neurosurgery at Queen Square, London and 
included the following patient groups: PoTS, MSA, PD, PAF, Hyperhidrosis, AMS and 
autonomic peripheral neuropathy. Healthy control participants were recruited from the 
general population. Patients were either approached during follow up clinic 
appointments or recruited by mail from a database of patients at both London Autonomic 
Units. Participant inclusion/exclusion criteria are outlined in Tables 3.1 and 3.2. Fully 
informed written and verbal and ethically approved consent was obtained from all 
participants who were enrolled in prospective studies which included: AQQoL validation 
(Chapter 5)  and the evaluation of peripheral small nerve fibres (Chapter 8). The 
remaining studies included data from routine/standard clinical evaluations and therefore 
did not require ethical approval.  
 
Table 3.1 Inclusion/Exclusion Criteria in patients with Intermittent autonomic disorders 
(PoTS, Postural Tachycardia Syndrome; AMS, Autonomic (neurally) mediated syncope) 
Essential hyperhidrosis PoTS AMS
Patients Inclusion criteria 
Generalized or focal hyperhidrosis 
Orthostatic heart rate increment ≥ 30 
b.p.m. or to an absolute heart rate 
≥120 b.p.m within 5 minutes of head 
up tilting.
Transient loss of consciousness (LOC) and 
postural tone resulting from global cerebral 
hypoperfusion with spontaneous and 
complete recovery and no neurological 
sequelae
Symptoms of orthostatic intolerance. 
All three criteria must be fulfilled
Patients Exclusion Criteria
The presence of other disorders with 
transient LOC, e.g. seizure, hypoglycemia, 
catalepsy or aborted sudden cardiac death
a) Pregnant or lactating females
b)The presence of cardiovascular, metabolic, neurological or a respiratory disease and concomitant therapy with anti-cholinergic, alpha 
and beta adrenergic antagonists or other medication which could interfere with testing of autonomic function.
c) Chronic illnesses or other conditions that potentially involve the central nervous system that can affect autonomic function. These 
include congestive heart failure, recent (<6 months) myocardial infarction, severe anemia, diabetes mellitus, alcoholism, malignant 
neoplasms, amyloidosis, hypothyroidism and history of following diseases or treatments; sympathectomy
Adult males or females aged >18 years
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Table 3.2  Inclusion/exclusion Criteria in patients with Chronic Autonomic Failure 
PD, Parkinson's disease; MSA, Multiple System Atrophy; PAF, Pure Autonomic Failure 
 
3.3 Preparation 
Participants were asked to discontinue any medications which could alter their 
autonomic function for 24-48 hours before testing and to refrain from caffeine 
consumption and vigorous exercise the day prior to testing. None of the control 
participants were taking medications which could affect the autonomic nervous system.  
Full history and clinical examinations were performed in all participants. 
 
3.4 Cardiovascular Autonomic Function  
Participants performed a battery of screening cardiovascular autonomic function tests, 
which included a range of assessments, such as, pressor stimuli, the Valsalva 
Maneuver, Deep Breathing, Standing test and HUT, as well assessments of 
cardiovascular autonomic function during and after a range of common daily stimuli, 
e.g., exercise, food ingestion. From the screening autonomic function tests a severity 
score was derived (see chapter 4). The following section describes each autonomic 
function test in more detail. 
 
PD MSA PAF Peripheral Autonomic 
Neuropathy
Presence of at least two of the three 
cardinal features of the disease (resting 
tremor, bradycardia or rigidity) and are 
in the range of stage 1-4 on the Hoehn 
and Yahr scale (UK Parkinson's Disease 
Society Brain Bank clinical diagnostic 
criteria for Parkinson's disease)
Patients with possible or probable clinical 
diagnosis of MSA according the current 
Gilman's criteria (Gilman, S., et al. 2008)
Gradually progressive 
autonomic dysfunction with 
prominent orthostatic 
hypotension in the absence of 
cognitive, motor or sensory 
impairment.
Amiloid peripheral 
neuropathy, autonoic 
diabetic peripheral 
neuropathy, sensory and 
autonomic peripheral 
neuropathy 
Adult males or females aged >18 years
Parkinsonism due to drugs. 
a) Pregnant or lactating females
b)The presence of cardiovascular, metabolic, neurological or a respiratory disease and concomitant therapy with anti-cholinergic, alpha and beta 
adrenergic antagonists or other medication which could interfere with testing of autonomic function.
c) Chronic illnesses or other conditions that potentially involve the central nervous system that can affect autonomic function. These include 
congestive heart failure, recent (<6 months) myocardial infarction, severe anemia, diabetes mellitus, alcoholism, malignant neoplasms, amyloidosis, 
hypothyroidism and history of following diseases or treatments; sympathectomy
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3.4.1 Pressor stimuli 
Pressor stimuli included: 
 Isometric Exercise. One hand (the dominant hand) gripped a partially inflated 
sphygmomanometer cuff at sub-maximal pressure (one third of previously obtained 
maximal voluntary contraction) for 3 min.   
 Cold Pressor Test. A cold pack was applied to the hand for 3 min. 
 Mental arithmetic. Participants were asked to perform 2 min of rapid serial 
subtractions of 7 or 17 from a suitable starting number (e.g. 400 or 1000). 
 
Pressor stimuli activate the sympathetic nervous system centrally and increase blood 
pressure through peripheral vasoconstriction and a rise in total peripheral resistance 
(see Figure 3.1).  
Figure 3.1 Blood pressure (BP) and heart rate (HR) response to (A) cutaneous 
cold, e.g., cold pressor, and (B) Isometric Exercise in a normal healthy control 
individual. From Mathias et al. (2013). 
 
 
Cutaneous ColdBP        
Isometric Exercise 
B 
A 250 
0 
100 
0   
0 
100 
0  
250 
90 seconds 
90 seconds 
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3.4.2 Heart rate response to deep breathing 
Changes in respiration result in alterations in heart rate (sinus arrhythmia) providing 
information mainly on cardiac vagal nerve function. The variation is maximal at a 
breathing rate of 5-6 breaths/minute (see Figure 3.2). Participants were asked to breath 
at a rate of 6 breaths/min (inspiratory and expiratory cycles of 5 s each). Three 
repetitions were performed with adequate time for hemodynamic recovery in between. 
The average of the difference between minimum and maximum heart rates for each 
breath was obtained as a measure of the heart rate response to deep breathing 
(Mathias, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. The effect of deep breathing on heart rate and blood pressure in (a) a 
normal healthy individual and (b) a patient with autonomic failure. There is no 
sinus arrhythmia in the patient, despite a fall in blood pressure. Respiratory 
changes are indicated in the middle panel (Mathias, 2013). 
 
3.4.3 Valsalva manoeuvre 
The Valsalva Manoeuvre (VM) increases both intrathoracic and intra-abdominal 
pressure by straining against a closed glottis resulting in changes in blood pressure and 
heart rate and provides an assessment of cardiovagal and adrenergic function (see 
Figure 3.3). Participants were asked to blow with an open glottis into a disposable 
syringe connected to the mercury sphygmomanometer and maintain a forced expiratory 
pressure of 40 mmHg for 10-15 seconds (Mathias, 2013). Three repetitions were 
performed with adequate time for hemodynamic recovery in between. 
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The BP response to the VM in different phases, including phase 2 early (phase II_E), 
phase 2 late (phase II_L) and phase 4 (phase IV), were determined as previously 
described (Vogel et al., 2005), as well as the PRT, which is the time interval from the 
lowest BP in phase 3 to when BP returned to pre VM baseline as shown in Figure 3.3.  
The Valsalva ratio (VR) was calculated by the maximum HR generated by the VM 
divided by the lowest HR occurring within 30 seconds of the peak heart rate.  
Figure 3.3. Representative Valsalva maneuver from a healthy individual. The 
amplitude of phase I is measured from baseline to peak of phase I. Phase II Early 
is measured from baseline to the trough of phase II. Phase II Late is determined 
from the end of phase II Early to the beginning of phase III. Phase III is measured 
from the end of phase II Late to the trough of phase III. Phase IV was determined 
as its height above baseline. 
 
3.4.4 Head-up-tilting 
HUT is one of the most crucial diagnostic procedures used to identify the Postural 
Tachycardia Syndrome (see Figure 3.4) and the most commonly used technique to 
determine orthostatic tolerance and adrenergic impairment in patients with autonomic 
disorders. The test is performed as follows. 
 
Basal measurement  
Initially, basal measurements are performed with the participant lying supine in a quiet room 
and as comfortable as possible. An adequate number of readings, over at least a 5–10 
minute interval, may be needed to determine the stability (or lability), of supine blood 
pressure.  
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Duration of HUT 
The upright position is achieved using an electrically-operated tilt table, usually up to 60° for 
a period of 10 minutes (Mathias, 2013). Intermittent measurements of brachial blood 
pressure are obtained at 1, 3, 5, 7, and 10 minutes during head-up tilt. HUT is terminated if 
syncopal or pre-syncopal events occur, in this case measurements were made at the longest 
time upright. After the tilt, an additional 3 minutes of recording are obtained in the supine 
position. 
.  
 
Figure 3.4.  Blood pressure and heart rate profiles obtained while supine and 
during head-up tilt. a | Profile of a healthy individual. b | Profile from a patient with 
PoTS. The vertical dashed line indicates the onset of postural change (head-up 
tilt). Excessive tachycardia is observed after the onset of head-up tilt in the patient 
with PoTS. Abbreviation: PoTS, postural tachycardia syndrome. (From Mathias et 
al 2012). 
  
3.4.5 Standing test 
The standing test is an active change in posture which evokes initial cardiovascular 
responses that differ slightly from the responses to a passive HUT. Blood pressure and heart 
rate were measured with the participant lying supine at 1, 3 and 5 minutes. Five minutes of 
standing was then performed (Mathias, 2013). Blood pressure and heart rate were recorded 
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at 1, 3 and 5 minutes. The Standing test was terminated if syncopal or pre-syncopal events 
occurred, in this case, measurements were made at the longest time upright. 
 
3.4.6 Liquid meal Challenge  
Baseline measurements were made in the supine position for at least 10 min followed by 
HUT for 10 min. Patients were then returned to the horizontal and a liquid meal (66 g 
carbohydrate, 22 g fat and 18 g protein), made up to 300 ml, was administered via a flexible 
straw while the patient was supine. Measurements were continued for a further 45 min after 
which a head-up tilt to 60 ° was repeated for 10 min (see Figures 3.5 and 3.6). Symptoms 
were recorded throughout the test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Liquid Meal Challenge Protocol. The standard meal is ingested in the 
supine position and a period of subsequent monitoring is performed to assess the 
effects of the meal per se on cardiovascular function. Head-up tilting is performed 
before and after meal ingestion to assess the effect of food on orthostatic 
tolerance and cardiovascular autonomic function. 
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Figure 3.6. Changes in blood pressure and heart rate while supine and during 
head-up tilt, before and after ingestion of a balanced liquid meal. A greater rise in 
the heart rate is observed on head-up tilt after ingestion of the meal, compared 
with the rate during head-up tilt before the meal. (Mathias et al 2012). 
 
 
3.4.6.1 Octreotide protocol 
Patients were studied during the Liquid Meal Challenge Protocol with and without Octreotide. 
During the Octreotide trial, patients were given 50 mcg of Octreotide subcutaneously, 
followed 10 min later by HUT for 10 min (Figure 3.5). A positive Octreotide response was 
considered a significant HR decrease on HUT pre or post meal, relative to the Control trial, 
associated with improvement of orthostatic intolerance symptoms.  
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Figure 3.7 Liquid Meal Challenge Protocol with Octreotide. Patients are given 50 mcg 
of Octreotide subcutaneously, followed 10 min later by HUT for 10 min. The standard 
meal is ingested in the supine position and a period of subsequent monitoring is 
performed to assess the effects of the meal per se on cardiovascular function. Head-
up tilting is performed before and after meal ingestion to assess the effect of food on 
orthostatic tolerance and cardiovascular autonomic function and are compared with 
the liquid meal challenge without Octreotide. 
 
3.4.7 Modified Exercise test 
Baseline measurements were made in the supine position for at least 10 min followed by 
active Standing for 5 min. Patients returned to the horizontal position and rested for 10 min 
before exercising in the supine position by pedalling (60 rpm or higher) a cycle ergometer 
(Monark, Stockholm, Sweden) at workloads of 25, 50 and 75 Watts for 3 minutes at each 
stage. Measurements were made at the end of each stage of exercise and continued for a 
further 10 min post-exercise. A standing test was then repeated (see Figures 3.7, 3.8). 
 
Figure 3.8 Modified Exercise protocol. The participant performs incremental 
exercise in the supine position. Active standing is performed before and after 
exercise to assess the effect of exercise on orthostatic tolerance and 
cardiovascular autonomic function.   
 
Octreotide (50 µg)
Supine 1 (10') HUT 1 (9') Supine 2 (10') Supine post meal (45') HUT 2 (9')
0 10 20 30 75 85
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Figure 3.9. Changes in blood pressure and heart rate observed during standing, as 
well as before and after a graded supine cycling exercise in a PoTS patient. The 
patient’s blood pressure (top line, systolic blood pressure; bottom line, diastolic 
blood pressure) and heart rate responses to exercise are preserved, but while 
standing after exercise (even 10–15 min later) the heart rate remains elevated and 
above the rate measured before exercise. From Mathias et al., (2012). 
 
 
3.4.8 Modified whole body heat challenge 
Baseline measurements were made after equilibration, in the supine position for at least 10 
min followed by active Standing for 5 min in a thermoneutral environment (22°C). 
Participants returned to the supine position, and whole body heat challenge began. After 
internal temperature increased 0.5-1°C a second standing test was performed. Whole body 
heating was performed by exposure to a hyperthermic climate with a room temperature of 
42°C and wrapping the patient in blankets.  
 
 
 
3.4.9 Instrumentation 
3.4.9.1 Blood Pressure 
 
Beat-to-beat blood pressure was measured using photoplethysmography of a digit on the left 
hand (Finometer, TNO-TPD, Biomedical Instrumentation). The Finometer is a non-invasive 
technique to measure finger arterial blood pressure, using an inflatable finger cuff with a built 
in photoelectric plethysmograph. Each cuff has an infrared sensor running parallel to the 
digital artery and a pressure transducer, controlled by a valve, allowing rapid inflation and 
deflation of the cuff. The volume of the cuff is rapidly adjusted, under feedback control, to 
keep the infrared signal amplitude constant. This in turn keeps the finger volume constant 
throughout the arterial pulse cycle. The signal output is displayed on screen, showing a real 
time continuous waveform, which is usually indistinguishable from that of a peripheral 
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arterial, e.g., brachial, waveform. The Finometer technique has been validated by 
comparison with intra-arterial blood pressure during a range of manoeuvres, including 
orthostasis, and accurately reflects intra-brachial or radial blood pressure (Langewouters et 
al., 1998; Hirschl et al., 1999; van der Does et al., 2013). It is also reliable for tracking 
changes in arterial blood pressure (Langewouters et al., 1998; van der Does et al., 2013). 
Participants are asked to keep the finger movements to a minimum during testing and a 
height correction unit is applied to the device and/or the hand is positioned at heart level to 
avoid unwanted hydrostatic effects of any changes in the arm. Blood pressure was recorded 
continuously online (Powerlab systems, ADInstruments, Australia). Blood pressure and heart 
rate were also monitored intermittently throughout protocols using upper arm automated 
sphygmomanometry (GE Dinamap Pro 400, GE Healthcare, Buckinghamshire, UK). 
 
3.4.9.2 Heart Rate  
 
Heart rate was measured continuously throughout testing using electrocardiography (ECG). 
Four chest wall electrodes were placed at the supraclavicular areas and a reference 
electrode was placed at the left midaxillary line just above the apex of the rib cage. The R-R 
interval was converted to heart rate, which was displayed continuously online. 
 
3.5 Evaluation of peripheral small nerve fibres  
 
Participants underwent a range of peripheral nerve function tests and punch skin biopsies 
as outlined below. Fully informed consent was obtained for all human tissues, which were 
collected with approval of the Local Ethics Committee.  
 
3.5.1 Thermal perception thresholds 
Thermal perception threshold testing of unmyelinated and small myelinated sensory fibers 
was performed using the TSA II–NeuroSensory Analyzer (Medoc, Ramat Yishai, Israel) 
(Anand et al., 1996; Wellmer et al., 2001; Atherton et al., 2007) by the same examiner. 
Measured ramps of ascending or descending temperature were applied to the skin of the foot 
or hand through a 30 × 30 mm Peltier contact thermode and detection thresholds were 
recorded when the participant signals the onset of a particular sensation. This is based on 
the Peltier principle that metal elements are heated or cooled, depending on the direction of 
flow of electric current (Fruhstorfer et al., 1976). The plate was placed at the site of interest, a 
current of 3 amps was then delivered to the plates and the subject was asked to press a 
switch as soon as the plate was felt to be either warm or cool. Once the switch was pressed, 
the direction of the current and therefore the direction of the temperature change was 
Page 65 
 
reversed. If the plate was initially heated, the switch was pressed when the plate was felt to 
be warm; the plate would then start to cool and the switch was pressed again when this 
sensation was appreciated. Thermal thresholds were determined for warm perception, cool 
perception, heat pain and cold pain from a baseline temperature of 32°C, with a change in 
temperature of 1°C/sec. The mean of four tests for each modality was recorded. Changes in 
temperature > 6.4°C for warm sensation, and > 2.3°C for cool and > 10.4°C for heat pain, 
were considered abnormal (Wellmer et al., 2001; Atherton et al., 2007; Narayanaswamy et 
al., 2012).  
 
3.5.2 Vibration Perception thresholds 
Vibration perception thresholds to test large sensory fibers were measured by the same 
examiner using a biothesiometer (Biomedical Instrument Company, Newbury, OH, USA) 
placed on the metatarsophalangeal joint of the right and left big toe. The intensity of the 
vibratory stimulus was increased by increasing the voltage to the stimulator and the 
participant indicated when they felt the sensation of vibration. Results were expressed on an 
arbitrary scale in "volts" (Guy et al., 1985; Coppini et al., 2001). Three ascending and three 
descending trials were carried out, and the mean values obtained. Values >12 V were 
considered abnormal. 
 
3.5.3 Nerve Conduction Studies 
Nerve conduction studies (NCS) of the common peroneal and sural nerves in the right leg 
were performed in a standard manner by the same examiner on a Medtronic Keypoint 
electromyelogram (Medtronic, Minneapolis, MN, USA). Common peroneal motor conduction 
studies were performed by recording with surface electrodes on the extensor digitorum 
brevis muscle of the right foot and stimulating at the ankle. The reference electrode was 
placed slightly distal to the fifth matatarsophalangeal joint on the lateral surface of the joint. 
Ankle stimulation was performed with the cathode 8 cm (in a straight line) proximal to the 
active electrode and slightly lateral to the tendon of the tibial anterior muscle. The anode was 
proximal. Below fibula head stimulation was performed with the cathode slightly posterior and 
inferior to the fibula head.   Sural antidromic sensory action potentials of <5 lV amplitude and 
40 m/s conduction velocity were considered abnormal, and common peroneal nerve 
(compound muscle action potential from extensor digitorum brevis) values <3 mV amplitude 
and 40 m/s conduction velocity were considered abnormal (Narayanaswamy et al., 2012). 
 
3.5.4 Skin biopsy technique 
Skin biopsies have became a valuable diagnostic tool for small-fiber-predominant neuropathy 
by the quantification of intra-epidermal nerve fiber density (IENFD); a population of fibers 
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largely undetectable though nerve conduction studies and sural nerve biopsies (Herrmann et 
al., 1999). In this study 3 mm diameter skin punch biopsies to a depth of 4 mm were used as 
larger myelinated and autonomic structures reside at these depths. 
 
3.5.4.1 Tissue collection: calf skin biopsy  
Two 3 mm diameter skin punch biopsies were collected under local anaesthesia from the leg 
(lateral calf) for immunohistology (see Table 3.3). 
  
3.5.4.2 Immunohistology 
One of the two skin biopsies was snap frozen and stored at -70°C, and the other immersed in 
fixative (modified Zamboni's fluid – 2% formalin; 0.01 M phosphate buffer; 15% saturated 
picric acid; pH 7.2), then washed in phosphate buffered saline (PBS; 0.1 M phosphate; 0.9% 
w/v saline; pH 7.3) containing 15% w/v sucrose for an hour, before snap freezing in an 
optimum cutting tissue embedding medium (Tissue-Tek OCT, RA Lamb Ltd, Eastbourne, 
U.K.) to allow for best orientation. Frozen sections were collected onto coated glass slides 
and post-fixed in freshly prepared, 4% weight/volume paraformaldehyde in 0.15M phosphate 
buffered saline (PBS) for 30 min.  Endogenous peroxidase was blocked by incubation in 
Industrial methylated spirit containing 0.3% volume/volume hydrogen peroxide for 30 minutes 
(for both frozen and Zamboni fixed specimens).  After rehydration, by washing in phosphate-
buffered saline, sections were incubated overnight with primary antibodies (see Table 3.3) 
where antibodies to the structural nerve marker PGP9.5 and neuropeptides (CPON/NPY, 
VIP, CGRP, Substance P) were used only on the pre-fixed (Zamboni) samples.  Slides are 
placed by three or by four in a Petri dish containing a moist paper towel.  
 
Sites of primary antibody attachment were revealed using nickel-enhanced, avidin-biotin 
peroxidase (ABC - Vector Laboratories, Peterborough, UK) as previously described (Akbar, 
2009).  Briefly, sections were first rinsed then incubated with biotinylated (biotin labelled) 
secondary antibodies for 40 minutes. Avidin and biotinylated enzyme complex are mixed and 
left for 30 minutes to form the avidin/biotinylated enzyme complex. Avidin has four binding 
sites for biotin. Sections are rinsed and incubated with ABC (avidin/biotin complex) for at 
least one hour. Following a rinse, sections are immersed in a nickel salt rich solution (DAB 
solution). Ammonium and glucose is added to the DAB solution and to start the reaction 
glucose oxidase is finally added. Sections are left to develop for 8-10 minutes. Finally, 
sections were stained for nuclei in 0.1% w/v aqueous neutral red. The dehydration process 
consisted of immersing the slides in a succession of solutions containing a gradually 
increasing percentage of IMS (30%, 70%, 90%, 100%) to finish in xylene for 4 minutes. 
Slides were mounted in a xylene-based mountant (DPX; BDH/Merck, Poole, UK), prior to 
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analysis. Negative controls included omission of primary antibodies or replacement with 
normal pre-immune serum (Akbar et al., 2008; Akbar et al., 2010).  
 
3.5.4.3 Immunostaining analysis 
Intraepidermal nerve fibres (IENF) were counted along the length of four non-consecutive 
sections. Only fibers that intersect the dermal–epidermal basement membrane were included 
excluding more superficial fragments. This method has been well documented to have high 
inter-observer reliability and reproducibility between laboratories (Smith et al., 2005). 
 
The length of epithelium in each counted section was measured using computerised 
microscopy software (Olympus ANALYSIS 5.0 Soft, Olympus UK Ltd., Southend, Essex, UK) 
and results expressed as fibres/mm length of section.  The sub-epidermal neural plexus runs 
parallel to the skin’s surface and is a dense nerve bundle from which individual cutaneous 
nerves branch; it, like many densely innervated structures, has proven difficult to quantify, 
although marked disease-related reductions have been noted (Nolano et al., 2001; Atherton 
et al., 2007; Manganelli et al., 2007; Narayanaswamy et al., 2012). 
 
According to our standard protocol, sub-epidermal fibres (SENF) were measured by image 
analysis where digital photomicrographs were captured via video link to an Olympus BX50 
microscope. The grey-shade detection threshold was set at a constant level to allow 
detection of positive immunostaining and the area of highlighted immunoreactivity obtained 
as a percentage (% area) of the field scanned. Images were captured (x40 objective 
magnification) along the entire length and the mean values used for statistical analysis. 
Quantification was performed by two independent blinded observers and there were no 
significant differences between observers. 
 
Table 3.3 Antibody characteristics and target structures 
Antibodies Target Immunoreactive structure Host Source Dilution
Anti-PGP 9.5 Protein gene product 9.5 Axons Rabbit Ultraclone Ltd, Isle of 
Wight, UK
1:50,000
Anti-TRPV1 Transient receptor potential vanilloid 
type-1Capsaicin receptor
Sensory neurons activated by 
capsacin, heat (>43 ͦC)and acid 
(pH<5.9)
Rabbit GSK, Harlow, UK 1:10,000
Anti-GAP- 43 Growth-associated protein 43 Marker of nerve fibres that are 
regenerating/ remodeling
Rabbit Sigma-Aldrich, 
Dorset, UK
1:80,000
Anti-CPON C-terminal flanking peptide of NPY Sympathetic fibres. Rabbit 1:4,000
Anti-CGRP Calcitonin gene related peptide Vasodilatory peptidergic fibres Rabbit 1:2,000
Anti-VIP Vasoactive intestinal peptide Autonomic cholinergic and 
adrenergic fibers (i.e., innervating 
sweat glands,
hair follicles, AVAs, Merkel 
complexes)
Rabbit 1:5,000
Anti-Col IV Collagen IV Basal membrane, blood vessels Mouse Abcam UK 1:1000
Chemicon Europe 
Ltd., Hampshire, UK
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3.6 Questionnaires 
Participants completed some or all of the following questionnaires: 
 
1) Quality of Life scales; 36 item Short Form Health Survey (SF-36). Rating scale for health 
related quality of life in which the participants rate how much and what types of activities are 
affected by their condition. The SF-36 is a self-reported questionnaire that has been used to 
assess quality of life in various medical populations, and consists of 36 items that define 8 
category scales: physical functioning (PF), role limitation caused by physical problems (RP), 
bodily pain (BP), general health (GH), vitality (VIT), social functioning (SF), role limitation 
caused by emotional problems (RE), and mental health (MH). Scales range from 0 to 100 
and a higher score indicates better quality of life. The 8 category scales are often 
aggregated in 2 summary scales: the physical component summary scale (PCS) and the 
mental component summary scale (MCS) (Manocchia et al., 1998). 
 
2) Unified Multiple System Atrophy Rating Scale (UMSARS) and Unified Parkinson’s 
Disease Rating Scale (UPDRS) are validated disease-specific scales that represent the 
diverse signs and symptoms of MSA and PD, respectively, such as daily living activities and 
mobility. The scales comprise the following components: Part I, historical, 12 items; Part II, 
motor examination, 14 items; Part III, autonomic examination; and Part IV, global disability 
scale (Wenning et al., 2004).  
 
3) Autonomic questionnaire (See Chapter 5). 
 
3.7 Statistical Analyses 
Statistical analyses were performed online using SPSS. Descriptive statistics are presented 
as mean (± 1 SD) for data that were normally distributed. Quantitative variables were 
compared between groups using an ANOVA when there were more than two groups or by 
independent t-tests for 2 groups. When conditions necessary for the application of these 
tests were not met, non-parametric tests were used to compare two groups (Mann Whitney U 
Test) or a Kruskal-Wallis test for more than 2 groups. Pearson correlation coefficients were 
used to examine pairwise correlations between normally distributed variables. Spearman 
rank order correlations were used for analysis of relationships of qualitative variables or non-
normally distributed variables. Mixed model repeated measures ANOVA was used for 
comparison of data collected over more than two different time points in 2 or more different 
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participant groups or 2 or more conditions in the same participant group. Statistical 
significance was defined as a 2-tailed p value of <0.05. 
Author’s contribution  
 
a) Study 1 (Chapter 4): Standard evaluation of patients with autonomic disorders: 
Cardiovascular Autonomic Function Score (CAF score). Valeria Iodice designed the CAF 
score and collected and analyzed the data. 
b) Study 2 (Chapter 5): Assessment of Autonomic Symptoms in Autonomic Disorders: 
AUTONOMIC and musculoskeletal QUESTIONNAIRE AND QUALITY OF LIFE SCOREs 
(AQQoL). Valeria Iodice designed the AQQoL score, enrolled the patients and collected 
and analyzed the data.  
 
c) Study 3 (Chapter 6): Familial Postural Tachycardia Syndrome and EDS III. Valeria 
Iodice collected and analyzed the data. 
 
d) Study 4 (Chapter 7): Diagnosing PoTS: Additional investigations beyond the HUT and 
standing tests. Valeria Iodice collected and analyzed the data. 
 
e) Study 5 (Chapter 8): Evaluation of peripheral small nerve fibres in PoTS. VI enrolled 
the patients, performed the sensory tests, nerve conduction studies and skin biopsies. 
Valeria Iodice, Dr Yiangos Yiangou and Dr Paul Facer performed the immunohistology 
and Immunostaining analyses 
 
f) Study 6 (Chapter 9): The beneficial effects of the somatostatin analogue, Octreotide, on 
orthostatic intolerance and cardiovascular autonomic function before and after food 
ingestion in the Postural Tachycardia Syndrome (PoTS). Valeria Iodice collected and 
analyzed the data. 
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4. Chapter four: Standard evaluation of patients with autonomic disorders: 
Cardiovascular Autonomic Function Score (CAF score)  
 
4.1. Introduction  
  
In patients with autonomic disorders, cardiovascular autonomic screening tests are critical in 
order to determine whether autonomic function is normal or abnormal and to evaluate the 
degree of dysfunction if any abnormalities are present. A broad battery of tests can provide a 
global assessment of cardiovascular autonomic function, including the effect of daily life 
stimuli, such as food and exercise (Mathias, 2013). The London Autonomic Units have 
developed a battery of non-invasive cardiovascular autonomic function tests that are 
standardized and have been used on a broad spectrum of patients with autonomic disorders.  
 
Autonomic cardiovascular screening tests are often the first key diagnostic approach in 
patients with suspected autonomic disorders in order to provide information regarding the 
presence of, amongst other features, 1) orthostatic hypotension, which is often the cardinal 
feature in patients with widespread autonomic failure (Gilman et al., 2008), or 2) postural 
tachycardia and/or a tendency to autonomic (neurally) mediated syncope; key features 
observed in intermittent autonomic disorders (PoTS or Syncope) (Mathias et al., 2012). 
Furthermore, standardized cardiovascular autonomic tests are also directed towards the 
determination of autonomic overactivity, as observed in patients with baroreflex failure 
(Biaggioni et al., 1994; Heusser et al., 2005) or PoTS (Jordan et al., 2002; Thieben et al., 
2007). Cardiovascular autonomic dysfunction  can range from minor to severe should 
dysfunction be present. Dysfunction of a singular component, parasympathetic or 
sympathetic nerve function for example, as well as combinations of both parasympathetic 
and sympathetic nerve impairments, can occur, but the extent of these impairments can vary 
significantly between patient groups or even within the same patient group or even the same 
patient over time (Mathias, 2013). Normal autonomic cardiovascular function testing results 
do not necessarily exclude the presence of an autonomic impairment however, likewise, 
sub-clinical involvement of autonomic dysfunction can occur without evident autonomic 
symptomatology. For example, the latter might occur in patients with early stage type II 
diabetes (Hendriksen et al., 1993; Fakhrzadeh et al., 2012; Sun et al., 2012a). Furthermore, 
sympathetic dysfunction with or without an impairment of parasympathetic function can 
present in early stage de novo PD, even without orthostatic hypotension (Buob et al., 2010; 
Oka et al., 2011). Moreover, sub-clinical involvement of the autonomic nervous system 
affecting mainly the sympathetic vasomotor and parasympathetic cardiovascular fibers has 
been described in patients with chronic inflammatory demyelinating polyradiculoneuropathy 
Page 72 
 
and spinobulbar muscular atrophy (Stamboulis et al., 2006; Rocchi et al., 2011) and in 
patients with systemic disorders such as β-thalassemia (Stamboulis et al., 2012) or Behcet’s 
disease (Borman et al., 2012). For these reasons, it is of relevance to test patients with 
suspected autonomic dysfunction and grade their impairment, if present, in order to define 
the distribution and the degree of autonomic involvement. Therefore, a severity score based 
on the results of cardiovascular autonomic function screening tests in patients with 
autonomic disorders can provide a quantitative measure of overall autonomic dysfunction 
and can be used to detect differences in autonomic involvement between disorders and/or 
track changes in autonomic involvement over time. 
 
There is currently only one cardiovascular autonomic function grading scale; the Composite 
Autonomic Severity Scale (CASS; see Table 4.1), which is directed at grading autonomic 
impairment in patients with widespread autonomic failure (Low, 1993). However, this scale is 
of little use in patients without damage to the autonomic nervous system but with intermittent 
autonomic dysfunction because it only scores for indexes of autonomic failure, or 
underactivity, and not exaggerated or overactivity of the autonomic nervous system (Low, 
1993). Therefore, the aim of this study was to develop a quantitative severity score from our 
cardiovascular autonomic function screening tests for patients with different degrees of 
autonomic impairment (autonomic failure and intermittent autonomic disorders).  
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4.2. Methods 
 
Participants 
We included consecutive patients with different degrees of autonomic dysfunction in order to 
have a broad spectrum of cardiovascular autonomic impairment from autonomic overactivity 
to minimal, modest or severe cardiovascular autonomic failure. We therefore included 
patients with intermittent autonomic dysfunction, such as PoTS, AMS, and patients with 
primary chronic autonomic failure (defined as having severe and symptomatic OH) such as 
MSA and PAF, patients with peripheral neuropathy and autonomic failure (AF, Periph_AF), 
patients with PD and AF (PD_AF) and patients with only mild autonomic dysfunction, such 
as PD (PD_No AF) and peripheral neuropathy (Periph_No AF) without OH or autonomic 
symptoms and healthy normal controls. Patients were tested off medications.  
 
Experimental Design 
All participants underwent our battery of cardiovascular autonomic function screening tests 
as outlined in Chapter 3. Briefly, participants underwent the following tests: 
 
1. HUT (10 min rest in the supine position on a tilt bed and then tilted head up at 60 
degrees for up to 10 min). 
2. Isometric Exercise. 3 min of handgrip exercise at 30% of maximal voluntary force.  
3. Cold Pressor Test. 3 min of a cold pack applied to the hand. 
4. Mental arithmetic. 2 min of subtracting 7 or 17 from a suitable starting number 
(e.g. 400 or 1000). 
5. Deep Breathing. Breathing at a rate of 6 breaths per minute for 1 min.  
6. Standing test. Standing still for up to 5 minutes after 10 min supine rest. 
7. Valsalva maneuver. 20 s of a single breath against a fixed resistance (40 mmHg).  
 
In all tests blood pressure was monitored continuously using digital 
photoplethysmography and/or intermittently using upper arm sphygmomanometry. Heart 
rate was continuously monitored via 5 electrode patches taped to the chest. Changes in 
blood pressure were calculated using pre-maneuver baseline and the last blood 
pressure during the maneuver. 
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Cardiovascular Autonomic Function Score  (CAF score)  
 
A 14 point cardiovascular autonomic function scale was modified from a previous composite 
autonomic severity score (CASS; see Table 4.1) (Low, 1993). This previous scale included 
assessment of: 1) heart rate responses to the Valsalva Manoeuvre (VM) and deep breathing 
(DB) as measures of cardiovagal (e.g., parasympathetic) function; 2) BP responses during 
phases II and IV of the VM, the BP responses to standing and tilt tests, as well as pressor 
responses, as measures of adrenergic (e.g., sympathetic) function. Typically, these 
assessments and their grading are able to reveal autonomic failure, e.g., underactivity of 
cardiovascular autonomic function.   
 
As a modification of this scale, our cardiovascular autonomic function scoring scale also 
included a measure of cardiovascular autonomic function ‘overactivity’ in order to quantify 
the autonomic impairment in patients with suspected ‘hyperactive’ autonomic function, for 
example, PoTS and partial or complete afferent baroreflex failure and AMS. The overactivity 
score is based on the BP and HR responses to HUT, standing and pressor stimuli (see 
Table 4.2). For example, in patients with PoTS, a cardinal hallmark feature includes an 
exaggerated HR increase of > 30 bpm on standing or head-up tilting, while in patients with 
partial or complete afferent baroreceptor impairment, an exaggerated BP response to 
pressor stimuli, in particular to mental arithmetic, is often associated with labile BP (Biaggioni 
et al., 1994; Ketch et al., 2002).  
 
4.2.1. CAF Score construction 
The following section describes how the CAF score scale was constructed and the methods 
of testing and scoring. 
 
4.2.1.1. Adrenergic score  
Adrenergic impairment in its most severe form is manifested with neurogenic orthostatic 
hypotension (OH), which is a cardinal feature of autonomic failure. OH is defined as a fall in 
more than 20 mmHg systolic blood pressure and/or a fall in diastolic blood pressure of at 
least 10 mmHg within 3 minutes on standing/head up tilting (to 60°)  (Lahrmann et al., 2006). 
Evidence of OH was coded as the most severe adrenergic impairment and was given a 
score of 5 in our scale (see Table 4.2).  
 
Changes in blood pressure and heart rate during the VM provide an assessment of the 
baroreflex pathways. The VM evokes characteristic BP hemodynamic responses, and its well 
known profile consists of 4 phases. Phase I is characterized by a transient rise in BP due to 
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the act of expiration, which is followed by a fall in BP due to reduced venous return (Phase II 
early; Phase II_E). Efferent sympathetic discharge subsequently occurs and causes a rise in 
BP (Phase II late; Phase II_L). Phase II_L is followed by a transient fall in BP corresponding 
to the termination of expiration and is a mechanical phase (Phase III) lasting 1-2 seconds. 
The fall in BP during phase III is promptly recovered as a result of increased venous return 
while the arterial vascular bed is still constricted. Hence, in normal subjects there is a 
transient BP overshoot after Phase III called Phase IV which confirms intact baroreflex 
function (Korner et al., 1976).  
 
The BP response during the VM can show different patterns of abnormalities. In sympathetic 
vasoconstrictor failure, the VM results in a continuous fall in blood pressure during Phases II 
and III with no stabilization; following release there is only a slow return to baseline without 
the overshoot, consistent with the lack of sympathetic vasoconstrictor function. This is 
evident with a reduced or absent late Phase II and/or absent Phase IV (Mathias, 2013). The 
adrenergic component of the baroreflex during the VM can also be evaluated by the BP 
recovery time (BPRT), which is the time (in seconds) that the BP takes to recover from phase 
III to pre VM baseline. BPRT is a good indicator of baroreflex adrenergic impairment and 
correlates with the presence and severity of adrenergic failure (Vogel et al., 2005). Patients 
with early sympathetic vasoconstrictor impairment can present with different degrees of BP 
response impairments to the Valsalva manoeuvre without clear evidence of OH. We scored 
abnormalities of the BP response to the Valsalva manoeuvre as 3 or 4 depending on the 
absence of phase II late or IV or both and whether the BPRT is also prolonged or not (see 
Table 4.1). BPRT was calculated offline using the data acquisition software (Chart, 
ADInstruments, Sydney, Australia). 
 
In previous autonomic scoring scales, adrenergic scores derived from the analysis of the VM 
also considered BP responses during phase II early (Phase II_E) with scores ranging from 1 
to 3 depending on the response in this phase. More specifically, a score of 1 was given if 
there was evidence of a Phase II_E decrease of <40 but >20 mmHg Systolic BP, a score of 2 
if there was a Phase II_E decrease of <40 but >20 mmHg mean BP and an absent phase II 
late or Phase IV, and a score of 3 if there was a Phase II_E decrease of >40 mmHg, an 
absent phase II late and IV (Low, 1993). However, we have found that the BP decrease 
during Phase II_E early was not a robust enough index considering that a pronounced Phase 
II_E BP decrease of >40 mmHg can present in some young and elderly normal control 
individuals. For this reason we decided to adopt a conservative approach and not include 
phase II early as part of our scoring system. For similar reasons we have only scored an 
absence of Phase II late and an abnormal Phase IV rather than just a reduced phase II_L. 
Page 76 
 
This is because even though Phase II_L is a reliable index of adrenergic function, this can be 
zero in mild adrenergic failure and in some elderly normal subjects and its quantitative value 
is limited (Vogel et al., 2005).  
 
A minimal impairment of sympathetic vasoconstrictor function without abnormalities in the 
VM and no OH can present with absent BP responses to some or all pressor response 
stimuli and we have graded this as 1 if the BP responses were compromised in 2 out of the 3 
pressor stimuli or 2 if the BP responses were absent to all pressor stimuli (see Table 4.1). 
 
4.2.1.2. Cardiovagal score.  
Cardiovagal function can be assessed by different methods, including changes in HR in 
response to deep breathing (DB), to HUT and Standing and to the Valsalva manoeuvre. 
Parasympathetic failure often manifests with impairment of HR responses to both deep 
breathing and the Valsalva manoeuvre. Absent HR responses to both deep breathing and 
the Valsalva manoeuvre are coded as the most severe cardiovagal impairment and given a 
score of 5. A reduced HR response to deep breathing can present in early stage diabetic 
peripheral neuropathy and cardiac autonomic neuropathy (Spallone et al., 2011) or in PD 
patients without OH (Buob et al., 2010). The impairment of cardiovagal function is scored as 
1 if there is a minimal impairment of the DB response (HR change during DB that is reduced 
but not less than 50% of normal age matched values), or a reduced Valsalva ratio (VR) (Low, 
1993), 2 or 3 if there is moderate impairment with a decrease of the DB response that is less 
than 50% of normal values or reduced VR, or both (Table 4.1). A severe impairment of 
cardiovagal function is scored as 4 if the HR response to DB is absent and the VR is 
reduced.  
 
4.2.1.3. Overactivity score 
Overactivity of the sympathetic pathway occurs in patients with autonomic (neurally) 
mediated syncope who often have an antecedent increase in sympathetic nerve activity 
which then progresses to a sudden fall in BP and HR (Cooke et al., 2009). A sympathetic 
‘surge’ is often associated with situations of increased alertness such as might occur in a 
subject who gets an injection or sees something unpleasant.  
 
Furthermore, evidence of parasympathetic activation and overactivity have been described in 
a sub-group of patients with AMS, where the fall in heart rate is due to increased cardiac 
parasympathetic activity and manifested as cardioinhibitory syncope (Mehlsen et al., 2008; 
Mathias, 2013). This also occurs in a subset of patients with PoTS who can have an 
elevation in parasympathetic outflow that precedes vasovagal syncope (Alshekhlee et al., 
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2008). Parasympathetic overactivity was characterised as a sudden drop in HR during HUT 
consistent with the cardioinhibitory form of AMS or a mixed form of AMS where a drop in BP 
is also associated with drop in HR and was scored as 4.  
 
Patients with the cardioinhibitory form of AMS have different hemodynamic profiles during 
orthostasis relative to patients with vasodepressor AMS, including, a slower activation of 
compensatory mechanisms and abnormal cardiovascular reflexes (Holmegard et al., 2012). 
In particular, patients with cardioinhibitory AMS are 1) unable to increase heart rate as fast 
as vasodepressor AMS patients; 2) often have a burst in plasma adrenaline at syncope 
(Vanderheyden et al., 1998) and 3) present with increased low frequency HR power and a 
low frequency/high frequency HR power ratio during active standing which suggests 
increased sympathetic nerve activity (Stauss, 2003). Given these temporal differences in 
hemodynamic profiles between cardioinhibitory and vasodepressor AMS patients, the 
vasodepressor form of AMS was scored as 3.  
 
The underlying pathophysiology of PoTS is heterogeneous and sympathetic overactivity of 
either a central or peripheral origin has been postulated (Bonyhay & Freeman, 2004, 2007). 
Regardless of the complex and varying pathophysiological mechanisms in PoTS, the 
common cardiovascular feature is the exaggerated HR rise in the upright position. In line with 
the clinical definition of PoTS, an enhanced sympathetic activity, manifested as a marked 
rise in heart rate of 30 bpm or greater occurring within 10 min of HUT or standing, or a heart 
rate while upright of >120 bpm, but without orthostatic hypotension (Mathias et al., 2012), 
was scored as 2. A minimal sympathetic overactivity can also be detected as an increased 
SBP response to pressor stimuli, as in patients with partial or complete afferent baroreflex 
failure (Mathias, 2013), and this was scored as 1 if there is an exaggerated response to at 
least 2 out of 3 pressor stimuli (Mathias et al., 2013b). 
 
 
4.2.1.4. Sudomotor score  
Sudomotor function was not assessed as it is not part of our autonomic screening tests and 
for this reason is not included in our cardiovascular autonomic function score.  
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Table 4.1. Cardiovascular Autonomic Function Score (CAF score) and 
Composite Autonomic Severity Score (CASS) 
1= absent BP responses to two pressor stimuli 1= Phase II E decrease of <40 but >20 mmHg 
mean BP or Phase II L does not return to 2= absent BP response to all three pressor stimuli 2= Phase II E decrease of <40 but >20 mmHg 
mean BP  + Phase II late or IV absent 3= Phase IIL or phase IV absent or prolonged BPRT 3= Phase II E decrease of > 40 mmHg + absent  
Phase II late and  IV
4= absent Phase IIL and Phase IV and prolonged BPRT 4= criteria for 3 + OH (systolic BP decrease of ≥ 30 
mmHg; mean BP decrease of ≥20 mmHg)
5= 4+ OH on HUT or standing
1= HRDB decreased (above 50% of normal value) or 
decreased VR
1= HRDB or VR mildly decreased (above 50% of 
minimum)
2= HRDB decreased to < 50% of normal value 2= HRDB or VR decreased to < 50% of minimum
3=  Both HRDB decreased to < 50% of normal value 
and reduced VR
3=  Both HRDB and VR decreased to < 50% of 
minimum
4= absent HRDB and reduced VR
5= absent HRDB and VR
1= exaggerated BP responses to 2 pressor stimuli 
2= sustained HR increase > 30 bpm on HUT for 10 
minutes or standing or 
3= spontaneous drop in BP and HR on HUT or standing 
consistent with AMS 
4= spontaneous drop in HR on HUT or standing 
consistent with cardiohinibitory AMS (pure or mixed 
form)
1= Single site abnormal on quantitative 
2= Single site < 50% of lower limit on 
quantitative sudomotor axon reflex test (on 
thermoregulatory sweat test, anhidrosis 25-50 %)
3=  Two or more sites < 50 % of lower limit on 
quantitative sudomotor axon reflex test (on 
thermoregulatory sweat test, anhidrosis > 50 %)
CARDIOVASCULAR AUTONOMIC FUNCTION SCORE 
Adrenergic score 
Cardiovagal score
Cardiovascular instability/ over activity score
COMPOSITE AUTONOMIC SEVERITY SCORE (CASS)
Sudomotor score
Adrenergic score 
Cardiovagal score
 
Abbreviations: AMS, autonomic (neurally) mediated syncope; BPRT, blood pressure recovery 
time; DB, deep breathing; HR, heart rate; HUT, head-up tilt; OH, Orthostatic Hypotension; 
Phase IIL, Phase II late; VR, Valsalva ratio. 
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Table 4.2 Outline of cardiovascular autonomic function screening tests  
and derived CAF score 
HUT
Standing test
VM
DB 
Pressor response 
Cutaneous cold
Isometric exercise
Mental arithmetic 
BP responses HR responses
Autonomic Function Tests
 
Abbreviations: HUT, head-up tilt; VM, Valsalva manoeuvre; DB, deep breathing   
 
Colour codes:  
Adrenergic score
Cardiovagal score
Cardiovascular instability/ over 
activity score
 
 
4.2.2. Statistical analyses 
Data are presented as mean (± 1 SD). The Kruskal-Wallis test was used to compare 
cardiovascular autonomic function test and CAF scores between autonomic failure patient 
groups and intermittent disorder patient groups. If there was a significant main effect, Mann-
Whitney U tests were then used to compare between 2 specific patient groups with 
Bonferroni corrections. All tests were 2-sided and a p value of <0.05 was considered 
significant. 
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4.3. Results 
We studied 409 individuals with chronic primary autonomic failure, intermittent autonomic 
dysfunction and healthy normal controls. Patients and healthy controls for the chronic 
primary autonomic failure disorders group included 54 patients with MSA, 39 with PD (17 
without and 22 with AF), 20 with PAF, 21 with peripheral neuropathy (12 with familial 
amyloidosis, 5 with diabetic peripheral neuropathy, 4 with sensory motor peripheral 
neuropathy; of whom 9 had and 12 did not have AF) and 23 healthy controls. Patients and 
healthy controls for the intermittent autonomic disorders group included 181 with PoTS, 38 
AMS, and 33 healthy controls. Patient characteristics are described in Table 4.3.  
 
Table 4.3 Characteristics of patient and healthy control groups 
 
Diagnosis N of patients Age (yrs) Disease duration (yrs)
MSA 54 (33 M) 61± 8 5±2
PD 39 (26 M) 68 ± 8 7±3
PAF 20 (14 M) 69 ± 9 7.5± 5
Peripheral Neuropathy 21 (11 M) 56 ± 14
Normal control 23 (10 M) 56 ± 9 N/A
PoTS 181 (23 M) 30 ± 10 14±9
AMS 38 (10 M) 44 ± 15
Normal control 33 (16 M) 36± 14  N/A
 
Abbreviations: Multiple system atrophy (MSA), Parkinson's disease (PD), Pure autonomic 
failure (PAF), Postural Tachycardia Syndrome (PoTS); Autonomic (neurally) mediated syncope 
(AMS)  
 
 
4.3.1. Autonomic function tests and CAF score in chronic primary 
autonomic failure 
 
4.3.1.1. Autonomic function tests  
Autonomic function test results are described in the following section and also illustrated in 
Table 4.4. Supine SBP was significantly higher in PAF compared with normal controls 
(P<0.05), while there was no difference between MSA, PD_AF and NC. The fall in BP on 
HUT was greater in patients with MSA, PAF and PD_AF compared with PD, Peripheral 
neuropathy with and without AF (P< 0.01) and controls (P< 0.001). The drop in SBP and 
DBP on HUT was significantly greater in PAF compared with MSA patients (P<0.01 and 
P<0.05, respectively). Patients with peripheral neuropathy_AF showed a greater change in 
SBP and DBP on HUT compared with normal controls (both P<0.05). PD and peripheral 
neuropathy patients without AF showed no difference in the changes in SBP and DBP on 
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HUT compared with NC. OH was present in 51/54 MSA patients (94%), in all patients with 
PAF and PD_AF and 9/21 (33%) patients with peripheral neuropathy. There was no 
difference in HR on HUT between all patient groups and NC. 
 
BP responses (delta SBP) to isometric exercise were significantly reduced in patients with 
MSA and PAF compared with NC and PD_AF (P<0.01) and there was no difference 
between Peripheral_AF and NC. BP responses to mental arithmetic were significantly 
reduced in patients with MSA compared with other patient groups and NC (P<0.05).The BP 
responses to MA were not different between PD patients with and without AF, peripheral 
neuropathy with and without AF, PAF and normal controls. The BP responses to the cold 
pressor test were significantly reduced in patients with PAF compared with other patient 
groups and NC (P<0.01). There was no difference in the SBP response to the cold pressor 
test between MSA and PD_AF. PD and peripheral neuropathy patients without AF showed 
no difference in BP responses to pressor stimuli compared with NC. 
 
Compared to NC, the HR response to deep breathing was significantly reduced in patients 
with AF (MSA, PAF, PD_AF and Periph_AF; P<0.01), moderately reduced in patients with 
PD_No AF (P<0.05) with no difference between Periph_No AF and normal controls. The 
Valsalva ratio was significantly reduced in patients with MSA and PAF and Periph_AF 
compared with NC (P<0.01). PD and peripheral neuropathy patients without AF showed no 
difference in the Valsalva ratio compared with NC. PRT was significantly prolonged in 
patients with AF (MSA, PD_AF and PAF) compared to NC (P<0.01) and PRT was 
significantly increased in MSA compared to PD_AF (P<0.05). PRT was also prolonged in 
patients with PD_No AF compared with NC (P<0.05). 
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Table 4.4 Autonomic function tests in patients with chronic autonomic disorders  
 
MSA PAF NC
AF No AF AF No AF
Supine SBP 138 ± 22 150 ± 29 
$ 138 ± 24 127 ± 16 138 ± 25 124 ± 12 130 ± 18 
Supine DBP 81 ± 12 83 ± 14 75 ± 12 71 ± 10 75 ± 10 70 ± 8 74 ± 7 
Supine HR 75 ± 10 64 ± 10 66 ± 11 64 ± 10 77 ± 13 75 ± 11 68 ± 8
Δ SBP (Supine-9' HUT)
47 ± 22 
$$$
66 ± 20 
$$$
 42 ± 17
$$$  7 ± 7 31 ± 11
$$$ 6 ± 19 1 ± 13
Δ DBP ( Supine-9' HUT) 21 ± 13 
$$$
30 ± 15 
$$$
13 ± 10 
$$$  -3 ± 6 9 ±11 
$$ 2 ± 5  5 ± 4
Isometric exercise (∆ SBP) 0.75 ± 10 
$
 -3 ± 10 
$ 12 ± 20 26 ± 18 15 ± 15 11 ± 13 15 ± 9 
Mental arithmetic (∆ SBP)  -1.1 ± 7 
$  11 ± 15 12 ± 12 17 ± 13  1 ± 8 11 ± 15 8 ± 7 
Cutaneous cold (∆ SBP) 8 ± 11 2 ± 9 
$$  14 ± 8 12 ± 7  9 ± 10 10 ± 11 17 ± 12
Valsalva ratio
1.2 ± 0.3 
$$ 
1.1 ± 0.3
$$ 1.5 ± 0.6 1.5 ± 0.2 1 ± 0.07 
$$ 1.3 ± 0.2 1.6 ± 0.3 
Deep Breathing 5 ± 3 
$$$
 4 ± 2.5 
$$$
5 ± 3
 $$$
9.4 ± 3 
$
 4 ± 3 
$$$ 12 ± 5 16 ± 8
PRT 23 ± 16 
$$
 30 ± 12 
$$
13 ± 8
 $$
6 ± 12 
$  -  - 1 ± 0.6
PD Peripheral Neuropathy
 
Abbreviation: MSA, Multiple system atrophy; PD, Parkinson's disease; PAF, Pure autonomic failure; AF, autonomic failure; NC, 
normal control.  $ P<0.05, $$ P< 0.01, $$$ P< 0.001 vs. NC
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4.3.1.2. CAF score in Chronic primary autonomic failure 
Patients with MSA and PAF and PD_AF and Perip_AF had the highest adrenergic and 
cardiovagal scores among patients with neurodegenerative disorders and were significantly 
higher compared with NC (P<0.001). There was no difference in adrenergic and cardiovagal 
scores between MSA and PD_AF and no differences between MSA and PAF patients (see 
Table 4.5). Patients with PD_No AF and Periph_No AF had significantly higher adrenergic 
and cardiovagal scores compared with NC (P<0.05 and P<0.01, respectively). More 
specifically, in both these patient groups the adrenergic impairment consisted of an absent 
Phase II_L and Phase IV and prolonged BPRT (adrenergic score = 4) in 4/17 (24%) and 
3/12 (25%) patients with PD_No AF and Perip_No AF, respectively. Also a mild adrenergic 
impairment score with absent responses to 2 pressor stimuli (adrenergic score = 1) was 
present in 3/12 (25%) with Perip_No AF. When comparing PD patients with and without AF, 
PD patients with AF had higher adrenergic and cardiovagal scores compared to PD_No AF 
(P< 0.001; see Table 4.5). 
 
Table 4.5 CAF score in Chronic autonomic disorders 
Diagnosis Adrenergic Cardiovagal Overactivity Total
MSA 4.8 ± 1 
$$$
2.2 ± 1 
$$$ 0 7 ± 1.4
$$$
PAF 5 ± 0 
$$$
2.6 ± 1.4 
$$$ 0 7.6 ± 1.4
$$$
AF 5 
$$$
2 ± 1.1 
$ 0 7 ± 1.2 
$$$ 
No AF 1 ± 1.8 
$
0.9 ± 0.9 
$ 0.1 ± 0.4 2.1 ± 2 
$
AF 5 
$$$
1.8 ± 1.8 
$$ 0.1± 0.3 6.3 ± 1.6 
$$$
No AF 1.2 ± 1.7 
$$
1 ± 1.3 
$$ 0 2.2 ± 2
$$
NC 0 0.1 ± 0.3 0.1 ± 0.5 0.2 ± 0.7
PD
Peripheral Neuropathy
Abbreviation: MSA, multiple system atrophy; PAF, pure autonomic failure; PD, 
Parkinson's disease. $ P<0.05, $$ P< 0.01, $$$ P< 0.001 vs. NC 
 
4.3.2. Autonomic function tests and CAF score in Intermittent autonomic 
disorders 
 
4.3.2.1. Autonomic function tests  
Supine SBP was significantly lower in patients with PoTS compared with normal controls (P< 
0.01). HR while supine and on HUT and standing was significantly higher in PoTS compared 
with AMS and NC (P<0.001). SBP on HUT was significantly lower in patients with AMS 
compared with NC (P<0.05). There were no differences in supine and HUT DBP among 
patient groups and normal controls (see Table 4.6). 126/181 (70%) patients with PoTS met 
the diagnostic criteria on HUT or standing. The remaining patients met the criteria for PoTS 
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during the liquid meal challenge or the modified exercise test (see Chapter 7). Syncopal 
episodes of the vasodepressor form occurred on HUT in 14/38 (37%) patients with AMS and 
21/181 (11%) with PoTS. A cardioinhibitory form of AMS on HUT occurred in 5/38 (13%) 
patients with AMS and 3/181 (1.6%) patients with PoTS. There were no patients with the 
mixed form of AMS. 
 
BP responses (delta SBP) to isometric exercise were significantly reduced in patients with 
PoTS compared to AMS and NC (P<0.01). There were no differences in BP responses 
(delta SBP) to mental arrhythmic and cold pressor tests between patients and normal 
controls. There was no difference in the HR response to deep breathing and the Valsalva 
ratio between patients and normal controls. BPRT was normal in patients with intermittent 
autonomic disorders. 
 
Table 4.6 Autonomic function tests in patients with  
intermittent autonomic disorders and healthy controls 
PoTS AMS NC
Supine SBP 113 ± 11 
$$
117 ± 18 121 ± 11
Supine DBP 66 ± 7 68 ± 8 68 ± 7
Supine HR 70 ± 12 
$$
65 ± 10 * 64 ± 8
9' HUT SBP 114 ± 17 110 ± 21 
$
119 ± 20
9' HUT DBP 72 ± 10 70 ± 11 72 ± 10
9' HUT HR 96 ± 16 
$$$
79 ± 11*** 78 ± 9
∆ HR 9' HUT 26 ±13 
$$$
13 ± 7 14 ± 8
∆ HR 5' Standing 28 ± 13 
$$$
18 ± 7 
$ 
6 ± 8
Isometric exercise
∆ SBP 15 ± 12
 $$
19 ± 12 21 ± 11
∆ SBP 7 ± 9 7 ± 9 9 ± 12
Cutaneous cold
∆ SBP 13 ± 11 16 ± 11 11 ± 7
Valsalva ratio 2 ± 0.4 2 ± 0.3 2 ± 0.3
Deep Breathing 19 ± 7  18 ± 9 19 ± 7
Mental arithmetic
 
Abbreviations: Postural Tachycardia Syndrome (PoTS); Autonomic (neurally) mediated 
syncope (AMS). 
$ 
P<0.05, 
$$ 
P< 0.01, 
$$$
 P< 0.001 vs. NC, * P<0.05, ** P<0.01 *** P<0.001 vs. 
PoTS 
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4.3.2.2. CAF score in Intermittent autonomic disorders 
The Overactivity score was above 0 in 79% of the intermittent disorder patients. More 
specifically, it was 1, indicative of mild overactivity (exaggerated response to 2 pressor 
stimuli) in 22% of the patients; 2, consistent with exaggerated increase of HR > 30 bpm on 
HUT or standing in 61%; 3, consistent with AMS of the vasodepressor form in 12%, and 4, 
evidence of AMS of the cardioinhibitory type in 2% of the patients. Cardiovascular 
overactivity and total scores were significantly higher in PoTS and AMS compared with 
healthy controls (P<0.001; see Table 4.7).  
 
In patients with PoTS, adrenergic and cardiovagal scores were normal (score=0) in 96% and 
84% of the patients, respectively. The remaining patients showed mild adrenergic 
impairment (adrenergic score = 1, absent BP responses to two pressor stimuli) in 3% of the 
patients and mild cardiovagal impairment in 15% of the patients (cardiovagal score = 1, 
reduced HR response to deep breathing). AMS patients had normal adrenergic and 
cardiovagal scores in 95% and 72% of the patients, respectively. Only mild adrenergic and 
cardiovagal dysfunction were present in the remaining patients (score = 1). An Overactivity 
score of 1 was present in 10 % of the patients, while 36% had a score of 3 and 13% a score 
of 4, consistent with evidence of vasodepressor and cardioinhibitory forms of AMS, 
respectively.  
 
Table 4.7 CAF score in PoTS, AMS and healthy controls 
Diagnosis Adrenergic Cardiovagal Overactivity Total
PoTS 0.04 ± 0.2 0.1 ± 0.3 1.6 ± 0.9
 $$$
1.8 ± 1.1 
$$$
AMS 0.05 ± 0.2 0.2 ± 0.4  1.7 ± 1.5 
 $$$
2 ± 1.6 
$$$
Normal control 0 0.03 ± 0.1 0.1 ± 0.3 0.1 ± 0.3
 
Abbreviations: Postural Tachycardia Syndrome (PoTS); Autonomic (neurally) mediated 
syncope (AMS). 
$ 
P<0.05, 
$$ 
P< 0.01, 
$$$
 P< 0.001 vs. NC 
 
When evaluating AMS patients who presented with a syncopal episode during HUT, either of 
the vasodepressor or the cardioinhibitory form, there were no differences in adrenergic and 
cardiovagal scores compared with AMS patients who did not present with a syncopal 
episode during head up tilting (both P<0.05). 
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4.4. Discussion 
The aim of this study was to develop a quantitative severity score from our cardiovascular 
autonomic function screening tests for patients with different degrees of autonomic 
impairment (autonomic failure and intermittent autonomic disorders). We designed a 
cardiovascular autonomic function scoring (CAF score) system, adapted from an existing 
cardiovascular autonomic function grading scale (Low, 1993), able to quantify the degree of 
adrenergic and cardiovagal dysfunction and overactivity of cardiovascular autonomic 
function in patients with different impairments of the autonomic nervous system. The CAF 
score was able to quantify the degree of cardiovascular autonomic function impairment and 
differentiate between patients with severe and widespread autonomic failure (MSA, PAF and 
PD_AF), moderate autonomic impairment (PD no_AF and peripheral neuropathy_AF), and 
peripheral neuropathy without autonomic impairment and normal controls. Furthermore, the 
CAF score was also able to quantify the degree of autonomic dysfunction in patients with 
intermittent autonomic disorders who can present with mild adrenergic impairment, as in 
patients with PoTS, and features of overactivity of both the sympathetic and parasympathetic 
systems leading to an excessive increase of HR while upright or AMS either of the 
vasodepressor or cardioinhibitory type.    
 
A standardized battery of autonomic function tests provides a reproducibile and non-invasive 
assessment of cardiovascular autonomic function and is able to detect cardinal features of 
autonomic impairment, such as postural hypotension in patients with a likely generalized 
autonomic disorder as well as postural tachycardia and autonomic (neurally) mediated 
syncope in patients with intermittent autonomic dysfunction (Mathias, 2013). It is also quite 
common to grade autonomic impairment using a severity score based on the results of 
cardiovascular autonomic function screening tests in patients with suspected autonomic 
dysfunction in order to provide a quantitative measure of overall autonomic dysfunction, 
define the distribution and the degree of autonomic involvement and detect differences in 
autonomic involvement between disorders and/or track changes in autonomic involvement 
over time. The majority of cardiovascular autonomic function screening tests are directed 
torwards the determination of autonomic failure, however, and there is currently only one 
cardiovascular autonomic function grading scale; the Composite Autonomic Severity Scale 
(CASS), which is directed at grading autonomic impairment in patients with widespread 
autonomic failure (Low, 1993). However, autonomic overactivity is of importance in patients 
with intermittent autonomic disorders. Cardiac vagal activity can be increased in patients 
with AMS and  paroxysmal hypertension is present in patients with high spinal cord injury 
(Mathias, 2006; Weaver et al., 2012). The Composite Autonomic Severity Scale, therefore, is 
of little use in patients without damage to the autonomic nervous system but with intermittent 
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autonomic dysfunction because it only scores for indexes of autonomic failure, or 
underactivity, and not exaggerated or overactivity of the autonomic nervous system. A need 
therefore exists for a sensitive scoring scale that is able to quantify autonomic impairment as 
characterised by overactivity of the autonomic nervous system and can provide a grading of 
autonomic function early, when treatment has the greatest potential of success. 
Furthermore, evaluation of therapeutic benefits from advances in molecular biology, 
genetics, pharmacology, and other sciences will require high sensitivity and specificity 
scoring which could be used as an end point for clinical trials.  
 
Among patients with intermittent autonomic disorders we evaluated the autonomic scoring in 
patients with PoTS and AMS and the CAF score provided a sensitive and specific index of 
defining the severity of autonomic impairment in these patient groups. This study confirmed 
that patients with intermittent autonomic disorders generally do not have damage to the 
autonomic nervous system. Only a mild adrenergic and cardiovagal impairment was present 
in a subgroup of PoTS patients which would be consistent with a possible limited autonomic 
neuropathy in some of these patients (Jacob et al., 2000; Singer et al., 2004). Overactivity of 
both sympathetic and parasympathetic nervous systems has been postulated in PoTS and 
This study quantified this in terms of confirmed evidence of exaggerated increases of HR > 
30 bpm on HUT or standing in 61% of the patients emphasizing the concept that a screening 
cardiovascular autonomic evaluation alone is not always able to capture the full spectrum of 
orthostatic intolerance and not always sufficient to reveal a PoTS diagnosis and hence 
quantify their autonomic dysfunction. Overactivity of both sympathetic and parasympathetic 
systems, manifested as AMS of either the vasodepressor or cardioinhibitory type, was 
confirmed in 14% of the AMS patients using the screening cardiovascular protocol and was 
reflected in higher CAF score compared to normal controls. 
 
In the present study the widespread autonomic failure in patients with MSA, PAF, PD_AF, 
and Perip_AF. was confirmed by the highest CAF scores compared with patients with 
moderate autonomic impairment (PD_No AF and Periph_No AF) and no autonomic 
impairment (normal controls). Adrenergic scores were higher in these patients with 
widespread autonomic failure compared with patients with moderate or mild adrenergic 
impairment. OH, coded as the most severe adrenergic impairment with an adrenergic score 
of 5, was present in 94% of patients with MSA and 42% of patients with PD. This is in line 
with previous studies confirming the high frequency of OH in PD (Piha et al., 1988; Senard et 
al., 1997). However, the presence of orthostatic hypotension does not separate MSA from 
PD with AF (Smith & Mathias, 1996; Riley & Chelimsky, 2003; Lipp et al., 2009; Kimpinski et 
al., 2012b). Furthermore, in this study orthostatic hypotension was more pronounced in PAF 
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patients compared with MSA, which has been described previously (Mabuchi et al., 2005) 
and is consistent with the degree of autonomic failure, which often is more severe and 
possibly of a more rapid onset in PAF than in MSA. Compensatory mechanisms, including 
those affecting the cerebral vasculature, are more likely to be operative in MSA than in PAF 
(Brooks et al., 1989). 
 
In PD patients without OH (PD_No AF) there was evidence of impaired cardiovagal function 
confirmed by significantly higher cardiovagal scores compared with normal controls. It was 
also present as a mild adrenergic impairment, including abnormal BP responses to the VM 
(absent phase II_L and IV) and prolonged BPRT, as confirmed by an adrenergic score of 4 
in 24% of the patients. The latter is of great clinical relevance as PD patients could have an 
early autonomic impairment before the widespread autonomic failure presents which impacts 
their quality of life. CAF score was able to quantify adrenergic and cardiovagal impairments 
in these patients and it may be a helpful quantitative measure of autonomic non-motor 
dysfunction in PD. Early involvement of the autonomic nervous system in PD has been 
emphasized in many studies (Buob et al., 2010; Oka et al., 2011) which is of importance 
considering that non-motor dysfunction, and in particular early autonomic impairment, can 
affect quality of life in patients with PD (Duncan et al., 2013; Song et al., 2013). Autonomic 
impairment was also quantified in patients with peripheral neuropathy without OH. In this 
patient group adrenergic impairment was present in 25% of the patients. Cardiovagal 
function was moderately impaired in 41% of the patients. A subclinical involvement of the 
autonomic nervous system has been previously documented in patients with peripheral 
neuropathy (Stamboulis et al., 2006; Rocchi et al., 2011).  
 
 
In conclusion, patients with different autonomic disorders could be detected and 
differentiated and their autonomic impairment could be quantified by the CAF score. The 
CAF score was able to quantify the degree of autonomic overactivity in patients with 
intermittent autonomic disorders and could be a helpful tool not just to detect impairments 
but also to track changes in autonomic involvement in response to individual treatments 
and/or for use in prospective controlled therapeutic trials.  
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5. Chapter Five: Assessment of Autonomic Symptoms in Autonomic Disorders: 
AUTONOMIC and musculoskeletal QUESTIONNAIRE AND QUALITY OF LIFE 
SCOREs (AQQoL)Introduction 
Cardiovascular and sudomotor autonomic dysfunction is detected using various physiological 
tests. These tests only measure objective signs of cardiovascular and sudomotor autonomic 
dysfunction however, and do not investigate subjective symptoms of cardiovascular and 
sudomotor autonomic dysfunction, as well as symptoms of other autonomic domains such as 
bladder, gastrointestinal, vasomotor, sleep and sexual function and allied non-autonomic 
features, such as musculoskeletal function, which can frequently and simultaneously occur in 
a number of autonomic disorders. Moreover, physiological tests do not evaluate the impact of 
the subjective symptoms of autonomic dysfunction on overall daily, or quality, of life.  
 
Measures of autonomic symptoms and quality of life are increasingly being recognized as 
important outcome measures for clinical trials in autonomic disorders. Autonomic symptoms 
and quality of life scores may be valuable for assessing the effects of symptomatic 
treatments and also disease-modifying and neuroprotective agents. This has only been 
partially addressed in patients with neurodegenerative disorders such as MSA (Wenning et 
al., 2004; Damon-Perriere et al., 2012; Kaufmann et al., 2012; Meissner et al., 2012) and PD 
(Visser et al., 2004; Wenning et al., 2004; Chaudhuri et al., 2006) but has not been evaluated 
in patients with intermittent autonomic disorders, and in particular PoTS, who often present 
with severe disability and multi-system involvement (Mathias et al., 2012). Little is known 
about the quality of life and its determinants, including allied features such as 
musculoskeletal function, in patients with PoTS (Benrud-Larson et al., 2002; Kimpinski et al., 
2012a).  
 
The Autonomic Symptom Profile (ASP) or Composite Autonomic Symptoms Scale 
(COMPASS) (Suarez et al., 1999) is the only validated autonomic multi-domain instrument 
designed to evaluate the severity and distribution of autonomic symptoms in patients with 
different autonomic disorders and has been used in many autonomic function research 
studies (Benrud-Larson et al., 2002; Low et al., 2004; Thaisetthawatkul et al., 2004; Benrud-
Larson et al., 2005). There are a few problems that have however limited the use of this 
questionnaire over time, including: 1) the highly time consuming and complicated algorithm 
integral to the COMPASS; and, 2) the presence of redundant questions for scoring 
autonomic symptoms (Sletten et al., 2012). These limitations have been addressed with a 
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revised version of the COMPASS (COMPASS 31) which includes 31 questions in 6 domains 
(Sletten et al., 2012) and is easy to administer and provides an autonomic multi-domain 
score. This revised version has so far only been evaluated in normal healthy control 
individuals however. Furthermore, the COMPASS 31, as well as single domain 
questionnaires previously validated in patients with neurodegenerative disorders or in 
patients with PoTS (Visser et al., 2004; Wenning et al., 2004; Schrezenmaier et al., 2005; 
Chaudhuri et al., 2006; Damon-Perriere et al., 2012; Kaufmann et al., 2012; Meissner et al., 
2012), do not address the need for a comprehensive autonomic symptoms and quality of life 
instrument.  Indeed, there are no multi-domain symptom assessment tools that also assess 
the impact on quality of life for each autonomic domain. Therefore, there is a need for a self-
completed questionnaire that at the same time assesses autonomic symptoms and the 
impact on daily life in a range of autonomic and allied domains in a broad spectrum of 
autonomic disorders.  
 
Patients with PoTS, AMS and Hyperhidrosis can present with non-autonomic allied features, 
such as musculoskeletal involvement and small fibre dysfunction (Mathias et al., 2013a). 
Assessing these allied features is crucial in terms of diagnosis, prognosis and management 
of these patients. Also for young adults, musculoskeletal impairment is a major cause of 
activity limitation and a key component which needs to be taken in account into the overall 
evaluation of quality of life in patients with chronic conditions (Verbrugge & Patrick, 1995). 
Autonomic questionnaires currently available focus on either peripheral involvement of the 
autonomic nervous system or have been designed mainly for patients with chronic primary 
autonomic failure, and therefore may not be sufficient to accurately assess musculoskeletal 
impairments and the degree of chronic fatigue and/or sleep problems which can occur in 
patients with PoTS and intermittent autonomic disorders (Hoad et al., 2008; Bagai et al., 
2013). There is also a strong familial component in several autonomic disorders, which can 
raise the possibility of genetic predisposition in these patients. However, the prevalence of 
familial autonomic dysfunction, especially in patients with intermittent autonomic disorders 
has not been thoroughly investigated. 
 
Therefore, the aim of this study was to design and validate a self completed questionnaire 
that assesses a range of autonomic domain symptoms, quality of life and allied non-
autonomic features in a large cohort of autonomic disorders, including peripheral 
neuropathies (diabetes, amyloidosis), intermittent autonomic disorders; PoTS, AMS and 
Hyperhidrosis, chronic primary autonomic failure (PAF, MSA, PD), and normal controls. More 
specifically, it was intended to examine the prevalence of autonomic symptoms and the 
relative quality of life, assess which sub-domain(s) of symptoms have the biggest impact on 
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a patient’s quality of life and evaluate the frequency of familial autonomic dysfunction in a 
cross-section of various intermittent and chronic autonomic disorders. 
 
5.2. Methods 
Experimental Design 
The AQQoL was designed to provide a broad evaluation of autonomic, as well as some allied 
non-autonomic, symptoms in several autonomic disorders. The questionnaire items were 
based on our clinical experience of autonomic disorders and a review of related literature 
(See Appendix 1 for the AQQoL). The AQQoL consists of 98 questions divided in 8 
autonomic function domains: Orthostatic Intolerance (OI, 30 questions), 
Gastrointestinal (GI, 11 questions), Bladder (BLD, 7 questions), 
Vasomotor/Secretomotor (VSM, 4 questions), Sudomotor (SDM, 11 questions), Muscle-
skeletal-connective (MSC, 27 questions), Sleep (Sp, 5 questions) and Sexual dysfunction 
in men (Sdys, 3 questions) and additional questions regarding medications, familial history of 
Sudomotor, Muscle-skeletal-connective, and Orthostatic Intolerance or other neurological 
disorders. 
 
Each symptom in each domain was assessed by two questions: the frequency of the 
symptom ("How often do you experience this problem?") followed by a question addressing 
the impact of each symptom on the patient’s daily activities/quality of life (if they answered 
that they did experience the symptom in the previous question). The frequency score was 
assessed on a 5 point scale (see Figure 5.1), ranging from 0 (never) to 4 (daily) for each 
question. A total frequency domain score was calculated as the sum of all of the scores for 
each symptom within each domain. Quality of life (QoL) for each symptom was scored on a 3 
point scale, ranging from 0 (no impact on quality of life) to 2 (Severe impact. It limits most of 
my daily activities). A total Quality of life (QoL) domain score was calculated as the sum of all 
of the scores for each symptom within each domain. A total Frequency and a total QoL score 
were calculated as the sum of the total domain Frequency and QoL scores. The number of 
questions in each domain and the possible maximum scores are presented in Table 5.1. 
Sexual dysfunction is only evaluated in men; the maximum score was therefore different 
between men and women. 
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FREQUENCY SCORE                                          QUALITY OF LIFE SCORE 
 
Figure 5.1 Example of Frequency and Quality of Life Scores for each symptom 
assessed in the AQQoL. The frequency score expresses the frequency of symptoms 
on a 5 point scale and the Quality of life score is scored on a 3 point scale. 
 
Table 5.1 The total AQQoL domain questions and maximum possible frequency 
(top panel) and quality of life (QoL) scores 
 
Question N Max score 
OI 30 120
GI 11 38
Bladder 7 28
Vasomotor/secretomotor 4 16
Sudomotor 11 44
Muscoloskeletal 27 32
Sleep 5 5
Sexual 3 3
Total Autonomic score
Male 254
Female 251
OI QoL 22 44
GI QoL 9 18
Bladder QoL 7 14
Vasomotor/secretomotor QoL 4 8
Sudomotor QoL 11 22
Muscoloskeletal QoL 18 36
Sleep QoL 5 10
Sexual QoL 3 6
Total QoL score
Male 158
Female 152
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5.2.1.  Participants 
Participants consisted of healthy volunteers and 7 patient groups with different intermittent 
and chronic autonomic disorders. The total sample consisted of consecutive patients seen in 
the London Autonomic Units from March 2011 to March 2013 with the following confirmed 
diagnosis: PoTS, AMS, Hyperhidrosis, MSA, PAF, PD with and without AF, Peripheral 
neuropathy with and without AF. Patients were asked in clinic or sent a questionnaire in the 
post and underwent autonomic function tests as briefly described below and outlined in the 
Methods chapter. 
 
5.2.2. Validation 
The AQQoL was compared with the Cardiovascular Autonomic Function Score (CAF score, 
see Chapter 4) to assess the degree of criterion validity. The CAF score consists of a battery 
of cardiovascular autonomic function tests from which a severity score of autonomic 
impairment is derived which objectively quantifies the degree of autonomic impairment in 
patients with chronic and intermittent autonomic disorders.   
 
5.2.3. Autonomic function tests 
Patients underwent the following cardiovascular autonomic function tests: 
8. HUT (10 min rest in the supine position on a tilt bed and then tilted at 60 degrees 
head up for up to 10 min). 
9. Isometric Exercise. 3 min of handgrip exercise at 30% of maximal voluntary force.  
10. Cold Pressor Test. 3 min of a cold pack applied to the hand. 
11. Mental arithmetic. 2 min of  subtracting 7 or 17 from a suitable starting number (e.g. 
400 or 1000) 
12. Deep Breathing. Breathing at a rate of 6 breaths per minute for 1 min.  
13. Standing test. Standing still for up to 5 minutes after 10 min supine rest. 
14. Valsalva maneuver. 20 s of a single breath against a fixed resistance (40 mmHg).  
 
In all tests blood pressure was monitored continuously using digital photoplethysmography 
and/or intermittently using upper arm sphygmomanometry. Heart rate was continuously 
monitored via 5 electrode patches taped to the chest. 
 
5.2.4. Quality of Life  
A subset of patients and normal controls (a total of 40 individuals) were also asked to 
complete the 36-Item Short-Form Health Survey (SF36), in order to assess the degree of 
criterion validity of the AQQoL quality of life scores with an established and validated quality 
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of life questionnaire (Manocchia et al., 1998). The SF-36 is a self-reported questionnaire that 
has been used to assess quality of life in various medical populations, and consists of 36 
items that define 8 category scales: physical functioning (PF), role limitation caused by 
physical problems (RP), bodily pain (BP), general health (GH), vitality (VIT), social 
functioning (SF), role limitation caused by emotional problems (RE), and mental health (MH). 
Scales range from 0 to 100 and a higher score indicates better quality of life. The 8 category 
scales are often aggregated in 2 summary scales: the physical component summary scale 
(PCS) and the mental component summary scale (MCS). 
 
5.2.5. Statistical design 
Statistical analyses were performed using SPSS. Data are presented as mean (SD) or 
median (interquartile range), where appropriate. The Kruskal-Wallis test was used to 
compare the frequency and quality of life autonomic domain scores between patient groups. 
A Bonferroni correction was applied for multiple comparisons, with a correction factor derived 
from the number of patient groups included. Generally, patient groups were divided into 
chronic autonomic failure or intermittent autonomic disorders and an appropriate age-
matched normal control group was also included within each broad group. For example, 
patients with widespread autonomic failure were grouped together (MSA, PAF, PD_AF, 
peripheral neuropathy_AF). Patients with peripheral neuropathy No_AF were compared with 
peripheral neuropathy_AF. Patients with PD no AF were compared with PD_AF. Intermittent 
autonomic disorders (PoTS, AMS, Hyperhidrosis) were grouped together. Spearman rank 
order correlations were used to examine relationships between categorical variables (Total 
AQQoL Frequency and QoL scores with CAF score and SF36 scores). Multiple regression 
analysis was conducted to determine the effect of various autonomic domains on quality of 
life scores. Autonomic domains (predictors) that showed significant differences in patients 
groups compared with normal controls were entered into the model using backward selection 
to the point where only those variables that were significant predictors remained in the 
model. The multiple coefficient of determination (R2) was used as the goodness-of-fit statistic 
for the model: it represents the proportion of variance in the outcome variable that can be 
accounted for by the predictor(s) in the model. Statistical significance was defined as a p 
value <0.05. 
 
5.3. Results 
A total of 266 patients agreed to participate in the study with an overall response rate of 89%. 
The aetiology of patients was as follows: PoTS (n=79), MSA (n=19), PD with and without 
autonomic failure (n=10), PAF (n= 9), Hyperhidrosis (n=11), Autonomic (neurally) mediated 
syncope (n=37) and peripheral neuropathy with and without AF (n=21). Forty healthy controls 
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were enrolled in the study. We included these patient groups to test the construct validity of 
the AQQoL on a broad spectrum of patients with autonomic disorders. A sub-group of 40 
participants (patients and healthy controls) also completed the SF 36. Demographic data of 
the subjects are described in Table 5.2 
 
Table 5.2 Participant characteristics 
Diagnosis N of patients Age (yrs)
MSA 19 (11 M) 60 ± 8
PAF 9 (5M) 67 ± 8
PD_AF 5 (3M) 67 ± 9
PD _ No AF 5 (3M) 63 ± 2
Peripheral Neuropathy_AF 14 (9M) 55 ± 16
Peripheral Neuropathy_ No AF 7 (2M) 59 ± 10
Controls 11 (5M) 59 ± 9
PoTS 79 (9 M) 33 ± 11
AMS 37 (8 M) 44 ± 15
Hyperhidrosis 11 (8M)  38 ± 12
Controls 28 (15M)  38 ± 18
 
Abbreviation: MSA, multiple system atrophy; PD_AF, Parkinson's disease with 
autonomic failure; PD_ No AF, Parkinson's disease without autonomic failure; Peripheral 
Neuropathy _AF, peripheral neuropathy with autonomic failure; Peripheral Neuropathy_No 
AF, peripheral neuropathy without autonomic failure; AMS, Autonomic (neurally) mediated 
syncope 
 
5.3.1. Autonomic cardiovascular function in Intermittent and chronic 
autonomic disorders 
 
Patients included in this study also were included in the CAF score validation study (Chapter 
4) where the results of their cardiovascular autonomic function tests were presented (see 
section 4.3). Therefore, for conciseness, their cardiovascular autonomic function data will not 
be re-presented here.  
 
5.3.1.1. Autonomic symptom domains and quality of life in Chronic autonomic 
failure disorders 
 
5.3.1.1.1. Autonomic symptom domains 
Patients with MSA and PAF scored higher (e.g., a more severe feature) in domains such as 
Orthostatic Intolerance, Bladder, GI and Vasomotor compared to normal controls and other 
chronic autonomic disorders (P<0.001; Table 5.3). Patients with Parkinson's disease with 
and without autonomic failure had significantly higher scores in the orthostatic intolerance 
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and sudomotor domains compared with controls (P<0.05; Table 5.3). Patients with peripheral 
neuropathy and autonomic failure had significantly higher scores in the majority of the 
autonomic domains, including the musculoskeletal (P<0.001; Table 5.3). There was no 
difference between patients with chronic autonomic failure and controls in the sleep and 
sexual dysfunction domains. The total autonomic score was significantly higher in patients 
with widespread autonomic failure (MSA, PAF and peripheral neuropathy with autonomic 
failure) compared with patients with a modest autonomic impairment (PD with AF) or mild 
autonomic impairment (PD and peripheral neuropathy without AF) and controls 
(MSA=PAF=Peripheral neuropathy_AF>PD_AF>PD no AF/Peripheral neuropathy no AF> 
Controls; see Table 5.3). 
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Table 5.3 Autonomic domain scores in Chronic Autonomic Disorders 
MSA PAF Control
with AF without AF with AF without AF
OI 37 ± 28 
$$$
44 ± 19 
$$$
19 ± 17
 $
19 ± 15 
$
41 ± 12 
$$$
9 ± 8 4 ± 4
GI 9 ± 6 
$$$
9 ± 8
 $$$
3 ± 3 5 ± 3 14 ± 7 
$$$
6 ± 9 0.9 ± 2
Bladder 15 ± 7 
$$$
13 ± 8 
$$$
5 ± 3 8 ± 3 
$
6 ± 5 2 ± 2 2 ± 3
Vasomotor 5 ± 3 
$$$
5 ± 3  
$$$
1.6 ± 3 3 ± 2  
$
7 ± 4  
$$$
3 ± 5  
$
0.4 ± 1.2
Sudomotor 5 ± 6
 $
6 ± 6  
$
5 ± 9  
$
1 ± 1.4 9 ± 6 
$$$
2 ± 4 0.3 ± 1.2
Muscoloskeletal 9 ± 5 
$
10 ± 5 
$
3 ± 3 6 ± 5 14 ± 6 
$$$
5 ± 4 5 ± 4
Sleep 2 ± 2 2 ± 1 2 ± 1 2 ± 1 2 ± 2 1.7 ± 1.7 0.8 ± 0.9
Sexual 0.8 ± 1 0.5 ± 1 0.6 ± 0.8 1.4 ± 1 0.4 ± 0.7 0.4 ± 0.7 0.4 ± 0.8
Total Autonomic score 74 ± 38 * 
 $$$
81 ± 24  
$$$
36 ± 15  
$$$
39 ± 21  
$$$
80 ± 32  ** 
$$$
25 ± 21  
$$$
9 ± 7
PD Peripheral Neuropathy
 
Abbreviation: AF, autonomic failure; OI, orthostatic intolerance, GI, gastrointestinal. $P< 0.05 vs. controls, $$P<0.01 vs. controls, 
$$$P< 0.001 vs. controls; *P< 0.05 MSA vs. PD with AF, **P< 0.01 vs. peripheral neuropathy without AF.  
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When evaluating the percentage of patients with any symptoms on the individual questions, 
symptoms of lightheadness, dizziness (OI) and shortness of breath were reported by 100% 
and 78% of PAF patients and 63% and 53% of MSA patients, respectively (Table 5.4). 
Orthostatic intolerance symptoms were also more frequently reported by patients with 
Peripheral neuropathy_AF compared with those without AF with syncope occurring in 50% 
and 29% of patients with peripheral neuropathy with and without AF, respectively (Table 5.6). 
There was no difference in occurrence of syncope between MSA and PAF whereas only one 
patient with PD_AF and none with PD_No AF reported syncope (Table 5.5). However, pre-
syncope occurred in all patient groups but more frequently in PAF (78% PAF, 68% MSA, 
20% PD with and without AF, 71% peripheral neuropathy_AF, 57% Peripheral 
neuropathy_NO AF) (Table 5.6; 5.7). Standing still was the most frequent syncope trigger in 
patients with PAF and MSA and peripheral neuropathy with AF (63%, 89%, 57%, 
respectively) (Table 5.5). Symptoms of orthostatic intolerance and syncope were worse on 
standing in the morning in particular in patients with PAF and peripheral neuropathy_AF 
(78% PAF, 53% MSA, 20% PD with and without AF, 64% peripheral neuropathy_AF, 14% 
Peripheral neuropathy_NO AF). Factors aggravating symptoms of OI and syncope, such as 
heat challenge and food ingestion, were often reported by both MSA and PAF and peripheral 
neuropathy _AF patients but were more frequent in those with PAF (78%) and only occurred 
in one patient with PD_AF (Table 5.5). OI symptoms were induced or were worse during 
straining accompanying micturition and or coughing in 56% of PAF, 21% of peripheral 
neuropathy _AF and 16% of MSA patients. Chest pain occurred mainly in patients with PAF 
(44% PAF, 36% peripheral neuropathy_AF, 29% Peripheral neuropathy_NO AF, 21% MSA, 
20% PD_ NO AF). 
 
Table 5.4. Frequency of Orthostatic intolerance symptoms in patients with 
Neurodegenerative disorders 
 
 
 
 
 
 
 
 
 
 
 
MSA (n=19) PAF (n=9)
with AF (n=5) without AF (n=5)
12 (63%) 9 (100%) 2 (40%) 2 (40%)
5 (26%) 5 (56%) 0 1 (20%)
4 (21%) 4 (44%) 0 1 (20%)
11 (58%) 6 (67 %) 1 (20%) 2 (40%)
10 (53%) 7 (78%) 2 (40%) 2 (40%)
OI (dizziness/lightheadness)
Palpitation
Chest pain
Blurred vision
Shortness of breath
PD
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Table 5.5. Frequency of Syncope and common triggers in patients with 
neurodegenerative disorders 
 
MSA (n=19) PAF (n=9)
with AF (n=5) without AF (n=5)
Syncope 9 (47%) 4 (44%) 0 0
13 (68%) 7 (78%) 1 (20%) 1 (20%)
standing early 
morning
10 (53%) 7 (78%) 1 (20%) 0
food ingestion 7 (37%) 7 (78%) 0 0
standing still 12 (63%) 8 (89%) 1 (20%) 0
physical exercise 9 (47%) 5 (56%) 1 (20%) 0
heat 6 (32%) 5 (56%) 0 0
micturition 3 (16%) 5 (56%) 0 0
coughing 2 (11%) 1 (11%) 0 0
head movements 4 (21 %) 2 (22%) 0 0
alchool 2 (11%) 4 (44%) 0 0
menstrual period 2 (11%) 0 0 0
Aggravating factors 
Syncope triggers
Pre-syncope
PD
 
  
 
 
 
 
Table 5.6. Frequency of Orthostatic intolerance symptoms in patients with 
Peripheral neuropathy with and without AF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OI (dizziness/lightheadness)
Palpitation
Chest pain
Blurred vision
Shortness of breath
with AF (n=14) without AF (n=7)
13 (93%) 4 (57%)
6 (43%) 2 (29%)
5 (36%) 2 (29%)
8 (57%) 1 (14%)
10 (71%) 0
Peripheral Neuropathy
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Table 5.7. Frequency of Syncope and common triggers in patients with peripheral 
neuropathy with and without AF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Constipation was the most frequent gastrointestinal symptoms reported by patients with  
MSA and PAF, PD without AF and Peripheral neuropathy_AF (67% in PAF, 63% in MSA, 
80% in PD_NO AF, 86% in peripheral neuropathy_AF) followed by nausea (56% in PAF; 
37% in MSA; 71% in peripheral neuropathy_AF, 40% in PD_No AF) and bloating ( 33% in 
PAF, 32% in MSA and 71% in peripheral neuropathy_AF) (Table 5.8, 5.9). Diarrhoea 
occurred more frequent in patients with peripheral neuropathy with and without AF compared 
with patients with PAF, MSA, and PD, (57% peripheral neuropathy_AF, 43% Peripheral 
neuropathy_NO AF, 33% PAF, 26% MSA, 20% PD with and without AF). 
 
Fatigue was reported by all patients with PAF, PD without AF and peripheral neuropathy with 
AF but only half as commonly in MSA, PD_AF and peripheral neuropathy without AF (Table 
5.10, 5.11). Difficult thinking and concentration occurred in both patients with chronic AF 
(MSA, PAF, PD_AF, and Peripheral neuropathy_AF) and PD_No AF without AF but was 
more frequent in those with PAF and only minimal in Peripheral neuropathy_ No AF (Table 
510, 5.11). 
 
 
 
 
 
with AF (n=14) without AF (n=7)
7 (50%) 2 (29%)
10 (71%) 4 (57%)
9 (64%) 1 (14%)
4 (29%) 0
8 (57%) 2 (29%)
5 (36%) 1 (14%)
6 (43%) 0
2 (14%) 0
3 (21%) 0
5 (36%) 0
1 (7%) 0
0 0
Peripheral Neuropathy
Syncope
standing early 
morning
food ingestion 
standing still
physical exercise
heat 
micturition
coughing
head movements
alchool
menstrual period 
Aggravating factors 
Syncope triggers
Pre-syncope
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Table 5.8. Frequency of gastrointestinal symptoms in patients with 
neurodegenerative disorders 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.9. Frequency of gastrointestinal symptoms in patients peripheral 
neuropathy with and without AF 
 
 
 
 
 
 
 
 
 
 
 
Table 5.10. Fatigue, sleep dysfunction in patients with chronic neurodegenerative 
disorders 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSA (n=19) PAF (n=9)
with AF (n=5) without AF (n=5)
Nausea 7 (37%) 5 (56%) 0 2 (40%)
3 (16%) 2 (22%) 0 3 (60%)
5 (26%) 3 (33%) 1 (20%) 1 (20%)
12 (63%) 6 (67%) 1 (20%) 4 (80%)
2 (11%) 0 1 (20%) 0
6 (32%) 3 (33%) 1 (20%) 0
5 (26%) 3 (33%) 2 (40%) 0
5 (26%) 1 (11%) 0 1 (20%)
Bloating
Loss of appetite
Loss weight
Abdominal pain/stomach ache
Diarrhoea
Constipation
Vomiting after meal
PD
Nausea
Bloating
Loss of appetite
Loss weight
Abdominal pain/stomach ache
Diarrhoea
Constipation
Vomiting after meal
with AF (n=14) without AF (n=7)
10 (71%) 1 (14%)
8 (57%) 2 (29%)
8 (57%) 3 (43%)
12 (86%) 0
4 (29%) 2 (29%)
10 (71%) 2 (29%)
7 (50%) 2 (29%)
4 (29%) 0
Peripheral Neuropathy
MSA (n=19) PAF (n=9)
with AF (n=5) without AF (n=5)
6 (32%) 5 (56%) 1 (20%) 3 (60%)
Fatigue 10 (53%) 9 (100%) 3 (60%) 5 (100%)
9 (47%) 8 (89%) 4 (80%) 3 (60%)
11 (58%) 7 (78%) 5 (100%) 4 (80%)
11 (58%) 6 (67%) 1 (20%) 2 (40%)
5 (26%) 2 (22%) 0 1(20%)
3 (16%) 2 (22%) 1 (20%) 0
"Stop breathing" when sleeping
Wake up "gasping" or "short of breath
Headache
Difficult thinking and concentration
Are you sleepy or feel tired during the day 
even though you slept through the nigh
Snore loudly
PD
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Table 5.11. Fatigue, sleep dysfunction in patients with peripheral neuropathy with 
and without autonomic failure 
 
 
 
 
 
 
 
 
 
The most common urinary symptoms was nocturia, reported by all patients groups but more 
frequent in PAF (100% PAF, 63% MSA, 60% PD_AF, 40% PD_NO AF, 86% Peripheral 
neuropathy_AF, 57% peripheral neuropathy_NO AF), followed by urinary urgency and 
frequency (78% PAF, 68% MSA, 60% PD_NO AF, 40% PD_AF 21% Peripheral 
neuropathy_AF). Urine leakage and difficulties with bladder emptying occurred in all patients 
groups but more frequent in MSA and PD_NO AF (Table 5.12; 5.13). Urinary incontinence 
and recurrent UTI occurred in patients with MSA, PAF and Peripheral neuropathy_AF but 
more frequent in those with MSA (Table 5.12; 5.13). 
 
Dry mouth and eyes as well as widespread reduction in sweating and facial flushing were 
reported mostly in patients with severe autonomic impairment including MSA, PAF and 
peripheral neuropathy_AF. Whereas hot intolerance were reported more frequently by 
patients with PAF and peripheral neuropathy_AF compared with MSA (56% PAF, 57% 
peripheral neuropathy_AF, 32% MSA) (Table 5.14; 5.15). Increased sweating involving any 
area was almost absent in patients with chronic autonomic failure.  
 
Table 5.12. Frequency of Bladder dysfunction in patients with chronic 
neurodegenerative disorders 
 
 
 
 
 
 
 
 
 
 
 
 
Fatigue
"Stop breathing" when sleeping
Wake up "gasping" or "short of breath
Headache
Difficult thinking and concentration
Are you sleepy or feel tired during the day 
even though you slept through the nigh
Snore loudly
with AF (n=14) without AF (n=7)
10 (71%) 2 (29%)
11 (79%) 3 (43%)
11 (79%) 1 (14%)
10 (71%) 4 (57%)
7 (50%) 3 (43%)
3 (21%) 1 (14%)
4 (29%) 1 (14%)
Peripheral Neuropathy
MSA (n=19) PAF (n=9)
with AF (n=5) without AF (n=5)
14 (74%) 4 (44%) 2 (40%) 4 (80%)
9 (47%) 4 (44%) 0 1 (20%)
13 (68%) 7 (78%) 2 (40%) 3 (60%)
13 (68%) 4 (44%) 1 (20%) 3 (60%)
12 (63%) 3 (33%) 0 0
6 (32%) 2 (22%) 0 1 (20%)
12 (63%) 9 (100%) 3 (60%) 2 (40%)
Difficulties with bladder emptying
Urinary incontinence
Recurrent UTI
Nocturia
Leaked urine
Difficulties passing urine
Urinary urgency/frequency
PD
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Table 5.13. Frequency of Bladder dysfunction in patients with peripheral 
neuropathy with and without autonomic failure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.14. Frequency of Vasomotor/secretomotor and sudomotor dysfunction in 
patients with chronic neurodegenerative disorders 
 
 
 
 
 
 
 
 
 
 
 
Table 5.15. Frequency of Vasomotor/secretomotor and sudomotor dysfunction in 
patients with peripheral neuropathy with and without autonomic failure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Leaked urine
Difficulties passing urine
Urinary ungency/frequency
Difficulties with bladder 
emptying
Urinary incontinence
Recurrent UTI
Nocturia
with AF (n=14) without AF (n=7)
2 (14%) 1 (14%)
3 (21%) 0
3 (21%) 0
4 (29%) 0
2 (14%) 0
4 (29%) 0
12 (86%) 4 (57%)
Peripheral Neuropathy
MSA (n=19) PAF (n=9)
with AF (n=5) without AF (n=5)
14 (74%) 6 (67%) 1 (20%) 2 (40%)
3 (16%) 3 (33%) 1 (20%) 3 (60%)
4 (21%) 1 (11%) 0 1 (20%)
5 (26%) 5 (56%) 1 (20%) 0
6 (32%) 2 (22%) 1 (20%) 0
3 (16%) 2 (22%) 0 0
0 2 (22%) 0 0
0 0 1 (20%) 0
2 (11%) 0 1 (20%) 0
3 (16%) 0 1 (20%) 0
6 (32%) 5 (56%) 0 0
Increased sweating feet
Facial sweating
Reduced hot tolerance
Hands/feet skin discoloration
Facial flushing
Widespread reduction in 
sweating (Anhidrosis)
Reduced sweating on your feet
Increased sweating armpit
Increased sweating hands
Dry mouth
Dry eyes
PD
Increased sweating feet
Facial sweating
Reduced hot tolerance
Hands/feet skin discoloration
Facial flushing
Widespread reduction in 
sweating (Anhidrosis)
Reduced sweating on your feet
Increased sweating armpit
Increased sweating hands
Dry mouth
Dry eyes
with AF (n=14) without AF (n=7)
9 (64%) 2 (29%)
9 (64%) 2 (29%)
6 (43%) 0
7 (50%) 1 (14%)
6 (43%) 0
1 (7%) 0
2 (14%) 1 (14%)
0 0
1 (7%) 0
6 (43%) 0
8 (57%) 2 (29%)
Peripheral Neuropathy
Page 105 
 
Back pain was the most common musculoskeletal symptoms reported by all patients groups 
but more frequent in Peripheral neuropathy_AF. Patients with peripheral neuropathy with and 
without AF also presented with pain involving other area rather than back were those whom 
most requested medication for pain (Table 5.16; 5.17) 
 
Table 5.16. Musculoskeletal involvement in patients with chronic neurodegenerative 
disorders 
 
 
 
 
 
 
 
 
Table 5.17. Musculoskeletal involvement in patients with peripheral neuropathy with 
and without autonomic failure 
 
 
 
 
 
 
 
 
 
 
 
MSA (n=19) PAF (n=9)
with AF (n=5) without AF (n=5)
7 (37%) 3 (33%) 0 1 (20%)
2 (11%) 1 (11%) 0 2 (40%)
Hip pain 7 (37%) 3 (33%) 0 1 (20%)
1 (5%) 2 (22%) 0 0
11 (58%) 7 (78%) 2 (40%) 3 (60%)
8 (42%) 1 (11%) 0 0
Knee pain
Back pain
Need medication for pain
Fingers pain
Elbow pain
PD
Hip pain
Knee pain
Back pain
Need medication for pain
Fingers pain
Elbow pain
with AF (n=14) without AF (n=7)
6 (43%) 1 (14%)
9 (64%) 0
6 (43%) 1 (14%)
4 (29%) 0
11 (79%) 3 (43%)
9 (64%) 2 (29%)
Peripheral Neuropathy
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5.3.1.1.2. Impact of autonomic and allied features on Quality of life 
Quality of life scores were significantly greater in patients compared with controls (e.g., 
quality of life was lower in patients). More specifically, patients with MSA showed a 
significantly higher impairment of their quality of life, mainly related to the orthostatic 
intolerance, bladder and GI domains, while patients with peripheral neuropathy and 
autonomic failure showed a significantly higher impairment of QoL as a result of symptoms of 
orthostatic intolerance, GI, muscle-skeletal and sudomotor domains (see Table 5.18). Using 
multiple regression analysis with QoL total score as the dependent variable and 6 autonomic 
domains including OI, GI, bladder, vasomotor/secretomotor, sudomotor and musculoskeletal, 
as predictors, significant predictors of the QoL total score were OI, GI, bladder and 
sudomotor (total R2 = 0.7; Table 5.19 and Fig 5.2). 
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Table 5.18. Quality of life scores in patients with Chronic autonomic disorders 
MSA PAF Control
with AF without AF with AF without AF
OI QoL 11 ± 10  
$$$
13 ± 8  
$$$
5 ± 4 6 ± 5 12 ± 8  
$$$
1.4 ± 1.8 0.5 ± 1
GI QoL 2 ± 2  
$$
3 ± 5  
$$
2 ± 4 
 $$
1.6 ± 2 
 $$
4 ± 3  
$$$
1 ± 2  
$$
0
Bladder QoL 6 ± 4 
 $$$
5 ± 4  
$$$
0.8 ± 1 1.4 ± 2 
 $
2 ± 3 
 $
0.2 ± 0.7 0
Vasomotor QoL 0.6 ± 0.8 0.8 ± 1 0.4 ± 0.8 0.4 ± 0.8 1 ± 1 0.5 ± 1.5 0
Sudomotor QoL 0.8 ± 1.5 1.4 ± 1.7 1 ± 1.7 0 2 ± 2 
$$
0.8 ± 2 0.1 ± 0.6 
Muscoloskeletal QoL 4 ± 4 3 ± 2 0.6 ± 0.5 3 ± 4 7 ± 3 
$$
2 ± 3 1.7 ± 3
Sleep QoL 1.6 ± 2 
$
1.6 ± 1.3 
$
1.8 ± 0.8 
$
0.6 ± 0.8 2 ± 3 
$
1 ± 2 
$
0.1 ± 0.4
Sexual QoL 2.3 ± 2.4 
$$
1.5 ± 2.1 
$$
0.4 ± 0.5 0.4 ± 0.5 0.3 ± 0.8 0.8 ± 2 0
Total QoL score 29 ± 17
 $$$
31 ± 13 
$$$
13 ± 7 
$
13 ± 10 
$
30 ± 17 
$$$
8 ± 10 3 ± 3
PD Peripheral Neuropathy
Abbreviation: AF, autonomic failure; OI, orthostatic intolerance, GI, gastrointestinal; QoL, quality of life. $P< 0.05 vs. 
controls, $$P<0.01 vs. controls, $$$P< 0.001 vs. controls; *P< 0.05 MSA vs. PD with OH, **P< 0.01 vs. peripheral neuropathy 
without AF. 
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Table 5.19. Multiple regression analysis of autonomic domain QoL and frequency 
scores in chronic autonomic disorders 
QoL score Parameter 
estimate 
Standard 
error 
p value
OI 0.404 0.052 < 0.0001
GI 0.567 0.181 0.003
Bladder 0.783 0.147 < 0.0001
Vasomotor/secretomotor -0.396 0.338 0.245
Sudomotor 0.563 0.114 < 0.0001
Musculoskeletal 0.191 0.217 0.383
 
Abbreviations: OI, orthostatic intolerance; GI, gastrointestinal; QoL, Quality of Life  
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Figure 5.2. Scatterplots showing the correlation between Total Quality of Life 
(QoL) score and Total autonomic domain symptom frequency scores in chronic 
autonomic disorders. 
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5.3.1.2. Autonomic symptom domains and quality of life in Intermittent 
autonomic disorders 
 
5.3.1.2.1. Autonomic symptoms 
Patients with PoTS scored higher (e.g., more severe features) in all autonomic domains 
compared with controls and patients with AMS and Hyperhidrosis (P<0.001 vs. controls and 
P<0.01 vs. AMS and Hyperhidrosis). More specifically, OI symptoms were present in all 
intermittent disorders patients with PoTS patients reporting the highest score (PoTS> AMS> 
Hyperhidrosis>controls) (Table 5.20). Patients with PoTS and AMS showed a multi-system 
impairment as confirmed by high scores in the majority of domains, including sleep 
dysfunction in PoTS which was significantly higher compared with AMS, Hyperhidrosis and 
controls. There was no difference in sleep dysfunction symptoms between patients with 
Hyperhidrosis and controls.  
 
Clinical diagnosis of joint hypermobility syndrome (JHS) was confirmed in patients with 
intermittent autonomic disorders with the following prevalence 74/79 (94%) in PoTS, 13/37 
(35%) in AMS and 2/11 (18%) in Hyperhidrosis. Of interest, patients with Hyperhidrosis 
scored higher than normal controls not just for the sudomotor domain but also for additional 
domains like OI, GI, vasomotor and musculoskeletal (see Table 5.5). Minimal bladder 
symptoms seemed to be reported only in patients with Hyperhidrosis while they were quite 
prominent in patients with PoTS and AMS (P<0.05 and P< 0.001 vs. Controls, respectively). 
The total autonomic scores confirmed the multi-system involvement in patients with 
intermittent autonomic disorders with the highest scores in PoTS, followed by AMS and 
Hyperhidrosis (PoTS >AMS>Hyperhidrosis>control; Table 5.20). 
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Table 5.20. Autonomic domain scores in Intermittent Autonomic Disorders 
 
 
 
 
 
 
 
 
 
Abbreviation: AMS, autonomic (neurally) mediated syncope, PoTS, Postural 
tachycardia syncope, OI, orthostatic intolerance, GI, gastrointestinal. *P<0.05 vs 
PoTS, **P< 0.01 vs PoTS, ***P< 0.001 vs PoTS; $P< 0.05 vs controls, $$P<0.01 vs 
controls, $$$P< 0.001 vs controls. 
 
When assessing the percentage of subjects with any complaint on the individual questions, 
orthostatic intolerance symptoms, including postural lightheadness, dizziness and 
palpitations, were the most common symptoms in PoTS followed by chest pain, shortness of 
breath and blurred vision while upright. These symptoms were also reported by patients with 
AMS and Hyperhidrosis, although less frequently than in PoTS patients (Table 5.21). 
Syncope was presented in 74%, 72% and 16% of AMS, PoTS and Hyperhidrosis patients, 
respectively. Patients with AMS or PoTS who did not report syncope within the 3 months 
prior to completing the AQQoL had frequent pre-syncopal episodes. Syncope was frequently 
triggered by standing still, particularly early in the morning, in 80% of PoTS and 61% of AMS 
patients. Factors aggravating symptoms of OI and syncope, including food ingestion, were 
often reported by both AMS and PoTS but were more frequent in those with PoTS and only 
occurred in minority of patients with Hyperhidrosis (Table 5.22). Physical exercise was an OI 
exacerbating factor in PoTS and AMS and only reported by 1 patient with Hyperhidrosis. 
Heat was a prominent syncope exacerbating factor, in particular in PoTS (80%), while 
present in only 45% of AMS patients and 16% of patients with Hyperhidrosis. Syncope 
occurring during the menstrual period was reported in 53% of PoTS and 18% of AMS 
patients (Table 5.22). OI symptoms were induced or were worse during straining 
accompanying micturition and or coughing in 34% PoTS, 18% AMS and, 9% Hyperhidrosis 
patients. 
 
AMS PoTS Hyperhidrosis Control
OI 41 ± 26**  $$$ 54 ± 21 $$$ 21 ± 19 *** $$$ 4 ± 4
GI 14 ± 9 $$$ 16 ± 8 $$$ 8 ± 8* $$ 0.9± 2
Bladder 8 ± 7 $$$ 7 ± 6 $$$ 4 ± 3 $ 1.2 ± 2
Vasomotor 5 ± 5 $$$ 7 ± 5 $$$ 6 ± 3 $$$ 0.3± 0.9
Sudomotor 11 ± 11 $$$ 13 ± 11 $$$ 21 ± 11* $$$ 0.5 ± 2
Muscoloskeletal 13 ± 8 $$$ 15 ± 8 $$$ 9 ± 2** $$$ 4 ± 3
Sleep 1.5 ± 1.3 ** $$ 4 ± 6 $$$ 1 ± 1** 0.7 ± 0.9
Sexual 0.1 ± 0.3 ** 1.5 ± 1.2 $ 0.5 ± 0.7 * 0.7 ± 0.9
Total Autonomic score 80 ± 48 * $$$ 99 ± 39 $$$ 62 ± 31 ** $$$ 8 ± 9
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Table 5.21. Frequency of Orthostatic intolerance symptoms and syncope in patients 
with intermittent autonomic disorders 
 
 
 
 
 
 
 
 
 
Table 5.22. Frequency of syncope and syncope triggers in patients with intermittent 
autonomic disorders 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nausea and abdominal pain/stomach-ache were the most frequent gastrointestinal 
symptoms reported by patients with intermittent autonomic disorders with the highest 
frequency in PoTS. The second most frequent gastrointestinal symptom was constipation in 
PoTS and AMS followed by bloating and diarrhoea. Loss of appetite occurred more 
frequently in PoTS compared with AMS and Hyperhidrosis (62% PoTS, 37% AMS, 16% 
Hyperhidrosis). This was associated with weight loss in 35%, 18% and 9% patients with 
PoTS, AMS and Hyperhidrosis, respectively (Table 5.23). 
 
 
 
AMS 
(n=38)
PoTS 
(n= 79)
Hyperhidrosis 
(n=11)
34 ( 89%) 77 (97%) 6 (55%)
25 (66%) 74 (94%) 8 (73%)
17 ( 45%) 72 (91%) 5 (45%)
24 (63%) 56 (71 %) 5 (45%)
18 (47%) 61 (77%) 6 (55%)
Palpitation
Chest pain
Blurred vision
Shortness of breath
OI (dizziness and lightheadness)
AMS 
(n=38)
PoTS 
(n= 79)
Hyperhidrosis 
(n=11)
Syncope 28 ( 74%) 57 (72%) 2 (16%)
31 (82%) 69 (87%) 4 (36%)
standing early morning 23 ( 61%) 63 (80%) 2 (16%)
food ingestion 14 (37%) 43 (54%) 1 (9%)
standing still 28 ( 74%) 69 (87%) 3 (27%)
physical exercise 24 (63%) 60 (76%) 1 (9%)
heat 17 ( 45%) 63 (80%) 2 (16%)
micturition 5 ( 13%) 22 (28%) 1 (9%)
coughting 7  (18 %) 27 (34%) 1 (9%)
head movements 9 (24 %) 35 (44%) 1 (9%)
alchool 8 (21%) 29 (37%) 0
menstrual period 7  (18 %) 42 (53%) 1 (9%)
Aggravating factors 
Pre-syncope
Syncope triggers
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Table 5.23. Frequency of Gastrointestinal symptoms in patients  
with intermittent autonomic disorders 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fatigue and headache were prominent features in patients with PoTS and AMS and as half 
as common in patients with Hyperhidrosis (96% PoTS, 71% AMS, 55% Hyperhidrosis) 
Difficulty thinking and concentrating were also reported in almost all patients but more 
frequently in PoTS (86% PoTS, 68% AMS and 64% Hyperhidrosis; Table 5.24). 
 
Table 5.24. Fatigue and sleep dysfunction symptom scores in patients with 
intermittent autonomic disorders 
AMS 
(n=38)
PoTS 
(n= 79)
Hyperhidrosis 
(n=11)
Nausea 26 (68%) 72 (91%) 5 (45%)
25 (66%) 62 (78%) 7 (64%)
20 (53%) 47 (59%) 4 (36%)
21 (55%) 51 (65%) 2 (16%)
5 (13%) 27 (34%) 1 (9%)
17 (45%) 49 (62%) 3 (27%)
14 (37%) 49 (62%) 2 (16%)
7 ( 18%) 28 (35%) 1 (9%)
Abdominal pain
Diarrhoea
Constipation
Vomiting after meal
Bloating
Loss of appetite
Loss weight
AMS 
(n=38)
PoTS 
(n= 79)
Hyperhidrosis 
(n=11)
27 (71%) 76 (96%) 6 (55%)
Fatigue 28 (82%) 75 (95%) 7 (64%)
26 (68%) 68 (86%) 7 (64%)
28 (74%) 67 (85%) 8 (73%)
11 (29%) 14 (18%) 2 (16%)
3 (8%) 12 (15%) 0
5 (13%) 22 (28%) 1 (9%)
Snore loudly
Are you sleepy or feel tired during 
the day even though you slept 
through the nigh
"Stop breathing" when sleeping
Wake up "gasping" or "short of 
breath
Difficult thinking and 
concentration
Headache
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The most common urinary symptom was nocturia, reported by all patients with intermittent 
disorders but more frequently in PoTS (81% PoTS, 76% AMS, 73% Hyperhidrosis), followed 
by urinary urgency and frequency (68% PoTS, 58% AMS, 55% Hyperhidrosis) and difficulties 
with bladder emptying (61% PoTS, 34% AMS, 16% Hyperhidrosis). Patients with PoTS and 
AMS also presented with prominent symptoms of urine leakage and recurrent UTI although 
more frequently in PoTS (Table 5.25). Secretomotor problems, particularly dry mouth and 
eyes, occurred mainly in patients with PoTS compared with AMS and Hyperhidrosis. 
Heat intolerance was the most frequent symptom of impaired thermoregulation and was 
more frequently reported by patients with Hyperhidrosis but also often occurred in patients 
with PoTS and AMS (73% Hyperhidrosis, 69% PoTS, 55% AMS). The second most frequent 
sudomotor symptom was facial flushing and facial sweating, which occurred more frequently 
in patients with Hyperhidrosis compared to PoTS and AMS. These were followed by 
increased sweating involving mainly the armpits, hands and feet (Table 5.26). 
Table 5.25. Frequency of Bladder dysfunction in patients with intermittent 
autonomic disorders 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.26. Frequency of Vasomotor/secretomotor and sudomotor dysfunction in 
patients with intermittent disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
AMS 
(n=38)
PoTS 
(n= 79)
Hyperhidrosis 
(n=11)
18 ( 47%) 42 (53%) 2 (16%)
6 ( 16%) 19 (24%) 0
22 (58%) 54 (68%) 6 (55%)
13 (34%) 48 (61%) 2 (16%)
9 (24%) 34 (43%) 0
7 ( 18%) 38 (48%) 1 (9%)
29 ( 76%) 64 (81%) 8 (73%)
Difficulties passing urine
Leaked urine
Urinary ungency/frequency
Urinary incontinence
Recurrent UTI
Nocturia
Difficulties with bladder emptying
AMS 
(n=38)
PoTS 
(n= 79)
Hyperhidrosis 
(n=11)
17 (22%) 56 (71%) 7 (64%)
15 (39%) 45 (57%) 4 (36%)
14 (37%) 53 (67%) 4 (36%)
20 (53%) 48 (61%) 7 (64%)
10 (26%) 23 (29%) 3 (27%)
5 (13%) 11 (14%) 1 (9%)
14 (37%) 27 (34%) 4 (36%)
7 ( 18%) 24 (30%) 5 (45%)
10 (26%) 20 (25%) 6 (55%)
15 (39%) 32 (41%) 6 (55%)
21 (55%) 53 (67%) 8 (73%)
Increased sweating feet
Facial sweating
Reduced hot tolerance
Increased sweating armpit
Increased sweating hands
Dry eyes
Widespread reduction in 
sweating (Anhidrosis)
Reduced sweating on your feet
Dry mouth
Hands/feet skin discoloration
Facial flushing
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Joint pain involving any joint occurred more frequently in PoTS patients compared with 
AMS and Hyperhidrosis (Table 5.27). 53% of PoTS patients and 34% with AMS needed 
polipharmacy for pain. No patients with Hyperhidrosis were taking medication for pain. 
Table 5.27. Musculoskeletal involvement in patients with intermittent autonomic 
disorders 
 AMS 
(n=38)
PoTS 
(n= 79)
Hyperhidrosis 
(n=11)
> 4 17 (45%) 44 (56%) 5 (45%)
Knee 
pain
17 (45%) 51 (65%) 3 (27%)
16 (42%) 50 (63%) 3 (27%)
Hip pain 13 (34%) 48 (61%) 2 (16%)
13 (34%) 25 (32%) 1 (9%)
Back 
pain
20 (53%) 60 (76%) 8 (73%)
13 (34%) 42 (53%) 0
Fracture 19 (50%) 34 (43%) 2 (16%)
9 (24%) 26 (33%) 1 (9%)
8 (21%) 8 (10%) 0
21 (55%) 53 (67%) 8 (73%)
16 (42%) 44 (56 %) 5 (45%)
23 (61%) 68 (86%) 7 (64%)
Paper thin like scar
Joint clicking
Need medication for pain
Dislocation
Visceral Ernia
Easy bruising
Elbow pain
Fingers pain
Beighton score
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5.3.1.2.2. Impact of autonomic and allied features on Quality of life  
Quality of life scores were significantly greater (e.g., a more severe feature) in autonomic 
intermittent disorders patients compared with controls. More specifically, patients with PoTS 
showed a significantly higher impairment of their quality of life compared with AMS and 
Hyperhidrosis (PoTS>AMS>Hyperhidrosis>Control). Sleep dysfunction seems to impair 
quality of life of PoTS patients to a greater extent compared with patients with AMS (see 
Table 5.28). Using multiple regression analysis with QoL total score as the dependent 
variable and autonomic domains including OI, GI, bladder, vasomotor/secretomotor, 
sudomotor and musculoskeletal as predictors, significant predictors of QoL total score were 
OI, GI, bladder, musculoskeletal and sudomotor (total R2 = 0.7; Table 5.29 and Figure 5.3).  
Table 5.28 Quality of life scores in patients with Intermittent autonomic disorders 
AMS PoTS Hyperhidrosis Control
OI QoL 16 ± 9 $$$ 18 ± 9 $$$ 8 ± 10 ** $$$ 0.2 ± 0.6
GI QoL 6 ± 4 $$$ 5 ± 4 $$$ 3 ± 4 $$$ 0.03 ± 0.1
Bladder QoL 3 ± 3  $$$ 2 ± 3  $$$ 1 ± 2  $$$ 0
Vasomotor QoL 1 ± 2  $$$ 1 ± 2  $$$ 0.3 ± 0.6  $$$ 0
Sudomotor QoL 3 ± 4  $$$ 3 ± 3  $$$ 8 ± 6 *  $$$ 0.06 ± 0.3
Muscoloskeletal QoL 6 ± 7 * $$ 8 ± 8 $$$ 3 ± 2 * $$ 0.7 ± 2
Sleep QoL 1.2 ± 1.7 *** $$$ 3 ± 2 $$$ 1.2 ± 2 *** $$$ 0.1± 0.3
Sexual QoL 0.1 ± 0.4 * 1.5 ± 1.5 0.1 ± 0.3 * 0
Total QoL score 33 ± 29 * $$$ 40 ± 22 $$$ 25 ± 22 * $$$ 1.2 ± 2
 
Abbreviation: AMS, autonomic (neurally) mediated syncope, PoTS, Postural 
tachycardia syncope, OI, orthostatic intolerance, GI, gastrointestinal. *P<0.05 vs 
PoTS, **P< 0.01 vs PoTS, ***P< 0.001 vs PoTS; $P< 0.05 vs controls, $$P<0.01 vs 
controls, $$$P< 0.001 vs controls. 
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Table 5.29. Multiple regression analysis of Total QoL and each autonomic domain 
scores in intermittent autonomic disorders 
QoL Parameter 
estimate
Standard 
error
p  value
OI 0.378 0.065 <0.0001
GI 0.638 0.203 0.002
Bladder 0.677 0.229 0.001
Vasomotor -0.002 0.307 0.994
Sudomotor 0.292 0.125 0.021
Muscoloskeletal 0.759 0.21 <0.0001
 
Abbreviations: OI, orthostatic intolerance; GI, gastrointestinal; QoL, Quality of Life 
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Figure 5.3. Scatterplots showing the correlation between Total Quality of Life 
(QoL) score and each autonomic domain frequency score in Intermittent 
autonomic disorder patients.   
 
 
 
 
 
A B 
C 
E F 
D 
E 
Page 119 
 
5.3.1.3. Familial Autonomic dysfunction 
Family history of syncope (family member in first generation, parents, brothers and sisters) 
was present in 57/137 (42%) patients with intermittent autonomic disorders. Family history of 
essential hyperhidrosis was present in 40/137 (29%) and familial JHS in 57/137 (42%) of 
patients with intermittent autonomic disorders. Family history of orthostatic intolerance was 
present in 6/60 (10%) patients with chronic autonomic disorders. These patients did not 
present with a family history of hyperhidrosis or JHS.  
 
5.3.2. AQQoL Validity  
Criterion validity was assessed by the degree of association between the AQQoL Autonomic 
Total and CAF score scores and the AQQoL  QoL total and SF-36 scores.  
 
5.3.2.1. Autonomic Symptoms Score 
There was a strong correlation between the Autonomic Total AQQoL Scores and the CAF 
scores in patients with Chronic autonomic disorders (see Figure 5.4), while there was no 
significant correlation in patients with intermittent autonomic disorders (see Figure 5.5). 
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Figure 5.4. Correlation between CAF score total score and AQQoL Autonomic total 
score in patients with Chronic Autonomic Disorders. Spearman rho = 0.33, P=0.01. 
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Figure 5.5. Correlation between CAF score total score and AQQoL Autonomic total 
score in patients with Intermittent Autonomic Disorders. Spearman rho = 0.05, 
P=0.5 
 
5.3.2.2. Quality of Life 
When assessing the criterion of validity of the AQQol Total QoL with the SF-36, there was a 
strong correlation between the AQQol Quality of Life total score and each SF-36 category 
score as well as between the AQQol QoL total score and the SF-36 total score (Table 5.30).  
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Table 5.30. Spearman correlations between the SF-36 category and summary 
scores and the Total Quality of life (QoL) score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviation: PF, physical functioning; role limitation caused by physical 
problems, RP; BP, bodily pain; GH, general health; VIT, vitality; SF, social 
functioning; RE, role limitation caused by emotional problems; MH, mental health; 
PCS, the physical component summary scale; MCS, the mental component 
summary scale.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spearman 
correlation 
P value
PF -0.75 < 0.0001
RP -0.76 < 0.0001
BP -0.55 < 0.001
GH -0.74 < 0.0001
VIT -0.78 < 0.0001
SF -0.68 < 0.0001
RE -0.57 0.0009
MH -0.36 0.04
PCS -0.73 < 0.0001
MCS -0.66 < 0.0001
Total QoL score 
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5.4. Discussion 
 
The aim of this study was to design and validate a self completed questionnaire that 
assesses a range of autonomic domain symptoms, quality of life and allied non-autonomic 
features (AQQoL) in a large cohort of autonomic disorders, including peripheral 
neuropathies, intermittent autonomic disorders and chronic autonomic failure. More 
specifically, it was intended to examine the prevalence of autonomic symptoms and the 
relative quality of life, assess which sub-domain(s) of symptoms have the biggest impact on 
a patient’s quality of life and evaluate the frequency of familial autonomic dysfunction in a 
cross-section of various intermittent and chronic autonomic disorders. The AQQoL is a novel 
tool for a questionnaire-based evaluation of a range of autonomic symptoms and 
musculoskeletal features and relative quality of life in patients with intermittent and chronic 
autonomic dysfunction. To our knowledge, this is the first self-report questionnaire which 
evaluates several autonomic domains and their impact on quality of life. Items were selected 
to ensure a low number of missing values and applicability to patients at all stages of 
disease. We took care to include areas that have been identified to be important to patients 
where multi-system involvement is a key component, e.g., with PoTS and JHS. We also 
included questions regarding family history and for the first time a quality of life score for 
each autonomic and allied domain. Current available autonomic questionnaires do not 
include allied domains, such as musculoskeletal, and they do not explore the contribution of 
each autonomic domain to quality of life impairment (Visser et al., 2004; Wenning et al., 
2004; Chaudhuri et al., 2006; Damon-Perriere et al., 2012; Kaufmann et al., 2012; Meissner 
et al., 2012; Sletten et al., 2012).  
 
There were significant differences between patients and normal controls in both autonomic 
and QoL scores for each domain. Moreover, there were significant differences between 
patients with varying severities of autonomic dysfunction, e.g., PD patients with and without 
autonomic failure and Peripheral Neuropathy patients with and without autonomic failure. 
Patients with neurodegenerative disorders had impairment of most of the autonomic domains 
but mainly involving the orthostatic intolerance, bladder and gastrointestinal domains. The 
scores were generally highest (e.g., a more severe feature) in patients with MSA compared 
with PD or peripheral neuropathy with autonomic impairment, which is consistent with the 
clinical findings of a more widespread involvement of the autonomic nervous system in MSA 
patients. These findings indicate that the AQQoL has the power to distinguish between 
normal healthy individuals and patients with autonomic disorders, as well as between 
patients with varying extents of autonomic impairments. Furthermore, the criterion validity 
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was also very strong when comparing the AQQoL with the validated SF-36 or when 
comparing the AQQoL with the CAF score in patients with chronic autonomic disorders.  
 
The CAF score is an autonomic function severity score derived from a battery of 
cardiovascular autonomic function tests. There was no correlation between the CAF score 
and the total autonomic scores in patients with intermittent disorders however. This is not too 
surprising considering that cardiovascular autonomic function is often normal during formal 
cardiovascular autonomic function testing in patients with intermittent autonomic disorders. 
Although the CAF score includes an ‘overactivity’ score which is higher in patients with 
intermittent autonomic disorders (see Chapter 4), this only partially quantifies the autonomic 
involvement in these patient groups. Furthermore, the intermittent nature of these disorders 
might explain the lack of autonomic dysfunction on testing in some patients, despite 
persistent autonomic symptoms. It might well be that extra cardiovascular involvement plays 
a major role in these disorders and possibly an impaired processing of viscerosensory 
information could lead to maintenance of the symptoms in patients with PoTS even in the 
absence of postural tachycardia or instability of the cardiovascular autonomic system 
(Benarroch, 2012).  
 
This study also evaluated the major symptoms contributing to several autonomic domains in 
patients with primary chronic autonomic failure and intermittent autonomic dysfunction. 
Lightheadness, dizziness (OI) and shortness of breath were the most common postural 
symptoms in PAF and MSA patients. Additional postural related symptoms, including chest 
pain and visual disturbances, were also more frequent in PAF compared with MSA. This is 
consistent with the greater degree of orthostatic hypotension documented in patients with 
PAF and confirmed in our patient groups (Mathias et al., 1999) (see Chapter 4). Interestingly, 
patients with neurodegenerative disorders also presented an OI score lower than patients 
with PoTS, which could be explained by compensatory mechanisms involving cerebral 
autoregulation in patients with primary chronic autonomic failure. Orthostatic intolerance 
symptoms were worse in the morning in patients with PAF and peripheral neuropathy_AF 
compared to patients with MSA and PD. Orthostatic symptoms are worse in the morning due 
to the nocturnal diuresis and natriuresis (Mathias et al., 1986) and indeed patients with PAF 
showed the highest frequency of nocturia compared with the other chronic autonomic 
disorders. Heat was also a prominent factor in aggravating symptoms of orthostatic 
intolerance in patients with PAF, while patients with MSA and PD were less sensitive to heat 
intolerance. This is consistent with previous studies describing hypohidrosis and heat 
intolerance as one of the earliest symptoms of patients with PAF and only noted at later 
stages in MSA (Mabuchi et al., 2005). 
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Gastrointestinal symptoms are common non-motor manifestations of parkinsonian 
syndromes and, in particular, constipation is the most frequent gastrointestinal symptom 
resulting from slow transit, colonic transit, and decreased phasic rectal contractions (Mathias, 
1996; Tseng & Chang, 2010). On the other hand, diarrhoea occurred more frequently in 
patients with peripheral neuropathy with and without AF compared with neurodegenerative 
disorders. Chronic diarrhoea could be the first manifestation in patients with systemic 
amyloidosis and peripheral involvement and diabetic autonomic neuropathy as a result of 
autonomic neuropathy of the enteric nervous system (Lysy et al., 1999; Pfluecke et al., 2013; 
Vinik & Erbas, 2013).  
 
Urinary incontinence and recurrent urinary tract infections were more frequent in patients 
with MSA compared with the other neurodegenerative disorders. The pathophysiological 
basis for incontinence in MSA is due to the diffuse involvement of different neural structures, 
including the basal ganglia, the pons, cerebellum, and intermediolateral cell columns and 
Onuf’s nucleus in the sacral spinal cord (Kirby et al., 1986; Pullen et al., 1997; Kirchhof et al., 
2003). In particular, urinary incontinence was not reported by PD patients with and without 
AF. The latter is quite intriguing given evidence of different bladder dysfunction in animal 
models of PD and MSA. More specifically, transgenic mice with neuronal overexpression of 
alpha synuclein (PD) differ significantly in their bladder dysfunction from transgenic mice with 
oligodendroglial overexpression of alpha synuclein (MSA) with a possible central and 
peripheral involvement in the MSA model (Boudes et al., 2013).  
 
PoTS patients showed higher autonomic and quality of life scores compared with other 
autonomic intermittent disorders and normal controls consistent with our clinical experience 
of high disability in this patient group likely to be due to their multi-system involvement. 
Patients with PoTS presented with involvement of other autonomic domains rather than just 
orthostatic intolerance. Bladder and gastrointestinal dysfunction symptoms were more 
frequent in PoTS compared with AMS patients. Vasomotor problems were common findings 
in patients with PoTS whereas they were moderate or mild in patients with AMS or 
neurodegenerative disorders. Another important domain which was impaired in PoTS 
patients was sudomotor function, in particular, hyperhidrosis. This is consistent with the 
“hyperactive” sub-group often reported in PoTS, whose features include anxiety, 
hyperadrenergic tone, hyperhidrosis and a normal or high blood pressure profile. Of interest, 
patients with Hyperhidrosis, who are generally considered patients with autonomic 
intermittent dysfunction limited to their sudomotor function showed impairment in other 
domains rather than only the sudomotor domain. This is of clinical relevance and may be an 
indicator of a more multi-system involvement in patients with Hyperhidrosis, in line with 
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evidence of a high prevalence of familial JHS among patients with intermittent disorders. 
Familial autonomic dysfunction is present in different autonomic disorders (predominantly 
intermittent autonomic disorders) and the genetic predisposition is likely to play a crucial role 
in pathogenesis of these diseases. However, this has not been extensively investigated, 
especially in intermittent autonomic disorders such as PoTS. Our findings showed that 
familial orthostatic intolerance symptoms, including syncope, hyperhidrosis and 
JHS/musculoskeletal features, are present with high prevalence in this patient group. 
 
Patients with PoTS have often a poor quality of life (Benrud-Larson et al., 2002) although 
contributing factors to this are still unclear. This study showed that a complex pattern of 
autonomic and allied features has an impact of PoTS patients' quality of life. The latter 
includes GI, bladder, vasomotor/secretomotor, sudomotor and musculoskeletal and sleep 
dysfunction. Orthostatic intolerance, bladder and GI were among the autonomic domains 
with the biggest impact on MSA patients' quality of life, while patients with peripheral 
neuropathy and autonomic failure mainly related their impaired quality of life due to 
orthostatic intolerance, GI, muscle-skeletal and sudomotor impairments. Identifying the 
contributing factors to poor quality of life in autonomic disorders provides suggestions in 
regards to patient management which will need to be multidisciplinary in patients with severe 
neurodegenerative disorders such as MSA and in patients with intermittent multi system 
involvement such as PoTS. 
 
In conclusion, the AQQoL is a helpful in detecting autonomic and non-cardiovascular 
impairments in patients with autonomic disorders. The strong correlation of both the 
autonomic and the QoL scores with other validated indexes of quality of life and autonomic 
function indicates that the AQQoL is a valid scale for assessment of autonomic symptoms 
and their impact on quality of life in autonomic disorders. While therapeutic options in the 
treatment of motor symptoms in neurodegenerative disorders and orthostatic intolerance 
remain restricted, greater attention should be paid to the treatment of non-cardiovascular 
domains, including bladder, gastrointestinal and sudomotor dysfunction as significant 
burdens in patients with chronic autonomic failure. In addition to these, musculoskeletal 
features were also identified as independent determinants of QoL in intermittent autonomic 
disorders. This should inform healthcare programs aimed at improving QoL in autonomic 
disorders. 
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Chapter 6. 
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6. Chapter six: Familial Postural Tachycardia Syndrome and EDS III 
 
6.1. Introduction 
 
Patients with intermittent autonomic dysfunction, including AMS, and PoTS, often present 
with a strong family history. This has been well documented in patients with AMS and 
previous studies have suggested a genetic component (Mathias et al., 1998; Mathias et al., 
2000; Newton et al., 2003; Newton et al., 2005; Holmegard et al., 2013). A community-based 
study (second-year medical students and their first degree relatives) aimed to evaluate the 
effect of family history on the likelihood of vasovagal syncope and demonstrated that both 
the sex of the individual and parental syncope history are strong univariate predictors of 
fainting (Serletis et al., 2006). Newton et al. reported two- and three-generation pedigrees for 
six families, as well as a four-generation family pedigree, with evidence of familial vasovagal 
syncope (Newton et al., 2003; Newton et al., 2005). Subsequently, a twin-family study 
provided additional evidence for a genetic aetiology of AMS (Klein et al., 2012). The 
evidence for a familial history and the associated features in PoTS are still poorly understood 
however. In our questionnaire based study, 37/86 (43%) PoTS patients presented with a 
positive family history of orthostatic intolerance (Chapter 5). PoTS is a complex syndrome 
arising from a heterogeneous pathophysiology (Mathias et al., 2012). Robertson et al., 
suggested that the pathophysiology of this complex syndrome could be attributed to a 
genetic mutation of a Norepinephrine Transporter (NET) gene (Robertson et al., 2000). 
However, the genetic screening of over 150 unrelated PoTS patients for the A457P NET 
mutation provided negative results and no other genetic mutations have as yet been directly 
linked to PoTS (Shannon et al., 2000; Ivancsits et al., 2003).  
 
Joint hypermobility syndrome, also known as EDS type III, is one of the most common 
heritable disorders of the connective tissue. In patients with EDS III autonomic symptoms 
similar to PoTS or AMS may occur and a very strong association between PoTS and EDS III 
has been reported in our patient cohort (Gazit et al., 2003; Mathias et al., 2012). Although a 
family history of orthostatic intolerance is frequently noted in these patients, familial 
orthostatic intolerance presenting with PoTS and its association with EDS III, as well as its 
associated features, have previously not been reported. The underlying mechanism linking 
PoTS and EDS III and/or another genetic variant (should they exist) is not yet clear. Given 
the heterogeneous pathophysiology of this complex syndrome, the elucidation of a possible 
molecular defect underlying the phenotype may help to confirm the specific phenotype and 
modify management and possible preventive therapies. The aim of this study was to 
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therefore evaluate the clinical features and the autonomic dysfunction and allied features in 
families with PoTS and EDS III. 
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6.2. Methods 
 
Patients with PoTS and with at least 1 family member with a history of orthostatic intolerance 
for more than 6 months and who were referred to our Autonomic centres were included in 
the study (Figure 6.1). Patients underwent clinical examination and autonomic function tests 
as previously described (Chapter 3). Symptoms of autonomic dysfunction and allied features 
were recorded at their first visit. 
 
Figure 6.1. PoTS Patients with a family history of orthostatic intolerance referred to 
the Autonomic Units and included in the study. 
 
 
 
 
 
 
 
 
 
 
Patients with a diagnosis of PoTS and with at least 1 family member with 
a history of orthostatic intolerance (OI) referred to the autonomic unit for 
orthostatic intolerance (n = 48) 
Clinical examination and questions regarding family history of PoTS, 
AMS and EDS III 
 
21 FAMILIES 
 48 patients tested 
 45/48 with confirmed EDS III 
 22 patients/family members 
with history of OI waiting to be 
formally assessed (they had 
not undergone autonomic 
function testing as yet) 
 Total of 70 subjects with OI  
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6.3. Results 
 
Patients 
Forty eight patients (39 Females) who belonged to twenty one families were referred to our 
Autonomic Centre with a history of chronic orthostatic intolerance and had undergone 
cardiovascular autonomic function assessment. A further 22 family members of these 
families were identified with a history of OI and are awaiting formal autonomic evaluation, 
resulting in a  total of 70 cases of chronic orthostatic intolerance identified in these kindreds 
(Figure 6.1).  
 
PoTS features 
Details of the numbers of patients with confirmed PoTS and EDS III and family members are 
provided in Table 6.1. Sample pedigrees for 8 families are shown in Figures 6.2-6.9. The 
mean age was 26 ± 13 years with 45/48 (94%) patients meeting the Brighton criteria for Joint 
Hypermobility Syndrome. Autonomic screening tests showed features of PoTS in all patients 
but three, with no evidence of autonomic failure. Results of autonomic screening tests are 
provided in Table 6.2. Supine and head-up tilting (HUT) noradrenaline levels were normal in 
all patients. 
 
Symptoms 
The most frequent autonomic symptoms were: OI, 100%; syncope 84%; fatigue 83%; 
bladder dysfunction 67%; gastrointestinal dysfunction 60% and headache, 67%. However, 
the severity of the JHS and PoTS clinical phenotype varied among affected family members.  
Examples of the variability in symptom severity are provided for each family pedigree 
(Tables 6.4-6.18). Patients belonging to the same family did not always present with similar 
symptoms and florid PoTS on testing, as in Family B.  
 
Family A showed a typical pattern of florid PoTS on testing associated with multiple 
symptoms, including syncope in a daughter and less severe symptomatology reported by 
her mother. The mother had a late symptom onset and showed evidence of PoTS on 
prolonged HUT and post food ingestion. A similar pattern with a heterogeneous clinical 
phenotype was also observed in Family C (Figure 6.4) or in Family E (Figure 6.6) with florid 
PoTS in 2 daughters and evidence of PoTS only on post-exercise standing (Family C) or 
ambulatory 24 h BP and HR monitoring in their mothers (Family E). A late onset of 
orthostatic intolerance symptoms was reported by the mothers in both cases. 
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Additional features, such as Arnold Chiari Malformation type 1 (ACM1) were present in two 
sisters (Family F, Figure 6.7) with an early onset of headache and OI at the age of 8 and 11 
and with marked evidence of PoTS in one of them (Figure 6.6, II3) and normal autonomic 
findings in the other sister despite the presence of multiple autonomic symptoms, ACM1 and 
EDS III. This is an example of persistent autonomic symptomatology and evidence of EDS III 
in the absence of PoTS on autonomic testing. A similar pattern was observed in Family G. 
Some patients also presented with a very low BP profile, evidence of AMS associated with 
EDS III and only mild evidence of PoTS on testing (Family D, Figure. 6.5).   
 
Family J (Figure 6.9) showed features of florid PoTS associated with EDSIII in the first 
generation (mother, Figure 6.9, I1) and history of orthostatic intolerance manifested as AMS, 
particularly marked in one of the non-identical twins. However, none of the second 
generation family members had EDS III.   
 
Table 6.1. Families with PoTS and EDS III  
Family N of family members 
with confirmed 
autonomic 
dysfunction
N of  family members 
with EDS III
N of Pt waiting for confirmation on 
autonomic testing 
A 2/mother, daughter 2 4,son, daughter, 2 sisters
B 2/sisters 2 1/father
C 3/mother, 2 daughters 3  -
D 2 sisters 2 1/brother
E 3/ mother, 2 daughters 3 1/grandson
F 2/sisters 2 4/sister, brother, mother, grandfather
G 2/sisters 2 4 daughter/3 daughters
H 2/sisters 2  -
I 2/mother, son 2 2 daughter/grandmother
J 4/non identical twin, 
brother, mather
1/mother  -
K 2/brother and sister 2  -
L 2/brother and sister 2 2 sister and mother
M 2/ mother/daughter 2/daughter, father 1/ father with EDS III
N 2/mother, daughter 2 1/son
O 2/mother, daughter 2  -
P 2/sisters 2  -
Q 3/mother, daughter, son 3  -
R 3/ mother, 2 daughter 3  -
S 2/sister and brother 2  -
T 2/mother, daughter 2  -
U 2/sister and brother 2  -
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Table 6.2. Autonomic function test results in 48 patients with PoTS or  
suspected PoTS and familial Orthostatic Intolerance 
 
Mean ± SD 
∆ HR HUT 28 ±12
∆ HR prolonged HUT 38 ±13
∆ HR Standing 29 ±20
∆ HR HUT post exercise 23 ±21
∆ HR HUT post meal 34 ±26
Median (min-max)
Supine norepinephrine level (pg/mL) 249 (208-325)
Standing norepinephrine level (pg/mL) 383 (343-468)  
Abbreviations: HR; Heart Rate, HUT; head up tilt. 
 
 
Family A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Family A pedigree. Black denotes patients with clinical features of orthostatic 
intolerance and EDS III confirmed by autonomic and clinical tests. Grey denotes relatives 
with clinical features of orthostatic intolerance (vasovagal syncope, postural tachycardia 
syndrome) who have never been clinically tested and are awaiting autonomic screening 
evaluation. The arrow indicates the first family member referred to the Autonomic centre 
 
 
 
I 1 
II1 II2 II3 
III1 III2 III3 
Page 133 
 
Table 6.3 Autonomic cardiovascular findings in Family A
AFT PT 24 h BP/HR Meal test Exercise test
II 1 
 +++ CP P+ N P+ N
III 3 P+ P+/AMS P+ P+ P+F
a
m
il
y
 A
 
Abbreviations: AFT, autonomic screening test (HUT, standing tests); PT, prolonged HUT; 
P+, meets the criteria for PoTS on HUT, liquid meal challenge of modified exercise test or 
ambulatory 24 H BP and HR monitoring; +++, exaggerated BP response; CP, cold pressor; 
AMS, autonomic (neurally) mediated syncope; N, normal results.  
 
 
Table 6.4. Clinical features in Family A 
 
II 1 III 3
Age at onset 
(years)/ symptoms 
onset
31/difficulty 
clotting
6/syncope
Lightheadness  +  +
Dizziness  +  +
Fatigue  +  +
Palpitation  -  - 
Nausea  -  +
Headache  -  +
Bladder dysfunction  -  - 
Visceral pelvic 
prolapse
bladder prolapse
Constipation  -  +
Diarrhoea  -  - 
Chest pain  -  - 
Syncope  -  +
Hyperhidrosis  -  - 
Venous Pooling  +  - 
Paper thin like scars  -  - 
Joint pain  +  +
Subluxation  +  -
Joint clicking  -  -
Easy Bruising  -  -
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Family B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Family B pedigree. Black denotes patients with clinical features of orthostatic 
intolerance and EDS III confirmed by autonomic and clinical tests. Grey denotes relatives 
with clinical features of orthostatic intolerance (vasovagal syncope, postural tachycardia 
syndrome) who have however never been clinically tested and are awaiting autonomic 
screening evaluation. The arrow indicates the first family member referred to the Autonomic 
centre. 
 
Table 6.5 Autonomic cardiovascular findings in Family B
AFT PT 24 h BP/HR Meal test Exercise test
II 1 P+ NA P+ P+ P+
II 2 P+; +++ CP 
and ISO P+ P+ P+ P+F
a
m
il
y
 B
 
Abbreviations: AFT, autonomic screening test (HUT, standing tests); PT, prolonged HUT; 
P+, meets the criteria for PoTS on HUT, liquid meal challenge of modified exercise test or 
ambulatory 24 H BP and HR monitoring; +++, exaggerated BP response; CP, cold pressor; 
ISO, isometric exercise, AMS, autonomic (neurally) mediated syncope; N, normal results  
 
II1 II2 
Tachycardia/ 
ablation 
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Table 6.6. Clinical features in Family B 
II1 II 2
Age at onset 
(years)/ 
symptoms onset
10/pains 
in her 
joints
?/ urinary 
frequency 
and 
urgency
Lightheadness  +  +
Dizziness  +  - 
Fatigue  +  +
Palpitation  ++  +
Nausea  +  +
Headache  -  +
Bladder 
dysfunction
 -  urinary 
frequency 
and 
urgency; 
recurrent 
UTI
Visceral pelvic 
prolapse
 -  -
Constipation  -  +
Diarrhoea  -  +
Chest pain  +  - 
Syncope  +  +
Hyperhidrosis  -  - 
Venous Pooling  +  +
Paper thin like 
scars
 ++  + 
Joint pain  ++  - 
Subluxation  ++  - 
Joint clicking  ++  +
Easy Bruising  ++  - 
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Family C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Family C pedigree. Black denotes patients with clinical features of orthostatic 
intolerance and EDS III confirmed by autonomic and clinical tests. Grey denotes relatives 
with clinical features of orthostatic intolerance (vasovagal syncope, postural tachycardia 
syndrome) who have however never been clinically tested and are awaiting autonomic 
screening evaluation. The arrow indicates the first family member referred to the Autonomic 
centre. 
 
AFT PT 24 h BP/HR Meal test Exercise test
I 1  +++ CP N N N P+ on pre and 
post exe 
standing
II1  +++ CP N N P+ P+
II 2 P+; +++ CP AMS P+ P+ P+
F
a
m
il
y
 C
Table 6.7 Autonomic cardiovascular findings in Family C
 
Abbreviations: AFT, autonomic screening test (HUT, standing tests); PT, prolonged HUT; 
P+, meets the criteria for PoTS on HUT, liquid meal challenge of modified exercise test or 
ambulatory 24 H BP and HR monitoring; +++, exaggerated BP response; CP, cold pressor; 
ISO, isometric exercise, AMS, autonomic (neurally) mediated syncope; N, normal results  
 
I 1 
II 1 II 2 
Page 137 
 
Table 6.8. Clinical features in Family C 
I1 II 1 II2 
Age at onset 
(years)/ 
symptoms onset
32/pains in 
her joints
17/ 
palpitation 
syncope
16/headache; postural 
dizziness; syncope
Lightheadness  +  +  +
Dizziness  +  +  +
Fatigue  -  +  +
Palpitation  +  +  +
Nausea  -  ++
Headache  +++  +  +++
Bladder 
dysfunction
 -  + urgency, frequency, 
stess incontinence
Visceral pelvic 
prolapse
uterine 
prolapse
 -
Constipation  +  +  - 
Diarrhoea  -  -  - 
Chest pain  +  +  +
Syncope  +  +  +
Hyperhidrosis  -  -  +
Venous Pooling  -  -  - 
Paper thin like 
scars
 +  +  - 
Joint pain  +  +  +
Subluxation  +  -  +
Joint clicking  -  +  +
Easy Bruising  +  +  +
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Family D 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 6.5 Family D pedigree. Black denotes patients with clinical features of orthostatic 
intolerance and EDS III confirmed by autonomic and clinical tests. Grey denotes relatives 
with clinical features of orthostatic intolerance (vasovagal syncope, postural tachycardia 
syndrome), who have however never been clinically tested and are awaiting autonomic 
screening evaluation. The arrow indicates the first family member referred to the Autonomic 
centre. 
 
AFT PT 24 h BP/HR Meal test Exercise test
II1 Low BP Low BP N N N
II 2 AMS P+; AMS NA NA NA
Table 6.9 Autonomic cardiovascular findings in Family D
F
a
m
il
y
 D
 
Abbreviations: AFT, autonomic screening test (HUT, standing tests); PT, prolonged HUT; 
P+, meets the criteria for PoTS on HUT, liquid meal challenge of modified exercise test or 
ambulatory 24 H BP and HR monitoring; N, normal results, NA, no applicable 
 
II1 
 
II3 
 
II2 
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Table 6.10. Clinical features in Family D 
II 1 II2 
Age at onset 
(years)/ symptoms 
onset
36/ 
syncope
?/postural 
dizziness; 
syncope
Lightheadness  +  +
Dizziness  +  +
Fatigue   -  +
Palpitation  +  +
Nausea   -   -
Headache   -   -
Bladder 
dysfunction
  -   -
Visceral pelvic 
prolapse
  -   -
Constipation   -   -
Diarrhoea   -   -
Chest pain   -   -
Syncope  +  +
Hyperhidrosis  +  - 
Venous Pooling  -  - 
Paper thin like 
scars
 -  +
Joint pain  +  +
Subluxation  -  -
Joint clicking  +  +
Easy Bruising  +  +
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Family E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Family E pedigree. Black denotes patients with clinical features of orthostatic 
intolerance and EDS III confirmed by autonomic and clinical tests. Grey denotes relatives 
with clinical features of orthostatic intolerance (vasovagal syncope, postural tachycardia 
syndrome), who have however never been clinically tested and are awaiting autonomic 
screening evaluation. The arrow indicates the first family member referred to the Autonomic 
centre. 
 
 
AFT PT 24 h BP/HR Meal test Exercise test
I 1  +++ MA NA P+ NA NA
II1 P+ P+; AMS P+ P+ P+
II 3 P+; AMS NA P+ P+ P+
Table 6.11 Autonomic cardiovascular findings in Family E
F
a
m
il
y
 E
 
Abbreviations: AFT, autonomic screening test (HUT, standing tests); PT, prolonged HUT; 
P+, meets the criteria for PoTS on HUT, liquid meal challenge of modified exercise test or 
ambulatory 24 H BP and HR monitoring; +++, AMS, autonomic (neurally) mediated syncope; 
N, normal results; NA no applicable 
 
 
 
 
 
 
 
II1 
I1 
II3 
 
II2 
 
III1  III2  
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Table 6.12. Clinical features in Family E 
I1 II 1 II 3
Age at onset 
(years)/ 
symptoms onset
50/ joints pain 15/Fatigue, 
joint pain
15/ palpitation 
syncope
Lightheadness  +  -  +
Dizziness  +  -  -
Fatigue  -  +  +
Palpitation  -  +  +
Nausea  -  -  -
Headache  +  -  +
Bladder 
dysfunction
 +  +  +
Visceral pelvic 
prolapse
 -  -  -
Constipation  -  +
Diarrhoea  -  -  -
Chest pain  -  -  -
Syncope  +  -  ++
Hyperhidrosis  -  -  -
Venous Pooling  +  +  +
Paper thin like 
scars
 -
Joint pain  +  +  +
Subluxation  -
Joint clicking  -  +  +
Easy Bruising  -  +  +
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Family F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Family F pedigree. Black denotes patients with clinical features of orthostatic 
intolerance and EDS III confirmed by autonomic and clinical tests. Grey denotes relatives 
with clinical features of orthostatic intolerance (vasovagal syncope, postural tachycardia 
syndrome), who have however never been clinically tested and are awaiting autonomic 
screening evaluation. The arrow indicates the first family member referred to the Autonomic 
centre.  
 
 
AFT PT 24 h BP/HR Meal test Exercise test
II 3 P + NA P+ P+ P+
II 4 N NA NA N N
Table 6.13 Autonomic cardiovascular findings in Family F
F
a
m
il
y
 F
 
Abbreviations: AFT, autonomic screening test (HUT, standing tests); PT, prolonged HUT; 
P+, meets the criteria for PoTS on HUT, liquid meal challenge of modified exercise test or 
ambulatory 24 H BP and HR monitoring; N, normal results  
 
II1 
 
I1 
II3 
 
II2 
 
II4 
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Table 6.14. Clinical features in Family F 
II 3 II 4
Age at onset 
(years)/ 
symptoms 
onset
8/ 
headache; 
ACM1
11/ Joint 
pain; 
ACM1
Lightheadness  +  +
Dizziness  +  +
Fatigue  -  +
Palpitation  +  +
Nausea  -
Headache  +  +
Bladder 
dysfunction
 +  +
Visceral pelvic 
prolapse
 -  -
Constipation  -  -
Diarrhoea  -  -
Chest pain  +  -
Syncope  -  -
Hyperhidrosis  +  +
Venous Pooling  +  -
Paper thin like 
scars
 -  -
Joint pain  +  +
Subluxation  -  -
Joint clicking  +  +
Easy Bruising  +  +
 
Abbreviations: ACM1, Arnold Chiari Malformation type 1 
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Family G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8. Family G pedigree. Black denotes patients with clinical features of orthostatic 
intolerance and EDS III confirmed by autonomic and clinical tests. Grey denotes relatives 
with clinical features of orthostatic intolerance (vasovagal syncope, postural tachycardia 
syndrome), who have however never been clinically tested and are awaiting autonomic 
screening evaluation, blue denotes subject who we do not have clinical information. The 
arrow indicates the first family member referred to the Autonomic centre. 
 
 
AFT PT 24 h BP/HR Meal test Exercise test
I 1 AMS NA N P+ P+
I 2 N NA Low BP N N
Table 6.15 Autonomic cardiovascular findings in Family G
F
a
m
il
y
 G
 
Abbreviations: AFT, autonomic screening test (HUT, standing tests); PT, prolonged HUT; 
P+, meets the criteria for PoTS on HUT, liquid meal challenge of modified exercise test or 
ambulatory 24 H BP and HR monitoring; N, normal results  
 
I1 I2 
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Table 6.16. Clinical features in Family G 
I 1 I 2
Age at onset 
(years)/ symptoms 
onset
13/postural 
dizziness
30/joint pain; 
palpitation
Lightheadness  +  +
Dizziness  +  +
Fatigue  +  +
Palpitation  +  +
Nausea  -  +
Headache  +  +
Bladder dysfunction  +  - 
Visceral pelvic 
prolapse
 -  - 
Constipation  -  - 
Diarrhoea  -  - 
Chest pain  +
Syncope  +  +
Hyperhidrosis  -  -
Venous Pooling  -
Paper thin like 
scars
 +
Joint pain  +
Subluxation  -
Joint clicking  +
Easy Bruising  +
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Family J 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 Family J pedigree. Black denotes patients with clinical features of orthostatic 
intolerance and EDS III confirmed by autonomic and clinical tests. Diagonal line        denotes 
relatives with clinical features of orthostatic intolerance (vasovagal syncope, postural 
tachycardia syndrome), but without EDS III. The arrow indicates the first family member 
referred to the Autonomic centre. 
 
 
AFT PT 24 h BP/HR Meal test Exercise test
I 1 P+ P+ P+ P+ P+
II 1 AMS NA N P+ N
II 2 NA NA P+ NA NA
II 3 N N N N N
Table 6.17 Autonomic cardiovascular findings in Family J
F
a
m
il
y
 J
 
Abbreviations: AFT, autonomic screening test (HUT, standing tests); PT, prolonged HUT; 
P+, meets the criteria for PoTS on HUT, liquid meal challenge of modified exercise test or 
ambulatory 24 H BP and HR monitoring; N, normal results, NA, no applicable 
 
 
I1 
II1 II2 II3 
Page 147 
 
 
Table 6.18. Clinical features in Family J 
I 1 II 1 II 2 II 3
Age at onset 
(years)/ 
symptoms onset
?/postural 
dizziness
13/fatigue 
post 
infection
12/fatigue 
post 
infection
10/syncope
Lightheadness  +  +  -  - 
Dizziness  +  +  +  - 
Fatigue  +  +  +  - 
Palpitation  +  -  -  - 
Nausea  -  -  -  - 
Headache  +  -  -  - 
Bladder 
dysfunction
 +  +  -  - 
Visceral pelvic 
prolapse
 -  -  -  - 
Constipation  +  +  -  - 
Diarrhoea  -  -  +  - 
Chest pain  +  -  -  - 
Syncope  +  +  -  +++ one 
with 
resuscitation 
needed
Hyperhidrosis  -  +  -  -
Venous Pooling  +  -  -  -
Paper thin like 
scars
 +  -  -  -
Joint pain  +  -  -  -
Subluxation  -  -  -  -
Joint clicking  +  -  -  -
Easy Bruising  +  -  -  -
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6.4. Discussion 
 
The aim of this study was to evaluate the clinical features and the autonomic dysfunction 
and allied features in families with PoTS and EDS III. To further understand the clinical 
features of familial orthostatic intolerance we sought families with multiple affected 
individuals with PoTS. In these families we also evaluated the incidence of EDS III. No family 
pedigrees of PoTS and EDS III have to date been published, and we have for the first time 
described 21, two and three generation, pedigrees with PoTS and EDS III. Our major 
findings were: 1) PoTS and EDS III can present in clusters and represent a genetic disorder; 
2) Autonomic features, joint hypermobility and allied features varied among affected family 
members; 3) Familial PoTS is more frequent in women suggesting, as in AMS, a sex-
dependent modulation of the postural tachycardia and EDS III phenotype; 4) Connective 
tissue and intermittent autonomic dysfunction disorders might share a polygenetic and a 
multifactorial pathophysiology. 
 
Why might PoTS represent a genetic disorder?  
There are several features of this syndrome that suggest a genetic origin. These include, the 
clinically persistent phenotype which does not improve in all patients and does not respond 
to multiple treatments (McDonald et al., 2011; Benarroch, 2012; Mathias et al., 2012), the 
strong association with an established hereditary disorder of the connective tissue, such as 
EDS III, and the presence of the disorder over two and three family generations. 
Furthermore, more than 50% of PoTS patients present with syncope/AMS which also runs 
as a trait in the family. AMS, as showed by several studies, has a strong genetic component 
(Mathias et al., 1998; Mathias et al., 2000; Newton et al., 2003; Newton et al., 2005; 
Holmegard et al., 2013). Different genes are thought to play a role in AMS pathophysiology, 
including the b1-adrenoceptor polymorphism (Gly389Arg) (Marquez et al., 2007), the C825T 
polymorphisms of the G protein b3 subunit (Lelonek et al., 2007) and the chromosome 
15q26 locus (Klein et al., 2013). We cannot exclude the role of these genes in familial PoTS 
pathophysiology as well.  
 
Family pedigrees 
This study provides evidence that familial PoTS is strongly associated with EDS III and, their 
association might represent a hereditary disorder. Families A and F confirmed a possible 
male-to-male transmission indicating that X-linked inheritance is unlikely. A mitochondrial 
transmission also seems unlikely as the trait was not passed through women only, and was 
not inherited by all children of affected females (see Family E). There was no family where 
the trait skipped a generation supporting a typical autosomal dominant pattern of inheritance. 
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The presence of families with disease in three generations (Families A, E, F, G) makes the 
possibility of an autosomal recessive inheritance combined with high disease allele 
frequency unlikely. However, the possibility of a genetically heterogeneous disease 
transmitted by various modes of inheritance cannot be excluded.  
 
Complete or incomplete penetrance?  
If we consider the evidence of PoTS or AMS on HUT or standing tests as the physiological 
correlates of the intermittent orthostatic intolerance genotype, we cannot exclude an 
incomplete penetrance as we have not tested family members without clinical symptoms. 
Asymptomatic family members who might still present with evidence of either AMS or PoTS 
on testing would support the hypothesis of an incomplete penetrance. Therefore, their 
evaluation will be of great value in defining the genetic cluster. The relatively high proportion 
of both men and women with PoTS and EDS III, despite having no parents with the same 
clinical features (see Families C and J), is consistent with an autosomal dominant 
transmission with incomplete penetrance. 
 
Possible genes involved in pathophysiology of PoTS and EDS III 
Benign joint hypermobility syndrome (BJHS), or Ehlers–Danlos syndrome type III, is a 
connective tissue disorder (Grahame, 1999) which shares several clinical features with 
PoTS, including fatigue, presyncope/syncope, constipation, anxiety, and orthostatic 
tachycardia (Gazit et al., 2003; Mathias et al., 2012). To date, the genetic basis of joint 
hypermobility remains largely unknown. Genes encoding collagens and collagen modifying 
enzymes have been considered possible candidate genes for EDS III. A mis-sense mutation 
in the COL3A1 gene, encoding type III collagen, which normally is present in patients with 
the vascular type of EDS, has been documented in a family with features of EDS of the 
hypermobility type (Narcisi et al., 1994). However, no other mutations in COL3A1 have been 
identified since in EDS III, and it is likely that the affected family with the mutation in the 
COL3A1 gene might have had a late onset of the vascular problem (Malfait et al., 2006). 
Mutations in a non-collagenous molecule, tenascin-X, have been identified in a subset of 
patients with EDS, hypermobility type, and JHS. Tenascin-X is a large extracellular matrix 
glycoprotein, belonging to the family of tenascins. The complete absence of tenascin-X was 
characterized by skin hyperextensibility, joint hypermobility, easy bruising and tissue fragility, 
but patients did not present the atrophic scarring, typical for classic EDS and it was 
concluded that Tenascin-X deficiency could cause a clinically distinct, recessive form of the 
Ehlers-Danlos syndrome (Schalkwijk et al., 2001; Zweers et al., 2003). Of interest, women 
heterozygous carriers suffered from generalized joint hypermobility, often associated with 
joint (sub)luxation and chronic musculoskeletal pain, whereas none of the heterozygous men 
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were hypermobile (Zweers et al., 2003). These findings are in accordance with the higher 
prevalence of EDS, hypermobility type, and JHS among women, as well as in PoTS.  
 
A single gene disorder or a polygenic and multifactorial syndrome? 
Although some features are consistent with a genetic basis of PoTS and EDS III with a 
possible autosomal dominant transmission, there are a number of reasons why this might 
not be indicative of a single gene disease but most likely a multifactorial and polygenic 
disorder. Family members included in this study were tertiary nationwide referrals and might 
represent the most severe cases with symptom penetrance or family affliction that does not 
reflect most people in the general population. Typical key characteristics that suggest a 
genetic origin are a persistent clinical phenotype and the absence of obvious infectious or 
autoimmune causes; this is not always the case in PoTS as patients are often associated 
with autoimmune disorders and may present with an improvement of symptoms over time. 
This indeed implies a multifactorial nature of this syndrome and the presence of subgroups 
of patients who might have different underlying pathophysiological mechanisms. The high 
heterogeneity of the clinical features between families and, more importantly, within the 
same family, is highly suggestive of a multifactorial syndrome instead of a monogenic 
pathophysiology.  
 
This study suggests that PoTS might be a genetic disorder in some patients with a likely 
multifactorial and polygenic pathophysiology and with possible variable expressivity. 
Connective tissue and autonomic dysfunction disorders may be influenced by genetic factors 
and could play a significant role in the pathophysiology of orthostatic tachycardia and 
orthostatic intolerance in such patients with an underlying genetic predisposition to both 
conditions. Genetic testing is warranted in PoTS patients and could provide an additional 
strategy for diagnosis and treatment of this very heterogeneous patient population.  
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Chapter 7. 
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7. Chapter Seven: diagnosing PoTS: Additional investigations beyond the HUT 
and standing tests  
 
7.1. Introduction 
Diagnosing PoTS remains a challenge in some patients. The factors that can make it difficult 
to diagnose PoTS include the intermittent nature of the syndrome, the multi-system 
involvement and the heterogeneous presentation and pathophysiology (Mathias et al., 2012). 
According to the current diagnostic criteria, PoTS is diagnosed when sustained excessive 
tachycardia is noted during a HUT or standing test, accompanied by orthostatic symptoms 
(Freeman et al., 2011). The HUT test has been used to investigate the pathophysiology of 
orthostatic stress for over half a century (Hellebrandt, 1943) and was utilized as a diagnostic 
method for unexplained syncope in the 1980’s (Kenny et al., 1986). The HUT test has since 
become the standard stress test for assessing orthostatic integrity and neurovascular 
competence. Protocols for the assessment of orthostatic intolerance and to reveal postural 
tachycardia, including the use of HUT and standing tests, are not standardized however and 
vary in terms of the type of orthostatic challenge used and the duration of the tests (Plash et 
al., 2013). Furthermore, in our clinical practice, we have encountered patients with chronic 
orthostatic symptoms who do not meet the criteria of excessive tachycardia on HUT or 
standing. The current assessment of orthostatic intolerance in PoTS does not take into 
account the potential exacerbation and worsening of the postural tachycardia in response to 
daily life stimuli, including, food ingestion, physical exercise and heat stress, which often 
occurs in PoTS patients (Mathias et al., 2012). Food ingestion and physical exercise 
exacerbate orthostatic intolerance due to splanchnic vasodilatation and vascular pooling in 
the muscle beds, respectively. These routine daily activities are critical for general health and 
wellbeing and as such require consideration in the autonomic function assessment of PoTS 
patients.  
 
The liquid meal challenge and modified exercise tests are well established additional 
autonomic function assessments in the diagnosis of post-prandial hypotension and exercise-
induced hypotension, respectively, mainly in patients with chronic autonomic failure (Smith & 
Mathias, 1995; Smith et al., 1995b; Puvi-Rajasingham & Mathias, 1996; Puvi-Rajasingham et 
al., 1997b, 1998). These investigations can provide key information about symptoms and 
diagnosis in relation to these daily activities. The extent to which these stimuli might actually 
reveal a PoTS diagnosis in suspected PoTS patients, however, has not been well described 
as yet (Mathias et al., 2012; C.J. et al., 2013).  
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Another risk factor for orthostatic intolerance is heat. Hyperthermia, or a raised internal 
and/or skin temperature, diminishes an individual's tolerance to orthostatic stress, and this 
has been very well described in patients with hypertension and diabetes (Pathak et al., 2005; 
Petrofsky et al., 2005; Basu et al., 2012). Similar to food and exercise, whether heat 
unmasks a PoTS diagnosis and/or exacerbates PoTS symptoms/features, and the 
mechanisms underlying such changes, if they are present, remain poorly understood 
however and warrant further study in PoTS. Therefore, the aim of this study was to evaluate 
the cardiovascular responses to food, exercise and heat stimuli in the assessment of PoTS 
patients. 
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7.2. Methods 
 
PoTS patients with a history of chronic orthostatic intolerance and postural tachycardia of 
more than six months who were extensively investigated with a full battery of autonomic 
cardiovascular testing including, HUT and standing tests and liquid meal challenge, modified 
exercise and heat challenge tests were evaluated. A subset of PoTS patients also underwent 
a whole-body heat challenge for the examination of sudomotor function (see section 3.4.8). 
Subjects with a history of AMS but without a history of postural tachycardia and subjects with 
essential Hyperhidrosis but without a history of orthostatic intolerance were included as case 
control groups. 
 
7.2.1. Autonomic Function Tests  
Patients underwent autonomic screening tests as detailed in Chapter 3 and briefly outlined 
below. 
 
Patients underwent the following cardiovascular autonomic function tests: 
 
1. HUT (10 min rest in the supine position on a tilt bed and then tilted at 60 degrees 
head up for up to 10 min). 
 
2. Standing test. Standing still for up to 5 minutes after 10 min supine rest. 
 
In all tests blood pressure was monitored continuously using digital photoplethysmography 
and/or intermittently using upper arm sphygmomanometry. Heart rate was continuously 
monitored via 5 electrode patches taped to the chest. 
 
7.2.2. Liquid meal challenge  
 
The patient was asked to fast overnight, and undergo HUT before and 45 min after food 
ingestion (in liquid form). After the pre-meal HUT patients consumed a liquid meal (66 g 
carbohydrate, 22 g fat and 18 g protein), made up to 300 ml, via a flexible straw while supine. 
BP and HR measurements were made for 45 min post-meal when the head-up tilt to 60° was 
repeated.  
 
7.2.3. Modified graded exercise challenge 
Exercise testing was performed on a supine bicycle ergometer to remove a postural 
influence. Patients performed a Standing test before and after the graded exercise test. 
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Patients exercised at workloads of 25, 50 and 75 Watts for 3 minutes each. Measurements 
were made at the end of each stage of exercise and continued for a further 10 min post-
exercise (recovery time). The standing test was then repeated. 
 
Heart rate recovery was calculated and defined as the change from the exercise peak heart 
rate to that measured after 2 minutes of recovery (heart rate recovery = heart rate peak - heart 
rate 2-min recovery) (Cole et al., 1999; Cole et al., 2000; Nishime et al., 2000). Peak HR was 
defined as the maximum HR during the exercise workload of 75 watts; the starting point for 
recovery was identified at 2 minutes post exercise. HR during recovery was measured during 
2-10 minutes post exercise. The heart rate recovery data were normalised to the heart rate 
achieved during exercise by expressing the HR reduction in recovery as a percentage of the 
maximum HR achieved during exercise ((peak HR during exercise – HR during Recovery) / 
peak HR during exercise). 
 
7.2.4. Whole body heat challenge test 
A subset of patients (20 females) with chronic orthostatic intolerance and postural related 
tachycardia and 20 case control subjects with essential Hyperhidrosis and without a history 
of orthostatic intolerance underwent a 5 min standing test in a thermoneutral environment 
(22°C) and after a whole body heat challenge (increase in internal temperature of ~0.5°C) in 
a warm room (42°C). Blood pressure and heart rate were measured intermittently and 
symptoms were recorded. Internal temperature was indexed using aural temperature. 
 
7.2.5. Statistical Analyses 
 
SPSS Statistics for Windows was used for statistical analyses. Continuous variables were 
expressed as mean (± 1 SD). Mann-Whitney U tests were used to compare between patient 
groups (PoTS vs. AMS or PoTS vs. Hyperhidrosis). Repeated measures ANOVA and post 
hoc tests using Bonferroni corrections were used to compare the HR, BP and the changes in 
HR responses for meal, exercise and heat challenge tests. Significance was set at P<0.05. 
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7.3. Results 
A total of 95 patients with PoTS were included in this study. The mean (SD) age was 27.6 
(±10.2) yr, the majority were female (84.5%).  
 
7.3.1. Autonomic function tests  
There was a significant increase in HR on standing and HUT (both P<0.001). 39/95 (41%) 
patients met the criteria for PoTS on HUT whereas 51/95 (54%) patients fulfilled the criteria 
on standing. 20/96 (21%) patients met the criteria for PoTS on both HUT and standing tests. 
Combining the HUT and standing tests revealed a diagnosis of PoTS in 67/95 (70%). The 
HR and BP responses during HUT and standing are presented in Table 7.1. There was no 
change in SBP on HUT but there was a significant decrease in SBP on standing which did 
not meet the criteria for OH (P<0.01). There was a significant increase in DBP on HUT and 
standing (both P<0.001). Syncopal episodes occurred in 9/96 (9%) patients during HUT and 
pre-syncopal episodes occurred in 8/96 (8%) patients during standing.  
 
Based on the HR responses to HUT and standing, patients were divided in 2 groups: 1) 
patients who did meet the criteria for PoTS on both HUT and standing (AFT_positive; n=20), 
2) patients who did not meet the criteria for PoTS on both HUT or standing (AFT_negative; 
n=22). When comparing these 2 sub-groups, AFT_negative patients had a significantly 
higher supine DBP and HR (both P<0.05). During HUT, SBP was significantly higher in the 
AFT_negative group but HR was lower compared to the AFT_positive group (P<0.05; Table 
7.2). By definition, the increases in HR on HUT and standing were lower in the AFT_negative 
group (both P<0.05).  
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Table 7.1. Autonomic screening test results in PoTS 
Mean ± SD
Supine SBP 112 ± 11
Supine DBP 65 ± 7
Supine HR 70 ± 12
HUT 9 ' SBP 113 ± 20
HUT 9 ' DBP 70 ± 10 **
HUT 9 ' HR 97 ± 15 **
∆ HR 9' HUT 26 ±13
Supine SBP 113 ± 11
Supine DBP 65 ± 8
Supine HR 70 ± 12
Standing 5 ' SBP 107 ± 17 *
Standing 5 ' DBP 71 ± 9 **
Standing 5 ' HR 99 ± 15 **
∆ HR 5' Standing 28 ± 13
 
*P<0.05; **P<0.01 vs. supine 
 
Table 7.2. Orthostatic cardiovascular responses in PoTS patients who did 
(AFT_positive) and who did not (AFT_negative) meet the criteria for PoTS on AFT 
AFT_positive AFT_negative
Supine SBP 113 ± 12 116 ± 10 
Supine DBP 64 ± 7 68 ± 6 *
Supine HR 63 ± 8 76 ± 12 ***
SBP 9' HUT 113 ± 34 117 ± 15 *
DBP 9' HUT 70 ± 12 73 ± 9 
HR 9' HUT 105 ±13 90 ± 13 * 
∆ HR 9' HUT 41 ± 8 14 ± 8***
Supine SBP 113 ± 11 116 ± 10 *
Supine DBP 63 ± 8 68 ± 10 *
Supine HR 64 ± 9 77 ± 11 **
Standing 5 ' SBP 100 ± 19 115 ± 14*
Standing 5 ' DBP 70 ± 8 74 ± 12 *
Standing 5 ' HR 108 ± 16 92 ± 12 *
∆ HR 5' Standing 43 ± 11 16 ± 7 ***
 
      Abbreviations: AFT, autonomic function tests (HUT and 
         standing tests). *P<0.05, **P<0.01 vs. AFT_positive 
Page 158 
 
7.3.2. Liquid Meal challenge test 
BP and HR responses to pre and post meal HUT and during the digestion period are 
described in Tables 7.3 and 7.4. Supine SBP and DBP were significantly lower (P<0.05) and 
resting HR was significantly higher (P<0.01) post meal in patients with PoTS. In the control 
group (AMS), there was only a significant reduction in DBP at 30 minute after meal ingestion 
associated with a significant increase in HR (Table 6.4). In both PoTS and AMS this did not 
meet the criteria for post-prandial hypotension. When comparing BP and HR in patients with 
PoTS vs. control (AMS), PoTS had a lower BP and higher HR throughout the digestion 
period compared with controls (both P<0.05).  
 
There was a significant HR rise on HUT pre-meal in both PoTS and AMS (P<0.01 and 
P<0.05, respectively). However, the HR rise on HUT pre-meal was greater in PoTS and  
31/95 (33%) patients met the criteria for PoTS on HUT pre-meal whereas no patients with 
AMS had a HR rise greater than 30 bpm on HUT pre-meal. There was a significant 
exacerbation of postural tachycardia on HUT post-meal (P<0.001) only in PoTS. 61/95 (64%) 
patients met the criteria for PoTS on HUT post meal whereas only 1 patient with AMS had an 
increase of 36 bpm on HUT post meal (Table 7.3). BP was well maintained during pre and 
post-meal HUT. 
 
Table 7.3. Cardiovascular responses to HUT pre and post meal in PoTS and AMS 
Pre meal Post meal Pre meal Post meal 
Supine SBP 112 ± 12 109 ± 14* 115 ± 12 114 ± 10
Supine DBP 65 ± 7 62 ± 7* 69 ± 10 67 ± 6
Supine HR 70 ± 12
†
77 ± 13**
†† 66 ± 7  70 ± 11 *
9' HUT SBP 107 ± 14 108 ± 15 115 ± 20 106 ± 23
9' HUT DBP 70 ± 9 67 ± 11 71 ± 10 66 ± 13
9' HUT HR 96 ± 15
$$ ††
104 ± 16**
$$ ††
83 ± 12
$$
83 ± 15
$$
∆ HR 9' HUT 25 ± 14 34 ± 15** 
†† 17 ± 8 17 ± 9
Mean ± SD 
AMSPoTS
 
*P<0.05,**P<0.01 vs. pre meal; $P<0.05, $$P<0.01 vs. supine; †P<0.05, †P<0.01 vs. 
AMS 
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Table 7.4. Cardiovascular responses during the digestion period in PoTS and AMS 
PoTS AMS
Supine SBP 114 ± 12 112 ± 12
Supine DBP 65 ± 7 
† 69 ± 9
Supine HR 71 ± 13
 † 63 ± 9
Meal ingestion 
Supine SBP_10 min post meal 109 ± 9 ** 
† 115 ± 12 
Supine DBP_10 min post meal 64 ± 7 
†† 70 ± 10
Supine_HR_10 min post meal 71 ± 13
 † 66 ± 9
Supine SBP_30 min post meal 108 ± 11 ** 111 ± 10
Supine DBP_30 min post meal 60 ± 7 **
† 65 ± 7*
Supine_HR_30 min post meal 75 ± 14 ** 
† 69 ± 9*
Supine SBP_40 min post meal 107 ± 11 **
† 114 ± 10
Supine DBP_40 min post meal 60 ± 8 ** 
†† 67 ± 6
Supine_HR_40 min post meal  75 ± 14 **  70 ± 11**
Mean ± SD
 
*P<0.05, **P<0.01 vs. pre meal; $P<0.05, $$P<0.01 vs. supine; †P<0.05, †P<0.01 vs. 
AMS 
 
Patients with PoTS who did not meet the criteria for PoTS on pre-meal HUT were divided 
into 2 groups based on their HR responses to post-meal HUT: 1) patients who did not meet 
the criteria for PoTS on either pre or post meal HUT (Meal_negative) (n=19). 2) patients who 
did meet the criteria for PoTS on post meal HUT (Meal_positive) (n=30). DBP at 40 min of 
the digestion period was significantly higher in the Meal_negative group (P<0.05). This was 
maintained on HUT (P<0.05). HR was higher in the Meal_positive group on post-meal HUT 
(Tables 7.5 and 7.6). 
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Table 7.5. Cardiovascular responses in PoTS patients who didn’t meet the criteria for 
PoTS on pre and post meal HUT (Meal_negative) and those who did meet the criteria 
on post meal HUT (Meal_positive)  
Pre meal Post meal Pre meal Post meal 
Supine SBP 112 ± 10 112 ± 11 115 ± 15 115 ± 15
Supine DBP 64 ± 7 64 ± 7 66 ± 6 68 ± 8
Supine HR 73 ± 12  73 ± 12 76 ± 13 78 ± 12
9' HUT SBP 113 ± 13 106 ± 12 113 ± 18 111 ± 16 
9' HUT DBP 70 ± 9 66 ± 8 69 ± 10 72 ± 10 *
9' HUT HR 92 ± 13  103 ± 12 90 ± 14 97 ± 13 **
∆ HR 9' HUT 18 ± 9 36 ± 9 14 ± 7 19 ± 5**
Mean ± SD 
PoTS_ Meal_negativePoTS_Meal_positive
 
* P<0.05 Meal_negative vs. Meal_positive; ** P<0.01 Meal_negative vs. Meal_positive 
 
 
 
Table 7.6. Cardiovascular responses during the digestion period in PoTS patients 
who didn’t meet the criteria for PoTS on pre and post meal HUT (Meal_negative) 
and those who did meet the criteria on post meal HUT (Meal_positive) 
Supine SBP 112 ± 11 116 ± 15
Supine DBP 64 ± 7 68 ± 8
Supine HR  73 ± 12  78 ± 12
Meal ingestion 
Supine SBP_10 min post meal 108 ± 7 107 ± 13
Supine DBP_10 min post meal 63 ± 8 64 ± 8
Supine_HR_10 min post meal 72 ± 12 76 ± 11 
Supine SBP_30 min post meal 107 ± 8 109 ± 15 
Supine DBP_30 min post meal 60 ± 6 61 ± 9
Supine_HR_30 min post meal 78 ± 16 79 ± 13
Supine SBP_40 min post meal 107 ± 9 107 ± 16
Supine DBP_40 min post meal 59 ± 8 62 ± 10 *
Supine_HR_40 min post meal  79 ± 13 77 ± 13 
Mean ± SD
PoTS_Meal_positive PoTS_ Meal_negative
 
* P<0.05 Meal_negative vs. Meal_positive 
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7.3.3. Modified Exercise test 
 
41/95 (43%) patients met the criteria for PoTS on standing pre exercise whereas only one 
patient with AMS had a HR rise greater than 30 bpm on standing pre exercise. There was a 
significant exacerbation of postural tachycardia on standing post exercise (P<0.001) only in 
PoTS and, in particular, exercise unmasked postural tachycardia in 12% of patients with a 
total of 54% (51/95) meeting the PoTS criteria on standing post exercise (Table 7.7). No 
patients with AMS had an increase in HR greater than 30 bpm on standing post exercise. BP 
was well maintained during pre and post-meal standing in both groups. 
 
Supine exercise produced significant increases in SBP, DBP and HR with the increasing 
workloads in both PoTS and controls (P<0.001; Table 7.8). However, the HR rise was 
consistently higher in PoTS compared with AMS (P<0.05). 
 
The mean HR recovery from exercise was 34±14, 41±15 and 41±15 bpm at 2, 5 and 10 
minutes post-exercise, respectively. These values equated to decreases of 28%, 33%, and 
34% at 2, 5 and 10 minutes, respectively. Relative to the 75 watts stage of exercise, at 10 
min of recovery post-exercise SBP dropped significantly (P<0.01), while DBP remained 
stable (P>0.05). HR remained significantly higher at 10 min of recovery post-exercise in 
PoTS compared with controls (Table 7.8).  
 
Table 7.7. Cardiovascular responses to standing pre and post exercise  
in PoTS and AMS 
Pre exercise Post exercise Pre exercise Post exercise
Supine SBP 119 ± 11 
†
115 ± 10 **
†
113 ± 14 109 ± 11*
Supine DBP 68 ± 6 68 ± 9 69 ± 6 66 ± 5
Supine HR 74 ± 13 
††
80 ± 14 **
††
61 ± 8 71 ± 9**
5' Standing SBP 115 ± 14 116 ± 14 117 ± 13 112 ± 12
5' Standing DBP 73 ± 8 71 ± 11 76 ± 6 71 ± 9
5' Standing HR 97 ± 16 
$$ ††
106 ± 17 ** 
$$ ††
77 ± 13 82 ± 14
∆ HR 5' Standing 24 ± 15 
††
27 ± 15 
$$ ††
15 ± 9 13 ± 7
PoTS AMS
Mean ± SD 
 
*P<0.05,**P<0.01 vs pre exercise; $P<0.05, $$P<0.01 vs supine; †P<0.05, †P<0.01 vs AMS 
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Table 7.8. Cardiovascular responses to exercise in PoTS and AMS 
PoTS AMS
Supine SBP 118 ± 10 112 ± 12 
Supine DBP 68 ± 6 67 ± 5
Supine HR 71 ± 13
†
61 ± 7
SBP_EX25W 130 ± 19 
$$
130 ± 15
 $$ 
DBP_EX25W 73 ± 9 
$$
73 ± 8 
$$
HR_EX25W 102 ± 16 
$$†
92 ± 12
$$
SBP_EX50W 136 ± 15 
$$
135 ± 14
$$
DBP_EX50W 74 ± 9 
$$
73 ± 8
$$
HR_EX50W 109 ± 18 
$$†
101 ± 13
$$
SBP_EX75W 143 ± 14 
$$
157 ± 20
$$
DBP_EX75W 75 ± 10
 $$
79 ± 9
$$
HR_EX75W 121 ± 21 
$$†
111 ± 15
$$
Supine SBP 122 ± 13 121 ± 14
Supine DBP 67 ± 7 66 ± 6
Supine HR 88 ± 18
†
78 ± 11
HRR 34 ± 14 31 ± 14
% HR decrease 28 ± 10 27 ± 11
Supine SBP 115 ± 10 109 ± 11
Supine DBP 68 ± 9 66 ± 5
Supine HR 80 ± 14
†
71 ± 9
HRR 42 ± 15 39 ± 10
% HR decrease 34 ± 10 34 ± 7
10' recovery post exercise
Mean ± SD 
2' recovery post exercise
 
$P<0.05, $$P<0.01 vs. supine; †P<0.05, †P<0.01 vs. AMS. 
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Patients were divided into 2 groups based on their HR responses to pre-exercise standing: 
1) patients who did not meet the criteria for PoTS on pre and post-exercise standing 
(Exercise negative) (n=32) and 2) patients who did not meet the criteria for PoTS on pre-
exercise standing but met the criteria on post-exercise standing (Exercise_positive) (n=16). 
Exercise_positive patients presented with a significantly lower SBP and DBP during exercise 
(P<0.05). The Exercise_positive group also showed a delayed recovery in HR and a lower 
DBP at 2 and 10 min post exercise (P<0.01).  
 
Table 7.9. Cardiovascular responses to modified exercise test in PoTS who did 
(Exercise_positive) and who did not (Exercise_negative) meet the criteria for PoTS on 
modified exercise testing.  
Pre Exercise Post Exercise Pre Exercise Post Exercise
Supine SBP 120 ± 8 115 ± 8* 121 ± 12 118 ± 11
Supine DBP 69 ± 5 64 ± 4** 
† †
69 ± 6 71 ± 13
Supine HR 76 ± 12 78 ± 12 75 ± 12 79 ± 11 
5' Standing SBP 118 ± 12 114 ± 15 117 ± 15 119 ± 16 
5' Standing DBP 71 ± 5 71 ± 7 73 ± 9 74 ± 12 
5' Standing HR 93 ± 14** 
†
108 ± 12** 
†
89 ± 13 ** 96 ± 11 **
PoTS_ exercise_negativePoTS_exercise_positive
Mean ± SD 
 
*P<0.05,**P<0.01 vs pre exercise; $P<0.05, $$P<0.01 vs supine; †P<0.05, †P<0.01 vs 
exercise negative. 
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Table 7.10. BP and HR recovery post exercise in PoTS who did (Exercise_positive) 
and who did not (Exercise_negative) meet the criteria for PoTS on the modified 
exercise test. 
PoTS_exercise_
positive
PoTS_exercise_
negative
Supine SBP 118 ± 7 119 ± 11 
Supine DBP 66 ± 5 70 ± 7
Supine HR 71 ± 11 72 ± 11
SBP_EX25W 129 ± 11
†
136 ± 18 
DBP_EX25W 73 ± 9 75 ± 9 
HR_EX25W 104 ± 10 98 ± 21 
SBP_EX50W 135 ± 13
††
143 ± 17 
DBP_EX50W 70 ± 7
††
78 ± 10 
HR_EX50W 108 ± 20 108 ± 16 
SBP_EX75W 142 ± 12 147 ± 18 
DBP_EX75W 71 ± 6 
†
78 ± 12 
HR_EX75W 119 ± 19 121 ± 20 
Supine SBP 120 ± 8 126 ± 15 
Supine DBP 64 ± 7* 68 ± 7 
Supine HR 89 ± 16 84 ± 12 
HRR 29 ± 12* 38 ± 11
% HR decrease 25 ± 9** 31 ± 7 
Supine SBP 115 ± 8 118 ± 11
Supine DBP 64 ± 4 ** 71 ± 13 
Supine HR 78 ± 12 79 ± 11
HRR 41± 14 44 ± 14
% HR decrease 34 ± 8 35 ± 8
Mean ± SD 
2' recovery post exercise
10' recovery post exercise
 
Abbreviation: HRR, heart rate recovery. *P<0.05, **P<0.01 vs. exercise negative 
 
Combining autonomic screening tests with liquid meal and modified exercise 
challenge tests 
 
Using only the screening tests, which include HUT and standing tests (AFT), 67/95 (70%) 
patients would have been diagnosed with PoTS. By adding the liquid challenge meal tests to 
the AFT, 86/95 (91%) of patients would have been diagnosed with PoTS with an increase of 
21% compared with only the AFT. Whereas, adding the modified exercise test to the AFT 
revealed the diagnosis of PoTS in 80/95 (84%) of patients with an increase of 14% 
compared with only the AFT.  
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7.3.4. Whole-body heating challenge test 
A subset of 20 female patients with chronic orthostatic intolerance and postural related 
tachycardia and 20 control subjects with essential Hyperhidrosis and without history of 
orthostatic intolerance underwent a whole body heat challenge. 
 
10/20 patients (50%) with chronic orthostatic intolerance and postural related tachycardia did 
not meet the criteria for PoTS on 10 minutes HUT while the excessive tachycardia was 
unmasked on standing post-heating in all of them (standing induced increases in heart rate 
pre- and post-heating were 27 and 36 beats/min, respectively, P<0.01). HR was higher after 
heating while supine and standing in PoTS compared to Hyperhidrosis patients (both 
P<0.05). Standing tests post-heating were terminated due to syncopal events in 5 PoTS 
patients, while no syncopal or presyncopal episodes were recorded in the Hyperhidrosis 
patients.  
 
Table 7.11. Hemodynamic responses to heat challenge in PoTS and Hyperhidrosis 
Normothermia Heat Stress Normothermia Heat Stress
BASELINE SUPINE
SBP, mm Hg 115 ± 14 116 ±14 128±20 125±21
DBP, mm Hg 67± 8 64±9 74±12 68±13
HR, bpm 73 ± 10 84±19**
††
68±11 70±8
Tcore, °C 36.9 37.6** 36.8 37.4
AFTER 5' STANDING
SBP, mm Hg 117±18 111±26 131±19 122±25
DBP, mm Hg 75±12 69±15 79±14 74±15
HR, bpm 100± 21
$$
116±28**
$$††
78±10
$
89±14**
$$
Δ HR, bpm 27 ± 14 36±18*
††
9±5 19±14
PoTS Hyperhidrosis
 
*P<0.05,**P<0.01 vs. normothermia; $P<0.05, $$P<0.01 vs. supine; †P<0.05, †P<0.01 vs. 
Hyperhidrosis. 
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7.4. Discussion  
 
This study describes for the first time the diagnostic value of adding the liquid meal challenge 
and modified exercise tests, and in some PoTS patients, whole body heat challenge testing, 
to the screening cardiovascular autonomic tests (HUT and standing tests) for the 
investigation of the Postural Tachycardia Syndrome. The major findings of the study are that: 
1) the combination of HUT and standing as part of the screening assessment increases the 
probability of diagnosing PoTS; 2) patients with chronic postural tachycardia do not always 
present with a 30+ bpm increase in HR on HUT or standing but can present with marked 
exacerbation of orthostatic tachycardia (that meets the criteria for PoTS) and symptoms in 
response to daily events such as food ingestion and exercise; 3) liquid meal challenge and 
modified exercise tests are complementary tests in the evaluation of these patients, revealing 
the diagnosis of PoTS in 91% and 84% of patients, respectively, compared with 70 % if only 
the AFT (HUT and standing tests) were used; 4) the BP and HR responses to meal and 
exercise are also of value in determining the underlying mechanisms to the postural 
tachycardia and might help with the management of these patients; 5) whole body heat 
challenge test can unmask or worsen tachycardia and associated symptoms in PoTS 
patients. 
 
A detailed clinical history will often be crucial in determining the daily triggers that worsen 
symptoms in PoTS patients. The first step in the diagnostic pathway in patients with 
suspected PoTS is excluding an impairment or damage to the autonomic nervous system 
which can be obtained by using screening cardiovascular autonomic function tests (AFT) 
(C.J. et al., 2013).  HUT and standing tests alone reveal the diagnosis of PoTS in 41% and 
51% of patients, respectively, in the current study. The difference in hemodynamic responses 
to these orthostatic challenge tests are due to differences in physiology between active and 
passive standing (Sprangers et al., 1991; Wieling et al., 2007). This was confirmed in this 
study with a significant decrease in SBP on standing which did not occur during HUT. 
Previous studies have described a transient fall in BP in the first phase of standing, indicative 
of a pronounced fall in systemic vascular resistance which is not found on HUT where, 
instead, a rise of DBP is observed (Sprangers et al., 1991; Tanaka et al., 1996; Wieling et al., 
2007). The latter has been confirmed by this study with a significant increase in DBP during 
HUT. 
 
Of interest, when comparing patients who showed a HR rise >30 bpm during either HUT or 
standing (AFT_positive) with the ones who did not meet the criteria for PoTS 
(AFT_negative), there was a significantly higher resting SBP and DBP and HR and a higher 
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SBP on HUT and standing in the AFT_negative group, despite a lower HR. This indicates 
that patients with low resting BP and less prompt increases in peripheral vascular resistance 
while upright are more prone to present with postural tachycardia. This might relate to the 
excessive venous pooling in the lower limbs in some PoTS patients (Streeten, 1990). The 
higher BP may also prevent the exacerbation of postural tachycardia on HUT and standing 
tests in the AFT_negative group via baroreflex mediated reductions in HR. 
 
A drop in BP was observed during the digestion period in the present study and was 
associated with an increase in HR, consistent with the splanchnic vasodilatation in response 
to food ingestion (Da Costa et al., 1985). Patients who showed an exacerbation of postural 
tachycardia after the meal had a lower DBP at 40 min of the digestion period and on post-
meal HUT, indicating a blunted peripheral vascular resistance increase or the presence of 
vasoactive gut peptides in PoTS which could be responsible for excessive vasodilatation, 
even in the absence of feeding. The latter is supported by a beneficial effect of a 
somatostatin analogue (gut vasoactive peptides inhibitor) in PoTS (See Chapter 9) 
(Raimbach et al., 1989; Hoeldtke et al., 2006). In PoTS, splanchnic hypervolemia has been 
documented in both the supine and HUT positions (Tani et al., 2000; Stewart et al., 2005) 
and this may explain the exacerbation of the postural tachycardia in the Meal_positive group. 
Therefore, the liquid meal challenge test can be crucial in determining the different 
pathophysiological mechanism underlying the syndrome and the presence of an increased 
splanchnic hyperemia in some PoTS patients. This will help with tailoring the most 
appropriate treatment in these patients, including the use of agent which could target the 
splanchnic circulation (See Chapter 9).  
 
In normal individuals exercise raises BP, while in autonomic failure BP may fall during 
exercise (Smith & Mathias, 1996; Puvi-Rajasingham et al., 1997a, 1998; Low et al., 2012). 
This occurs presumably due to venous pooling in the lower limbs with no opposed 
compensation by the calf muscle pump and/or sympathetic vasoconstriction in other vascular 
beds (Mathias, 2013). With the modified exercise test in the present study there was a rise in 
BP and HR with increasing workloads confirming intact sympathetic adrenergic function in 
the majority of PoTS patients. The value of the rate of decline in HR after the cessation of 
exercise has been described in patients with chronic cardiovascular disease but not well 
characterized in PoTS (Cole et al., 1999; Cole et al., 2000). PoTS patients presented with a 
significantly higher HR up to 10 min of recovery post-exercise compared with controls and 
the delayed HR recovery was even more profound in the Exercise_positive group which 
might indicate a decreased vagal activity and sympathetic overactivity in these patients (Arai 
et al., 1989). Vagal reactivation is the principal determinant of the decrease in heart rate 
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during the first 30 seconds of recovery post exercise (Cole et al., 1999), instead, in PoTS, the 
absence of this prompt recovery is likely due to decreased vagal activity and may also 
explain their exercise intolerance (Parsaik et al., 2012). 
 
It is noteworthy that the patients who had both a significantly lower SBP and DBP with the 
increasing workloads, and a delayed recovery in HR post exercise, are also the ones who 
showed an exacerbation of postural tachycardia on post-exercise standing. The higher HR in 
the Exercise positive group is most likely explained by a normal autonomically mediated 
compensatory response of the heart to the lower BP during the exercise and on standing 
post-exercise in order to maintain blood pressure and the required O2 delivery. The lower BP 
during exercise and on standing post-exercise is likely to be due to the vasodilatation in the 
muscle vascular beds during physical activity.  
 
PoTS patients also presented with an exacerbation of postural tachycardia on standing post-
heating. Exposure of healthy individuals to a hyperthermic environment causes a series of 
physiological responses including increased sympathetic nerve activity (Low et al., 2011) and 
, elevations in skin blood flow and sweating to facilitate heat dissipation. These are critical 
responses for thermoregulation and hemodynamic homeostasis (Allan & Crossley, 1972; 
Johnson et al., 1973; Rowell, 1974; Peters et al., 2000). The skin represents a significant 
fraction of the total vascular conductance during heat challenge (Johnson et al., 1973; 
Crandall et al., 1996). During heat challenge, skin blood flow can reach 50 to 70% of cardiac 
output and the change in the distribution of blood with heat challenge reduces the orthostatic 
tolerance to a given postural challenge (Wilson et al., 2006a). Mechanisms reducing 
orthostatic tolerance during heat challenge are not fully understood. Several factors that 
directly or indirectly affect cerebral perfusion pressure, cerebral blood flow, and thus 
oxygenation (Wilson et al., 2006b; Low et al., 2009) may contribute to reduced orthostatic 
tolerance. Reduced vagal baroreflex regulation of HR has been described in humans during 
heat challenge (Crandall et al., 2000) and could play a role in the exacerbation of postural 
tachycardia during heat challenge in PoTS.  
 
This study’s findings expand the use of additional and complementary autonomic function 
tests in diagnosing PoTS. First, the diagnostic importance of the liquid meal challenge and 
modified exercise tests in the assessment of patients with PoTS in addition to the screening 
cardiovascular autonomic function tests was demonstrated. Second, the recovery of heart 
rate is a marker that is easily calculated from data already contained in a standardized 
exercise test and can be a helpful marker to evaluate and monitor exercise intolerance in 
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these patients. Thirdly, the hemodynamic responses to whole body heat challenge in PoTS 
and the value of the latter in revealing exacerbated postural tachycardia were evaluated.  
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8. Chapter eight: Evaluation of peripheral small nerve fibres in PoTS 
 
8.1. Introduction 
The pathophysiology of PoTS remains poorly understood and heterogeneous, and some 
patients with PoTS might have an underlying small fiber neuropathy (Mathias et al., 2012). 
The latter has been postulated and supported by evidence including: (a) a partial 
dysautonomia with distal loss of sympathetic function and impaired noradrenaline release in 
response to physiological maneuvers and also to pharmacological stimuli, such as sodium 
nitroprusside and tyramine (Jacob et al., 2000; Tani et al., 2000); (b) possible splanchnic 
sympathetic denervation with mesenteric pooling (Tani et al., 2000); (c) a reduction in 
vascular resistance responses to orthostatic stress (Bush et al., 2000) and blunted arterial 
vasoconstriction (Stewart, 2002); (d) the presence of auto-antibodies to the α3 subunit of 
nicotinic receptors in some patients raising the possibility that an immune response directed 
at autonomic ganglia or more distal neurological targets in PoTS; (e) sudomotor denervation 
evidenced via an absent distal response on the quantitative sudomotor axon reflex test 
(QSART) and anhidrosis of the feet on the thermoregulatory sweat test (Schondorf & Low, 
1993). These features/causes of peripheral denervation can lead to venous pooling and leg 
swelling with subsequent central hypovolemia upon continuous standing that could 
contribute to the marked increase in HR while upright (Stewart et al., 2003). 
 
New insights into skin structures and their innervation have been enabled by the availability 
of immunohistochemical and skin biopsy techniques. For example, the quantification of 
intraepidermal nerve fiber density (IENFD) has become a common method to evaluate 
patients presenting with small-fiber-predominant polyneuropathy (McArthur et al., 1998; 
Sommer & Lauria, 2007; Lauria et al., 2010). Intraepidermal nerve fibres (IENF) are naked 
axons which lose the Schwann cell when crossing the dermal–epidermal junction (Kennedy 
& Wendelschafer-Crabb, 1993; Lauria et al., 2004; Ebenezer et al., 2007) and they widely 
express the capsaicin receptor and are considered nociceptors (Lauria et al., 2006). The 
discovery of the pan-axonal marker protein gene product 9.5 (PGP 9.5), an ubiquitin C-
terminal hydroxylase, provided unequivocal evidence of the presence of unmyelinated nerve 
fibers in the epidermis (Wilkinson et al., 1989; Wang et al., 1990).  
 
The skin biopsy, using a minimally invasive disposable punch, is a safe and painless 
procedure under local anaesthetic, and has become the "gold standard" for quantifying small 
nerve fibres, and assessing their phenotype and is a valuable diagnostic tool in confirming 
the diagnosis of small fibre neuropathy when clinical and neurophysiologic examinations are 
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not informative (Kennedy et al., 1996; Gibbons et al., 2006; Lauria et al., 2010). It  can also 
be used, most importantly, in identifying the involvement of small nerve fibres early in the 
course of neuropathies associated with disorders, such as diabetes (impaired glucose 
tolerance and early diabetes-associated neuropathy) (Smith et al., 2001) and HIV (McArthur 
et al., 2000; Verma, 2001; Polydefkis et al., 2002; Herrmann et al., 2006). Given the 
minimally invasive procedure and the excellent repeatability, the skin biopsy has also been 
used for longitudinal studies to track small fibre degeneration changes, such as in patients 
with diabetes, where significant reductions in the numbers of PGP 9.5-immunoreactive fibers 
as well as TRPV1-immunoreacive fibers were reported after 6-months follow-up, confirming 
the high sensitivity of IENFD in detecting small fibre neuropathy (Narayanaswamy et al., 
2012). 
 
PoTS is often associated with Joint Hypermobility Syndrome (JHS), which is the most 
common heritable disorder of connective tissue. There is no molecular diagnostic testing of 
JHS and the diagnosis is based on clinical evaluation and history (Remvig et al., 2007; 
Tinkle et al., 2009). Patients with PoTS and JHS often also experience cold and heat 
intolerance, which can be detected by thermal thresholds testing. Given the strong 
association between PoTS and JHS, possible connective tissue impairment in PoTS patients 
with JHS warrants further evaluation. The site of the lesion in these patients could involve the 
peripheral autonomic pathway and the blood vessel itself or the supporting tissue, such as the 
connective tissue structures. The aim of this study was to therefore evaluate autonomic function 
and peripheral small fibre morphology in PoTS using a combination of function and 
morphology studies (punch skin biopsy technique) in order to differentiate patients with 
PoTS who may present with different patterns of neuropathy and to further understand the 
underlying pathophysiology. 
 
8.2. Methods 
Prospective PoTS patients with a history of chronic orthostatic intolerance and postural 
tachycardia and JHS of more than six months, who fulfilled the criteria for PoTS on HUT and 
normal healthy controls were evaluated. Patients underwent autonomic screening tests, as 
well as sensory tests and skin biopsies as detailed in Chapter 3 and briefly outlined below. 
 
8.2.1. Autonomic function tests 
Patients underwent the following cardiovascular autonomic function tests: 
 HUT (10 min rest in the supine position on a tilt bed and then tilted at 60 degrees 
head up for up to 10 min). 
 Isometric Exercise. 3 min of handgrip exercise at 30% of maximal voluntary force.  
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 Cold Pressor Test. 3 min of a cold pack applied to the hand. 
 Mental arithmetic. 2 min of  subtracting 7 or 17 from a suitable starting number 
(e.g. 400 or 1000) 
 Deep Breathing. Breathing at a rate of 6 breaths per minute for 1 min.  
 Valsalva maneuver. 20 s of a single breath against a fixed resistance (40 mmHg).  
 
In all tests blood pressure was monitored continuously using digital photoplethysmography 
and/or intermittently using upper arm sphygmomanometry. Heart rate was continuously 
monitored via 5 electrode patches taped to the chest. 
 
8.2.2. Sensory tests 
1. Thermal perception threshold assessment was performed using a 30 × 30 mm thermode 
placed on the foot or hand. Thermal thresholds were determined for warmth perception, cool 
perception, heat pain and cold pain from a baseline temperature of 32°C, with a change in 
temperature of 1°C/sec. The mean of four tests for each modality was recorded. Changes in 
temperature > 6.4°C for warm sensation, > 2.3°C for cool and > 10.4°C for heat pain were 
considered abnormal (Wellmer et al., 2001; Atherton et al., 2007; Narayanaswamy et al., 
2012).   
 
2. Vibration perception thresholds were measured using a biothesiometer placed on the 
metatarsophalangeal joint of the right and left big toe. The vibration threshold was expressed 
in volts; values >12 V were considered 'abnormal' 
 
3. Nerve conduction studies (NCS) of the common peroneal and sural nerves in the right leg 
were performed. Sural antidromic sensory action potentials of <5 lV amplitude and 40 m/s 
conduction velocity were considered abnormal and values <3 mV amplitude and 40 m/s 
conduction velocity were considered abnormal for the common peroneal nerve (compound 
muscle action potential from extensor digitorum brevis) (Atherton et al., 2007). 
 
8.2.3. Calf skin biopsy 
Two 3 mm diameter skin punch biopsies were collected under local anaesthesia from the 
lateral calf. 
 
Immunohistology 
The immunohistological methods and antibodies used have been reported previously (Akbar 
et al., 2008). One of the two skin biopsies was snap frozen and stored at -70°C, and the 
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other immersed in fixative (modified Zamboni's fluid – 2% formalin; 0.01 M phosphate buffer; 
15% saturated picric acid (pH 7.2), then washed in phosphate buffered saline (PBS; 0.1 M 
phosphate; 0.9% w/v saline; pH 7.3) containing 15% w/v sucrose for an hour, before snap 
freezing in optimum cutting tissue embedding medium (Tissue-Tek OCT, RA Lamb Ltd, 
Eastbourne, U.K.) to allow for best orientation. Frozen sections were collected onto coated 
glass slides and post-fixed in freshly prepared, 4% w/v paraformaldehyde in 0.15M 
phosphate buffered saline (PBS) for 30 min. Endogenous peroxidase was blocked by 
incubation in Industrial methylated spirit containing 0.3% w/v hydrogen peroxide for 30 
minutes (for both frozen and Zamboni fixed specimens).  After rehydration, sections were 
incubated overnight with primary antibodies (Table 8.1) where antibodies to the structural 
nerve marker PGP9.5 and neuropeptides (CPON/NPY, VIP, CGRP) were used only on the 
pre-fixed (Zamboni) samples. Sites of primary antibody attachment were revealed using 
nickel-enhanced, avidin-biotin peroxidase (ABC - Vector Laboratories, Peterborough, UK) 
(Akbar et al., 2008). Negative controls included omission of primary antibodies or 
replacement with normal pre-immune serum. Sections were counter-stained for nuclei in 
0.1% w/v aqueous neutral red and mounted in xylene-based mountant (DPX; BDH/Merck, 
Poole, UK) prior to analysis.   
 
Immunostaining analysis 
Intraepidermal nerve fibres (IENF) were counted along the length of four non-consecutive 
sections. The length of epithelium in each counted section was measured using 
computerised microscopy software (Olympus ANALYSIS 5.0 Soft, Olympus UK Ltd., 
Southend, Essex, UK) and results expressed as fibres/mm length of section. Sub-epidermal 
fibres (SENF) were measured by image analysis where digital photomicrographs were 
captured via video link to an Olympus BX50 microscope. The grey-shade detection threshold 
was set at a constant level to allow detection of positive immunostaining and the area of 
highlighted immunoreactivity obtained as a percentage (% area) of the field scanned.  
Images were captured (x40 objective magnification) along the entire length and the mean 
values used for statistical analysis. Quantification was performed by two independent 
blinded observers and there was no significant difference between observers. 
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Table 8.1. Antibody characteristics and target structures. 
Antibodies Target Immunoreactive structure Host Source Dilution
Anti-PGP 9.5 Protein gene product 9.5 Axons Rabbit Ultraclone Ltd, Isle of 
Wight, UK
1:50,000
Anti-TRPV1 Transient receptor potential vanilloid 
type-1Capsaicin receptor
Sensory neurons activated by 
capsacin, heat (>43 ͦC)and acid 
(pH<5.9)
Rabbit GSK, Harlow, UK 1:10,000
Anti-GAP- 43 Growth-associated protein 43 Marker of nerve fibres that are 
regenerating/ remodeling
Rabbit Sigma-Aldrich, 
Dorset, UK
1:80,000
Anti-CPON C-terminal flanking peptide of NPY Sympathetic fibres. Rabbit 1:4,000
Anti-CGRP Calcitonin gene related peptide Vasodilatory peptidergic fibres Rabbit 1:2,000
Anti-VIP Vasoactive intestinal peptide Autonomic cholinergic and 
adrenergic fibers (i.e., innervating 
sweat glands,
hair follicles, AVAs, Merkel 
complexes)
Rabbit 1:5,000
Anti-Col IV Collagen IV Basal membrane, blood vessels Mouse Abcam UK 1:1000
Chemicon Europe 
Ltd., Hampshire, UK
 
 
8.2.4. Statistical Analyses 
Descriptive statistics are presented as mean (± 1 SD) for data that were normally distributed 
or median (interquartile range [IQR]) for non-normally distributed data. Quantitative variables 
were compared between groups using independent T-Tests or ANOVA or non-parametric 
tests where appropriate. For non-normally distributed data Mann Whitney U Tests were used 
to compare two groups and Kruskal-Wallis tests were used for comparing more than 2 
groups. Pearson correlation coefficients were used to examine pairwise correlations 
between normally distributed variables. Spearman rank order correlations were used for 
analysis of relationships of qualitative variables or non-normally distributed variables. Data 
was analysed online using SPSS. A p value of <0.05 was used to indicate significance.   
 
8.3. Results  
A total of 20 patients with PoTS and JHS (19 Females; median 33 years) and 11 normal 
controls (6 Females; median 25 years) were included in the study. PoTS patients were 
divided into neuropathic (PoTS_Neurop) and non-neuropathic PoTS (PoTS_No neurop), 
defined by abnormal IENFD (reduced PGP 9.5-immunoreactive fibers). Normal values for 
PGP have been presented previously (Lauria et al., 2010) and are in accordance with 
reports from other laboratories (Umapathi et al., 2006; Bakkers et al., 2009). PoTS_Neurop 
patients were older than PoTS no Neurop (age range 32-61 years; median 46 years vs. 
range 19-51 years; median 29 years). 
 
8.3.1. Autonomic function tests 
There were no differences in supine and HUT BP between the PoTS neurop, PoTS_No 
neurop and Control groups (P>0.05). HR during HUT was significantly higher in PoTS_No 
neurop compared with PoTS_Neurop (P<0.01; Table 8.2) and in both PoTS sub-groups 
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compared to Controls. There were no differences in the pressor, Valsalva ratio or deep 
breathing responses between the groups (P>0.05). 
 
Table 8.2. Autonomic function test results in patients with PoTS and healthy controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PoTS_Neurop; PoTS patients with a confirmed neuropathy, PoTS_No Neurop; PoTS patients 
without neuropathy, $$P<0.05 vs. Control, **P<0.01 vs. PoTS_No Neurop, *P<0.05 vs. PoTS_No 
Neurop. 
 
 
8.3.2. Sensory tests  
PoTS_Neurop showed higher cool and warm perception thresholds at the hands compared 
with PoTS_ No neurop and controls (both P < 0.05, Table 8.3). There were no significant 
differences in cool and warm perception thresholds at the feet or the heat and cold pain 
thresholds at either the hands or feet between PoTS patients and controls (both P > 0.05).  
No patients had elevated vibration perception thresholds and NCS showed no abnormalities 
for sensory and motor action potentials in patients and normal controls. 
 
PoTS_
Neurop 
(n=5)
PoTS_No 
Neurop 
(n=15)
NC (n=11)
Supine SBP 122 ± 12 117 ± 15 126 ± 15
Supine DBP 69 ± 3 73 ± 11 66 ± 7
Supine HR 67 ± 6 72 ± 10 65 ± 9
9' HUT SBP 126 ± 21 114 ± 14 117 ± 18
9' HUT DBP 72 ± 5 76 ± 12 69 ± 12
9' HUT HR 92 ± 9**
$$
106 ± 9
$$
79 ± 10
∆ HR 9' HUT 24 ± 6*
$$
34 ± 7
$$
14 ± 6
Isometric exercise
∆ SBP 16 ± 17 17 ± 10 30 ± 16
∆ SBP 9 ± 12 10 ± 11 9 ± 14
Cutaneous cold
∆ SBP 12 ± 11 11 ± 11 15 ± 11
Valsalva ratio 2 ± 0.7 2 ± 0.2 2 ± 0.3
Deep Breathing  19 ± 8  25 ± 9 17 ± 7
Mental arithmetic
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Table 8.3. Thermal thresholds in patients with PoTS and healthy controls. 
PoTS_Neurop PoTS_No Neurop NC
mean ± SEM [range]
Cold Detenction (Change  ͦC)
Right foot 5 ± 2 [1.4-14] 3 ± 0.4 [0.9-6.3] 3 ± 0.6 [1-7]
Left foot 5 ± 2 [1.2- 12] 3.5 ± 0.3 [1- 6] 3 ± 0.6 [1-7]
Right hand 4 ± 2 [1.5-10] *
$
1.4 ± 0.2 [0.8-4] 1 ± 0.1 [0.5-2]
Left hand 2.2 ± 0.5 [1.5-4] *
$
1.5 ± 0.2 [0.6-3.4] 1 ± 0.2 [0.8-3]
Warm Detenction (Change  ͦC)
Right foot 6 ± 2 [3-12] 5 ± 0.6 [1.5-11] 4 ± 1 [2-13]
Left foot 7 ± 2 [4-14] 5 ± 0.7 [1-12] 4 ± 0.4 [2-7]
Right hand 2 ± 0.4 [1-4] *
$
1.5 ± 0.1 [0.7-3] 2 ± 0.1 [0.8-3]
Left hand 2 ± 0.2 [2-3] *
$
1.4 ±  0.2 [0.2-3.2] 2 ± 0.1 [0.9-3]
Cold Pain Detenction (Change  ͦC)
Right foot 26 ± 2 [20-32] 20 ± 2 [2-32] 24 ± 3 [11-32]
Left foot 25 ± 4 [11-32] 20 ± 2 [8-32] 23 ± 2 [13-32]
Right hand 23 ± 3 [13-29] 22 ± 2 [4-32] 24 ± 2 [14-32]
Left hand 24 ± 5 [9-31] 21 ± 2 [3-32] 22 ± 1 [16-31]
Heat Pain Detenction (Change  ͦC)
Right foot 12 ± 1 [9-15] 11 ± 0.9 [6-18] 12 ± 1 [8-18]
Left foot 14 ± 2 [10-18] 11 ± 1 [4-18] 11 ± 1 [8-16]
Right hand 12 ± 2 [7-17] 11 ± 1 [1.2-18] 13 ± 1 [7-18]
Left hand 13 ± 2 [8-16] 10 ± 1 [1.2-18] 12 ± 1 [8-17]
 
PoTS_Neurop; PoTS patients with a confirmed neuropathy, PoTS_No Neurop; PoTS patients 
without neuropathy, $P<0.05 vs. Control, *P<0.05 vs. PoTS_No Neurop. 
 
 
8.3.3. Calf skin biopsy  
 
8.3.3.1. PGP9.5 - Pan–neuronal structural nerve marker  
Intra-epidermal nerve fiberss (IENF) were present in all samples examined and values 
obtained for IENF per mm length of section showed a significant decrease in the 
PoTS_Neurop patient group compared with the PoTS_No Neurop and normal control groups 
(both P<0.01, Figure 8.1). The number of intra-epidermal PGP 9.5-immunoreactive fibers 
per mm (mean ± SEM) was 2.92 ± 0.53, 7.94 ± 0.55 and 6.14 ± 0.37 in PoTS_Neurop, 
PoTS_ No Neurop and controls, respectively. Measurement (immunoreactivity % area) of 
sub-epithelial fibers showed no differences between patients and controls (P>0.05, Figure 
8.1).  
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Figure 8.1. PGP9.5 immunoreactive intra- and sub-epidermal nerve fibers in skin biopsies from 
(a) Control; (b) PoTS_Neurop, (c) PoTS_No Neurop (20x) (d) PoTS_No Neurop (40x). 
Measurement of PGP9.5-immunoreactive IENF (e) and SENF (f) in controls and patients. 
**p<0.01 PoTS_Neurop vs. PoTS_No Neurop, 
$$
p<0.01 PoTS_Neurop vs. control. 
 
8.3.3.2. TRPV1 - Sensory nerve marker and heat and capsaicin receptors  
Skin biopsies from all groups showed TRPV1-immunoreactive intra- and sub-epidermal 
nerve fibers (Figure 8.2). Measurement of intra-epidermal TRPV1-immunoreactive nerve 
fibers showed a significant decrease in PoTS_Neurop compared with PoTS_No Neurop and 
normal controls (both P<0.01, Figure 8.2). The number of intra-epidermal TRPV1-
immunoreactive fibers per mm (mean ± SEM) was 2.59 ± 0.28; 6.7 ± 0.64 and 5.47 ± 0.59 in 
PoTS_Neurop, PoTS_No Neurop and controls, respectively. Measurement 
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(immunoreactivity % area) of sub-epithelial fibers showed a significant decrease in 
PoTS_Neurop compared with PoTS_No Neurop (P<0.05, Figure 8.2). 
 
 
Figure 8.2. TRPV1- immunoreactive intra- and sub-epidermal nerve fibers in skin biopsies from 
(a) Control; (b) PoTS_Neurop, (c) PoTS_No Neurop.  Measurement of TRPV1-immunoreactive 
IENF (d) and SENF (e) in controls and PoTS patients. **p<0.01 PoTS_Neurop vs PoTS_No 
Neurop, 
$$
p<0.01 PoTS_Neurop vs control, 
$
p<0.05 PoTS_Neurop vs control. 
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8.3.3.3. GAP-43 – Nerve regeneration marker 
 
GAP-43 immunoreactive nerve fibers were sparse but seen in most of the samples, 
generally in the sub-epithelium (Figure 8.3). Measurement (% immunoreactive area) of GAP-
43 immunoreactivity showed no significant differences between patients and controls 
(P>0.05). 
 
 
Figure 8.3. GAP_43immunoreactive sub-epidermal nerve fibers in skin biopsies from 
(a) Control; (b) PoTS_Neurop, (c) PoTS_No Neurop. Measurement of GAP-43-
immunoreactive SENF (d) in controls and PoTS patients.    
 
 
8.3.3.4. Vasoactive Intestinal Polypeptide (VIP) 
VIP-immunoreactive nerve fibers were found predominantly around eccrine sweat glands 
(Figure 8.4). Image analysis (% area) of VIP immunoreactivity around sweat glands showed 
no significant differences between patients and controls (P>0.05).  
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Figure 8.4. VIP immunoreactive  nerve fibers associated with eccrine sweat glands in 
skin biopsies from (a) Control; (b) PoTS_Neurop, (c) PoTS_No Neurop. Measurement 
(% area) of VIP-immunoreactivity (d) in controls and PoTS patients. 
 
 
8.3.3.5. C-flanking peptide of neuropeptide Y (CPON) 
CPON-immunoreactive nerve fibers were found to be associated mostly with blood vessels 
(Figure 8.5) although some were found around eccrine sweat glands. Measurement (%area) 
of CPON-immunoreactivity showed no significant differences between patients and controls 
(P>0.05). 
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Figure 8.5 CPON - immunoreactive nerve fibers associated with blood vessels in skin 
biopsies from (a) Control; (b) PoTS_Neurop, (c) PoTS_No Neurop. Measurement of 
CPON-immunoreactivity (d) in controls and PoTS patients. 
 
 
8.3.3.6. Calcitonin gene-related peptide (CGRP) 
CGRP immunoreactive nerve fibers were most prominent in the sub-epidermis and present 
in biopsies from all patient groups and controls (Figure 8.6). Measurement (%area) of CGRP 
immunoreactivity showed no significant differences between patients and controls (P>0.05). 
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Figure 8.6 CGRP immunoreactive nerve fibers in the sub-epidermis in skin biopsies 
from (a) Control; (b) PoTS_Neurop, (c) PoTS_No Neurop. Measurement of sub-
epidermal CGRP immunoreactivity (d) in controls and patients.   
 
8.3.3.7. Collagen IV 
For the Collagen IV analyses, all PoTS patients were grouped together due to the link 
between JHS and collagen. Collagen IV immunoreactivity was found to be associated with 
basement membranes and blood vessels (Figure 8.7) although immunoreactivity was also 
found around eccrine sweat glands. Measurement (%area) of Collagen IV immunoreactivity 
showed significant decrease in PoTS compared with controls in both basement membranes 
and blood vessels (both P<0.05, Figure 8.7).   
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Figure 8.7 Collagen IV immunoreactivity in skin biopsies from Control (a, 40 X; b, 20 
X); and PoTS (c, 40 X; d, 20 X).  Measurement of Collagen IV immunoreactivity (e) in 
controls and PoTS patients. $p<0.05 vs. Control. 
 
Correlation Analyses 
There was no significant correlation between the reductions in IENF and Collagen IV and the 
cardiovascular autonomic function data, e.g., changes in BP and HR on HUT, or thermal 
thresholds data in PoTS patients (P>0.05). 
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8.4. Discussion 
 
The aim of this study was to evaluate autonomic function and peripheral small fiber 
morphology in PoTS using a combination of function and morphology studies (punch skin 
biopsy technique) in order to differentiate patients with PoTS who may present with different 
patterns of neuropathy and to further understand the underlying pathophysiology of PoTS. 
Our major findings were: 1) a subgroup of patients with PoTS and JHS have an underlying 
small fiber neuropathy confirmed by reduction in the numbers of PGP 9.5-immunoreactive 
fibers as well as TRPV1-immunoreacive fibers, and  impaired cool and warm perception 
thresholds, 2) PoTS patients with JHS also showed a reduction in Collagen IV in basement 
membranes and blood vessels in the skin; 3) multiple pathophysiological mechanisms could 
coexist in the same patients, including, a small fiber neuropathy, and collagen abnormalities, 
suggesting a multi-factorial disorder; 4) the skin biopsy is a valuable tool to differentiate 
PoTS sub-groups, e.g., those with and without a small fiber neuropathy. To our knowledge, 
this is the first prospective study of morphology and function of peripheral small nerve fibers 
and collagen IV in PoTS.  
 
PoTS remains a poorly understood disease affecting a predominantly young, female, and 
otherwise healthy population. It is increasingly apparent that PoTS has a strong association 
with JHS and that an involvement of connective tissue and peripheral small fibers can 
represent an underlying pathology in a subset of these patients. In this study, we evaluated 
the hypothesis that small nerve fibers, and collagen IV, the major constituent of basement 
membranes and small blood vessels in the skin, may be affected in PoTS using the skin 
biopsy technique. Skin biopsies have expanded the evaluation of autonomic disorders and 
quantification of autonomic nerve fibers. Autonomic innervation of sweat glands and 
pilomotor nerves have been quantified in diabetes (Wellmer et al., 1999; Gibbons et al., 
2009; Nolano et al., 2010) and loss of sudomotor fibers has been shown to correlate with 
hyperglycemia (Luo et al., 2012). Hereditary peripheral neuropathy affecting the somatic and 
autonomic small nerve fibers such as Fabry’s disease, familial dysautonomia and congenital 
insensitivity of pain (Scott et al., 1999; Nolano et al., 2000; Hilz et al., 2004; Schiffmann et 
al., 2006), primary erythromelalgia (Davis et al., 2006) and chronic regional pain syndrome 
type I (Oaklander et al., 2006) have all been assessed by using the punch skin biopsy 
technique. Patients with chronic idiopathic constipation have selective small fiber neuropathy 
with selective deficit of unmyelinated afferent fiber function in the feet or a selective post-
ganglionic sympathetic cholinergic fibers impairment in a subset of them (Raethjen et al., 
1997; Knowles et al., 1999). However, a systematic evaluation of peripheral somatic and 
autonomic small nerve fibers and Collagen IV in PoTS has not been described as yet. 
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The PoTS_Neurop sub-group showed impaired cool and warm perception thresholds 
indicating a functional impairment of A-delta and C-fibers. The reduction in the number of 
PGP 9.5 and TRPV1- immunoreactive fibers confirmed the involvement of small nerve fibers 
in the lower leg in this sub-group of PoTS. Significant reductions in the number of PGP 9.5-
immunoreactive fibers, as well as TRPV1-immunoreacive fibers, have been described in the 
early course of diabetic neuropathy (Narayanaswamy et al., 2012). However, patients with 
PoTS do not present with typical symptoms suggestive of a small fiber neuropathy, including 
acral burning pain. Patients with PoTS and JHS typically present with generalized muscle 
and joint pain which is distinct from the typical small fiber neuropathy presentation. In 
patients with painful small fiber neuropathy in the context of diabetes mellitus, the acral 
burning pain is due to the impairment of C-fibers and the loss of the filtering function that 
allows small fibers to conduct only a small fraction of all incoming volleys elicited by painful 
stimuli. As a result of this, impaired small fibers conduct the majority of elicited action 
potentials which generate burning pain (Sun et al., 2012b). Small fiber involvement has 
recently been described in patients with fibromyalgia (Uceyler et al., 2013) and the more 
localized complex regional pain syndrome (Oaklander & Fields, 2009). In patients with 
fibromyalgia and small fiber neuropathy, who experience deep muscle pain, but no acral 
burning pain, authors have postulated that deep muscle pain might be due to the loss of the 
filtering function not just in the skin but also in muscle and joint afferents (Uceyler et al., 
2013). An impairment of C fibers could also lead to a lower pain threshold and chronic 
muscle pain and, possibly, a similar process could occur in patients with PoTS_Neurop and 
JHS.   
 
There were no differences between PoTS and controls with regards to other skin markers, 
including GAP-43, VIP, CPON and CGRP. GAP-43 is a skin marker of regeneration and 
remodelling of nerve fibers. No active regenerative and collateral sprouting processes were 
observed in the PoTS_Neurop sub-group. The reason for this could be attributable to deficits 
in nerve growth factor production, or local inflammation and an inhospitable environment for 
axonal outgrowth to occur, as has been described in patients with diabetic small fiber 
neuropathy (Ebenezer et al., 2011). However the current sample is too small to confirm this 
hypothesis and larger study needs to be undertaken to confirm this.   
 
VIP is a marker of autonomic cholinergic and adrenergic fibers (i.e., innervating sweat 
glands, hair follicles, AVAs, Merkel complexes) while CPON is a marker of sympathetic 
fibers. There were no observed differences in these two markers between PoTS and 
controls although sudomotor denervation confirmed by absent distal responses on the 
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quantitative sudomotor axon reflex test (QSART) and anhidrosis of the feet on the 
thermoregulatory sweat testing (Schondorf & Low, 1993) have been described in 
neuropathic PoTS. We cannot exclude an effect of a small sample (only 5 PoTS_Neurop) in 
the current study, which could account for this lack of evidence.  
 
The sensory neuropeptide calcitonin gene-related peptide (CGRP) is present in nerve fibres 
in human skin and, in addition to a neurotransmitter role, it is also a trophic agent, as is 
substance P (Senapati et al., 1986). These two peptides have been shown to be reduced in 
neurodegenerative disorders, such as MSA, (Anand et al., 1988) and in hereditary familial 
dysautonomia (Hilz et al., 2004) but no similar pattern was documented in the PoTS_Neurop 
sub-group.  
 
PoTS patients with JHS showed abnormalities in Collagen IV in basement membranes and 
blood vessels. Collagen IV is the primary collagen found in the extracellular basement 
membranes separating a variety of epithelial and endothelial cells and mostly found in the 
lamina densa. It has an important role in wound healing as shown by several studies (Wick 
et al., 1980; Betz et al., 1992). Immunohistochemical stains with monoclonal antibodies have 
localized two basement membrane components, including the laminin and type IV collagen 
in the nerves and sensory nerve mechanoreceptors supplying human digital skin (Vega et 
al., 1995). PoTS and JHS can present in clusters and likely represent a genetic disorder and, 
in particular, connective tissue and intermittent autonomic dysfunction disorders might share 
a polygenetic and a multi-factorial pathophysiology (see Chapter 6). The evidence of a 
reduction in collagen IV in patients with PoTS and JHS supports the role of connective tissue 
dysfunction in the pathogenesis of PoTS and further studies, including different phenotypes, 
will need to be undertaken in the future. Furthermore, the PoTS_Neurop sub-group showed 
a lower HR on HUT possibly due to a decreased ability to elevate HR while upright. This 
might contribute to the poor response to medication in some of these patients (Mathias et al., 
2012). The PoTS_Neurop sub-group were slightly older than the PoTS_No neurop sub-
group and the contribution of aging on small fiber degeneration needs to be considered. 
There is a significant reduction in cutaneous nerve terminals with aging, with a linear 
reduction of IENF densities starting from adulthood (Chang et al., 2004). 
 
In conclusion, this study indicates that some patients with PoTS and JHS have an underlying 
small fiber neuropathy and that PoTS patients with JHS also have a reduction in Collagen IV 
in basement membranes and blood vessels in the skin. These findings suggest that multiple 
pathophysiological mechanisms could coexist in PoTS patients, suggesting a multi-factorial 
disorder and that a combination of morphological analyses of skin biopsies and peripheral 
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small nerve fiber function tests can differentiate PoTS subtypes and help further understand 
the underlying pathophysiology. 
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9. Chapter Nine: The beneficial effects of the somatostatin analogue, Octreotide, 
on orthostatic intolerance and cardiovascular autonomic function before and 
after food ingestion in the Postural Tachycardia Syndrome (PoTS)  
  
9.1. Introduction 
 
The Postural Tachycardia Syndrome (PoTS) is characterized by an excessive heart rate 
(HR) increase of ≥ 30 bpm or a HR > 120 bpm within 10 minutes of head-up tilting (HUT) or 
standing, and symptoms of orthostatic intolerance that include dizziness and palpitations 
(Freeman et al., 2011; Mathias et al., 2012). In addition to symptoms of orthostatic 
intolerance, there may be visceral involvement involving multiple systems that include the 
upper and lower gastrointestinal tract (Zarate et al., 2010) and urinary bladder (Mathias et 
al., 2012). The assumption of the upright position is the cardinal factor that induces 
orthostatic intolerance symptoms in PoTS, and vasodilatation induced by gravitational forces 
when upright appear causative. A subset of patients are worse after food ingestion or 
physical exertion (Mathias et al., 2012)(see Chapter 5) presumably as a result of 
vasodilatation within the splanchnic circulation or previously exercising skeletal muscles. 
After ingestion of food, multiple adjustments involving the nervous, cardiovascular and 
endocrine systems occur to counteract splanchnic vasodilatation and maintain blood 
pressure in normal individuals. Food lowers blood pressure in autonomic failure disorders, 
such as Pure Autonomic Failure and Multiple System Atrophy, as compensatory increases in 
sympathetic nervous activity (Mathias et al., 1989; Mathias, 1990, 1991; Mathias et al., 
1991) and vasoconstriction of the superior mesenteric artery are impaired or absent (Kooner 
et al., 1989b; Chaudhuri et al., 1992; Chaudhuri et al., 1994). In PoTS, splanchnic 
hypervolemia has been documented in both the supine and HUT positions (Tani et al., 2000; 
Stewart et al., 2005). The management of these patients is often challenging, and not always 
effective despite a combination of non-pharmacological measures, and multi-step 
pharmacotherapy. Current treatment includes Fludrocortisone, midodrine, beta blockers, 
ivabradine, and Pyridostigmine alone or in combination (Freitas et al., 2000; Raj et al., 
2005b; Raj et al., 2009; McDonald et al., 2011; Mathias et al., 2012).  
 
Octreotide is a somatostatin analogue, which inhibits the release of a range of peptides, 
prevents splanchnic vasodilatation and is effective in reducing postprandial hypotension in 
autonomic failure (Hoeldtke et al., 1986; Kooner et al., 1989a; Kooner et al., 1989b; 
Raimbach et al., 1989) and recently has also been shown to improve orthostatic tolerance in 
normal healthy control individuals (Jarvis et al., 2012). These findings suggest that 
Octreotide might be beneficial in improving the regulation of blood pressure during 
Page 191 
 
orthostasis as well as orthostatic intolerance in PoTS. Previous studies have reported an 
acute beneficial effect of Octreotide in PoTS in small patient groups (Hoeldtke et al., 2006, 
2007; Kanjwal et al., 2012). Its role in reducing orthostatic tachycardia in the fasted state and 
also after food ingestion has not been investigated however. Therefore, the aim of this study 
was to evaluate the pre and post-prandial cardiovascular autonomic function response to the 
acute use of Octreotide in PoTS patients resistant to current medications.  
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9.2. Methods 
 
Subjects 
We studied 21 PoTS patients who were previously treated with non-pharmacological 
measures and were also not responsive to first and second line pharmacological treatments, 
including, Fludrocortisone, midodrine, ivabradine and beta blockers alone or in combination.  
PoTS was confirmed on autonomic function screening HUT at 60º and was diagnosed by 
symptoms of orthostatic intolerance associated with a HR increase of ≥ 30 bpm or HR > 120 
bpm within 10 minutes of HUT as defined by current consensus criteria (Freeman et al., 
2011). Patients had at least a 6 months history of orthostatic intolerance symptoms. 
 
Study protocol 
Patients were studied on two separate days; with and without Octreotide. Baseline 
measurements were made after equilibration, in the supine position for at least 10 min. 
During the Octreotide trial, patients were then given 50 mcg of Octreotide subcutaneously, 
followed 10 min later by HUT for 10 min. Following return to the horizontal, a liquid meal (66 
g carbohydrate, 22 g fat and 18 g protein), made up to 300 ml and administered via a flexible 
straw was administered while the patient was supine. Measurements were continued for a 
further 45 min after which head-up tilt to 60 ° was repeated for 10 min. Symptoms were 
recorded throughout the test. HUT was terminated if syncopal or pre-syncopal events 
occurred, in this case measurements were made at the longest time upright. Blood pressure 
and heart rate were monitored throughout both protocols (upper arm) using automated 
sphygmomanometry. A positive response was considered a significant HR decrease on HUT 
pre or post meal (relative to the Control trial) associated with improvement of orthostatic 
intolerance symptoms.  
 
Statistical analysis 
Descriptive statistics are presented as mean ± 1 SD. Comparisons of absolute or changes in 
systolic and diastolic BP, mean arterial blood pressure (MAP) and HR across different time 
points (e.g., pre and post meal and/or supine vs. HUT) between trials were made using 
mixed model repeated measures ANOVA (main effects of time and trial) online (SPSS). 
MAP was calculated as diastolic pressure plus one-third of pulse pressure. Significance was 
set at P<0.05. 
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9.3. Results 
 
Twenty one female PoTS patients, (mean age 31 ± 12 years) were included in the study. 
The average disease duration was 5 ± 3 years.  
 
Liquid meal challenge without Octreotide:   
Baseline supine HR was 71 ± 13 bpm with an average increase during pre and post meal 
HUT of 26 ± 14 and 41 ± 15 bpm, respectively (Figure 9.1). MAP was well maintained during 
both pre and post meal HUT (Figure 9.2). There was a significant fall in MAP at 20, 30 and 
40 minutes following the liquid meal which did not meet the criteria for post prandial 
hypotension (Figure 9.2, P<0.05). Symptoms of orthostatic intolerance were reproduced 
during both HUT in all patients. 
 
Liquid meal challenge with Octreotide:  
Baseline supine HR was 70 ± 13 bpm with a significant decrease following Octreotide 
administration (58 ± 16 bpm, Figure 9.1; P<0.05) that persisted throughout the remainder of 
the protocol. There was no change in BP following Octreotide (Figures 9.2-9.3, P>0.05). The 
elevations in heart rate during pre- and post-meal HUT were significantly reduced during 
Octreotide (13 ± 9 and 18 ± 11 bpm, respectively, both P<0.05 vs. control; Figure 9.4).  
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Figure 9.1. Effect of Octreotide on Heart Rate supine and during head up tilting in PoTS 
patients before and after ingestion of a balanced liquid meal. *P<0.05 vs. Octreotide, $P<0.05 
vs. Supine. 
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Figure 9.2. The effect of Octreotide on MAP supine and during head up tilting in PoTS patients 
before and after ingestion of a balanced liquid meal. $P<0.05 vs. Supine, #P<0.05 vs. Pre-
Prandial Supine. 
 
MAP was maintained during both HUT (Figure 9.2, P>0.05). Both HUT were associated with 
an improvement in orthostatic intolerance symptoms relative to control. Five patients could 
not tolerate the 10 minutes of HUT pre and post meal without Octreotide; 3 of them were 
able to sustain 10 minutes of HUT without symptoms while on Octreotide. The remaining 2 
patients requested to terminate pre and post meal HUT in both trials, however HR was 
reduced pre and post meal after Octreotide in both patients and they reported an 
improvement of orthostatic symptoms (Pt 1 pre meal HUT increase in HR 46 vs. 6 bpm, post 
meal HUT 23 vs. 11 bpm, control vs. Octreotide, respectively; Pt 2 pre meal HUT increase in 
HR 46 vs. 10 bpm, post meal HUT 54 vs. 20 bpm, control vs. Octreotide, respectively). 
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Figure 9.3. The effect of Octreotide on Blood Pressure (Systolic upper series, Diastolic lower 
series) supine and during head up tilting in PoTS patients before and after ingestion of a 
balanced liquid meal.  $P<0.05 vs.  Supine, #P<0.05 vs. Pre-Prandial Supine. 
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Figure 9.4. Changes in Heart Rate during head up tilting in PoTS patients before and after 
ingestion of a balanced liquid meal with and without octreotide. *P<0.05 vs. Control, #P<0.05 
vs. Pre-prandial. 
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9.4. Discussion 
 
The aim of this study was to evaluate the pre and post-prandial cardiovascular autonomic 
function response to the acute use of Octreotide in PoTS patients resistant to current 
medications. We have demonstrated for the first time, the beneficial effect of 50 mcg of 
subcutaneous Octreotide on orthostatic haemodynamic responses before and after food 
ingestion in PoTS. Events in daily life such as food ingestion, exercise and heat, each of 
which cause vasodilatation, are now recognized as unmasking or aggravating tachycardia in 
PoTS (Mathias et al., 2012) and evaluating the BP and HR responses to such stimuli is of 
value in the assessment and management of these patients in their daily life (see Chapter 
7). In addition, as demonstrated in this study, a liquid meal challenge test aids the 
determination of whether drugs such as Octreotide reduce postural tachycardia and 
symptoms of orthostatic intolerance pre and post prandially. It is also of value in objectively 
evaluating the minimal test dose able to improve autonomic symptoms, whether there any 
adverse effects in a controlled environment, and thus provide evidence for individually 
tailored management.  
 
Subcutaneous injection of 50 mcg of Octreotide significantly reduced supine resting HR 
within 10 minutes of administration, reduced orthostatic tachycardia on HUT pre and post 
meal and improved symptoms of orthostatic intolerance, as well as syncopal and pre-
syncopal episodes. Splanchnic hypervolemia has been documented in PoTS and 
pharmacotherapy targeting the splanchnic circulation could have important clinical utility in 
the management of these patients (Tani et al., 2000; Stewart et al., 2005; Stewart et al., 
2006b). It is well documented that 50 mcg of subcutaneous Octreotide prevents splanchnic 
vasodilation in patients with autonomic failure (Kooner et al., 1989a; Armstrong & Mathias, 
1991; Cooper et al., 1991; Alam et al., 1995; Chaudhuri et al., 1995) and our findings, 
showing its beneficial effect in PoTS, support the concept that the ability to adequately 
regulate the splanchnic circulation is crucial in overall blood pressure and heart rate control 
in this patient group.  
 
The splanchnic circulation is a major vascular capacitance site and an important region for 
cardiovascular homeostasis (Greenway, 1983). Arterial blood pressure is determined by the 
product of cardiac output and total peripheral resistance (Guyton, 1981). Cardiac output 
distribution into the entire systemic circulation, which consists of many parallel circuits to 
major organs and tissues, varies among the individual vascular circuits with the splanchnic 
circulation receiving ~25-30% of resting cardiac output (Rowell, 1975). Splanchnic blow flow 
increases in circumstances with high metabolic demands, such as post feeding, and 
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appropriate perfusion can be obtained by either increased cardiac output or its redistribution 
from other vascular beds. Because of its important role in cardiovascular homeostasis and 
redistribution of blood flow, the splanchnic circulation needs to be finely regulated (Gelman & 
Mushlin, 2004).  
 
In the unfed state, Octreotide significantly reduced supine resting HR and reduced the 
orthostatic tachycardia on pre-meal HUT, suggesting an effect on resting splanchnic 
vascular tone. Resting vascular tone is regulated by numerous mechanisms, that include, 
neurally mediated constriction of large arteries and arterioles (>50 µm) under the influence of 
central and peripheral sympathetic pathways (Donald & Shepherd, 1980; Hilton & Spyer, 
1980);  metabolic mediated vasoconstriction by decreasing PO2, pH, and osmolarity and 
increasing PCO2 or adenosine (Sparks 1980); paracrine and autocrine mediated 
vasoconstriction by releasing local mediators such as endothelin 1 (Wiest et al., 2001),  
platelet activating factors and constrictor prostaglandins; and finally humoral mediated 
vasoconstriction involving angiotensin II, vasopressin, serotonin and activated complement 
(C5a) (Gardiner et al., 1988). In patients with PoTS, an excessive splanchnic blood flow at 
rest and during HUT has been documented, suggesting abnormal regulation of splanchnic 
vascular tone (Tani et al., 2000; Stewart & Montgomery, 2004; Stewart et al., 2005; Stewart 
et al., 2006b). As to which, individually or in combination, of these aforementioned 
mechanisms of splanchnic vascular tone regulation is impaired in PoTS has not been fully 
investigated. However, impaired neurally mediated vasoconstriction is unlikely to play a role 
as peripheral sympathetic vasoconstriction is usually normal in these patients (Stewart et al., 
2006b) and selective splanchnic sympathetic failure is unlikely to occur in them. It may be 
that in PoTS, metabolic and humoral mediated vasoconstriction abnormalities or the 
presence of substances causing excessive vasodilatation may play a role in splanchnic 
hyperemia at rest, and even during orthostasis. Adrenomedullin, a vasodilator peptide, is 
widely dispersed in vascular endothelium and has been found to be higher in PoTS patients 
suggesting, as one example, a role of vasoactive peptides into the pathophysiology of this 
disorder (Benditt & Chen, 2012; Zhang et al., 2012).   
 
In the unfed state, Octreotide may reduce orthostatic tachycardia and intolerance by 
enhancing the release of local vasocontrictor mediators such as Endothelin 1 (Wiest et al., 
2001), or act via the inhibition of the basal level of a range of vasoactive gut peptides 
including insulin, glucagone, pancreatic polypeptide, gastric inhibitory peptide, secretin, 
vasoactive intestinal polypeptide (VIP), cholecystokinin (CCK8)(Kooner et al., 1989a; Cooper 
et al., 1991). Higher basal levels of vasoactive gut peptides in PoTS could also be 
responsible for excessive vasodilatation even in absence of feeding.  
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A further finding in this study of importance is the immediate reduction in HR within 10 
minutes of Octreotide administration. Bradycardia in response to Octreotide, has been 
described in several case reports (Herrington et al., 1998; Dilger et al., 2004; Erem et al., 
2006; Batra et al., 2007). However the mechanism by which Octreotide induces an 
immediate and significant decrease in HR remains uncertain. A possible explanation may be 
its direct effect on the heart. Somatostatin has been reported to have negative inotropic and 
chronotropic effects (Herrington et al., 1998). An indirect negative inotropic effect may also 
be the result of Octreotide-induced VIP suppression (Henning & Sawmiller, 2001). The 
presence of VIP immunoreactive nerve fibers in and around the sinus and the 
atrioventricular nodes strongly suggest that this peptide can affect heart rate (Henning & 
Sawmiller, 2001). In the sino-atrial node, a VIP-induced increase in cAMP can activate the 
pacemaker If current and accelerate heart rate (Chang et al., 1994; Accili et al., 1996; 
Henning & Sawmiller, 2001). The mechanism of action of Octreotide on reducing HR may be 
via suppression of VIP release having a similar effect to the one induced by Ivabradine 
(McDonald et al.; Ewan et al., 2007).   
 
The beneficial effect of Octreotide on orthostatic intolerance and tachycardia at rest and pre 
meal was maintained post-prandially, likely due to similar mechanisms discussed above as 
well as the well known effect of Octreotide in suppressing post-prandial  secretion of several 
vasoactive peptides (Kooner et al., 1989a; Cooper et al., 1991) and associated splanchnic 
vasodilation.  
 
A further question in understanding the hemodynamic effect of Octreotide may relate to a 
direct vasoconstrictor effect. This cannot be excluded in this study. However it is unlikely, as 
there was no change in BP and MAP in our patients following Octreotide administration. A 
transient increase in blood pressure after Octreotide has been documented in patients with 
autonomic failure (Armstrong & Mathias, 1991), but in these patients impaired sympathetic 
innervation and supersensitivity, with up-regulation of vascular receptors is usually present. 
In addition, Octreotide was tested in an acute setting in the present study, and long term 
benefits alongside safety profiles will need to be addressed in future studies.  
 
In conclusion, Octreotide was an effective drug in reducing orthostatic tachycardia and 
improving symptoms of orthostatic intolerance in PoTS. This emphasizes the concept of the 
crucial role played by the regulation of the splanchnic circulation in these patients, and that 
of various gut peptides. Locally mediated vasodilatation may be one of a number of 
mechanisms in the pathophysiology of this disorder, and this targeted approach of reducing 
excessive blood pooling in the splanchnic vascular bed could provide a promising treatment 
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in PoTS patients. The protocol used may also provide a means of both subjectively and 
objectively determining the potential benefits of Octreotide both pre and post prandially.  
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10. Chapter Ten: Discussion and Future Directions 
 
The evaluation and accurate diagnosis of the cause of autonomic dysfunction continues to 
be challenging, particularly in disorders such as PoTS which has been considered in the past 
as a "medical unexplained symptoms/syndrome".  Little is still known about the varying PoTS 
phenotype, the role of genetic components and possible therapeutic strategies in the most 
complex resistant cases. This thesis examined autonomic function and symptoms in PoTS, 
as well as other autonomic disorders, using standard and novel methodologies in order to 
further understand the clinical phenotype and pathophysiology of PoTS and other autonomic 
disorders, as well as examine a novel treatment strategy for PoTS. This was achieved by 
assessing cardiovascular autonomic dysfunction and its symptoms, quantifying their severity 
in PoTS and other autonomic disorders and defining the type of autonomic dysfunction and 
investigating an acute pharmacological treatment in PoTS patients. This thesis has indeed 
advanced the understanding of the clinical features and pathophysiology of PoTS, providing 
insight for developing a new therapeutic strategy.  
 
PoTS is a complex multi-system disorder which can significantly impair of quality of life. The 
pathophysiology is heterogeneous and, in particular, in our cohort of patients, is linked to 
connective tissue disorders, such as JHS (Figure 10.1). Standardized methods to detect 
autonomic cardiovascular impairment and subtle changes reflecting intermittent autonomic 
dysfunction, should be accompanied by scales able to measure and quantify the degree of 
autonomic impairment in an intermittent autonomic disorder such as PoTS. This was 
addressed in this thesis by designing and validating a functional score (Cardiovascular 
Autonomic Function (CAF) score) in Chapter 4. The CAF score is a novel functional scale 
able to differentiate patients with a wide range of autonomic disorders and quantify the 
degree of autonomic overactivity in patients with intermittent autonomic disorders, such as 
syncope and PoTS. The CAF score could be of value in not just detecting autonomic 
impairments but also in tracking changes in autonomic involvement in response to individual 
treatments and/or for use in prospective controlled therapeutic trials. The CAF score 
instrument could generate unique severy score profiles in PoTS and other autonomic 
disorders and could provide specific outcome measures in health care research, e.g., 
randomised clinical trials. 
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Figure 10.1. Pathophysiology of Postural Tachycardia Syndrome (PoTS) adapted from recent 
review articles (Grubb et al., 2006; Mathias et al., 2012). The pathophysiology of PoTS is 
heterogeneous, including limited small fiber neuropathy (in our cohort of patients, it occurred in 
~20%) and splanchnic pooling, possibly present in ~64% of our PoTS patients as documented by 
the exacerbation of PoTS on HUT post meal. Familial history of orthostatic intolerance and, 
syncope occurred in up to 42% of patients. Additional aetiology could include humoral factors 
such as hyperadrenergic state and possible MAST cell activation syndrome, hypovolemia and 
physical deconditioning. These factors can coexist in the same patient and exert a synergistic 
effect on clinical presentation and responses to treatment. Furthermore, in our cohort of patients, 
PoTS is linked to connective tissue disorders, such as JHS. The circles in green represent the 
pathophysiological mechanisms evaluated in this thesis.  
 
Cardiovascular autonomic dysfunction is detected using various physiological tests. These 
tests only measure objective signs of cardiovascular autonomic dysfunction however, and do 
not investigate subjective symptoms of cardiovascular autonomic dysfunction, as well as 
symptoms of other autonomic domains such as bladder, gastrointestinal, vasomotor, sleep 
and sexual function and allied non-autonomic features, such as musculoskeletal function, 
which can frequently and simultaneously occur in a number of autonomic disorders. 
Moreover, physiological tests do not evaluate the impact of the subjective symptoms of 
autonomic dysfunction on overall daily, or quality, of life. Autonomic symptoms, 
musculoskeletal impairment and their relative impact on quality of life in patients with 
autonomic disorders has been assessed by a novel and validated instrument; the Autonomic 
and skeletal muscle Questionnaire and Quality of Life Score (AQQoL) in Chapter 5. The 
AQQoL is the first comprehensive autonomic and quality of life self-administered 
questionnaire aimed at exploring in more detail symptoms of a range of autonomic function 
domains, as well as selected non-autonomic features, and their impact of quality of life in a 
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range of autonomic disorders, including those with autonomic failure, moderate autonomic 
dysfunction and intermittent autonomic dysfunction. The AQQoL was able to detect a variety 
of autonomic and non-autonomic impairments, as well as decrements in quality of life, in 
patients with autonomic disorders. While therapeutic options in the treatment of motor 
symptoms and orthostatic intolerance in autonomic disorders remain restricted, greater 
attention should be paid to the treatment of non-cardiovascular domains, including bladder, 
gastrointestinal and sudomotor dysfunction as significant burdens in patients with autonomic 
dysfunction. The AQQoL provides a novel outcome measure of key autonomic dysfunction 
and allied symptoms with the potential of informing clinical practise as well as future clinical 
trials and longitudinal studies in autonomic disorders.  
 
PoTS has a strong genetic component, in particular considering the association with JHS. 
The pathophysiology is likely to be multifactorial including a polygenic component with 
possible variable expressivity. The findings of Chapter 5 indicated that a family history of 
orthostatic intolerance is quite common in intermittent autonomic disorders, including PoTS. 
Chapter 6 described for the first time 21 families with PoTS and JHS who presented with 
intra- and inter-family heterogeneity. Connective tissue and autonomic dysfunction disorders 
may be influenced by genetic factors and could play a significant role in the pathophysiology 
of orthostatic tachycardia and orthostatic intolerance in such patients with an underlying 
genetic predisposition to both conditions. Genetic testing is warranted in PoTS patients and 
could provide an additional strategy for diagnosis and treatment of this very heterogeneous 
patient population.  
 
Diagnosing PoTS remains a challenge in some patients. PoTS is diagnosed when sustained 
excessive tachycardia is noted during a head-up tilt or standing test, accompanied by 
orthostatic symptoms. The factors that can make a diagnosis difficult include the intermittent 
nature of the syndrome, the multi-system involvement and the heterogeneous presentation 
and pathophysiology (Mathias et al., 2012). Occasionally, patients with chronic orthostatic 
symptoms and suspected PoTS do not meet the PoTS diagnosis criteria on head-up tilt or 
standing. The current assessment of orthostatic intolerance in PoTS does not take into 
account the potential exacerbation and worsening of the postural tachycardia in response to 
daily life stimuli, including, food ingestion, physical exercise and heat stress, which often 
occurs in PoTS. Chapter 7 of this thesis highlighted the clinical relevance of additional 
cardiovascular autonomic function tests including daily life events, such as liquid meal, 
exercise and heat challenge tests, to the standardized cardiovascular autonomic function 
screening tests, in revealing a PoTS diagnosis and provided additional valuable information 
on tailoring management of symptoms. A typical and current diagnostic pathway, as well as a 
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proposed modified diagnostic pathway (that is used in our Autonomic Units), are presented in 
Figure 10.2. The current diagnostic pathway in our cohort of patients would only reveal a 
PoTS diagnosis in 70% of the patients, whereas using our modified pathway that 
incorporates cardiovascular autonomic function assessment during and after daily life events 
would reveal the diagnosis in 91% of patients. The modified diagnostic pathway would 
therefore reduce the proportion of patients who, although highly disabled, do not have a final 
diagnosis according to current autonomic cardiovascular evaluation (HUT and or standing 
tests),   
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Figure 10.2 Cardiovascular autonomic function diagnostic evaluation of PoTS using the typical 
approach (above dashed line) and a modified approach (below dashed line). Diagnosis rates (in 
%) of the patient sample are indicated at each step. The clinical history should address the 
trigger(s) and precipitating or aggravating factors of orthostatic intolerance. The patient should 
undergo comprehensive cardiovascular autonomic function investigation in addition to allied 
cardiac and neurological examination. Adding the liquid meal challenge and the modified exercise 
tests to the AFT would increase the probability and accuracy of diagnosing PoTS (e.g., 70 vs. 84-
91%).  
Patients with a history of orthostatic intolerance and clinical features 
consistent with PoTS 
Autonomic diagnostic evaluation 
 
AFT including Head up tilt and 
standing tests 
 
POSITIVE: 
HR rise > 30 bpm on HUT 
and/or standing tests 
NEGATIVE 
70% 
Liquid meal  
challenge test 
Modified 
exercise test 
30% 
POSITIVE: 
HR rise > 30 bpm on  
post meal HUT  
POSITIVE: 
HR rise > 30 bpm on  
post exercise standing 
64% 33% 
 AFT + Liquid meal challenge test --> 91% 
 
 AFT + Modified Exercise test-->84% 
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The pathophysiology of PoTS remains heterogeneous and some patients might have an 
underlying small fiber neuropathy. In Chapter 8 of this thesis the pathophysiology of PoTS 
was explored with the novel use of the punch skin biopsy technique. The Neuropathic PoTS 
phenotype was characterized with regard to somatic and autonomic small fiber impairments 
via sensory and skin biopsy morphology studies and thermal thresholds testing. Thermal 
thresholds assessment provides an objective measure of small fiber impairment and has the 
potential of being great value in the assessment and characterization of various PoTS 
phenotypes. For the first time, this study described the possible role played by small fiber 
dysfunction and collagen IV abnormalities into the pathogenesis of PoTS and Joint 
Hypermobility Syndrome. Future studies looking at additional skin markers, including laminin 
and other collagen components, will need to be undertaken in order to evaluate the possible 
role of other extracellular matrix components in PoTS pathophysiology, particularly in those 
with Joint Hypermobility Syndrome. Defining the PoTS phenotype using a combination of 
cardiovascular autonomic function challenges and skin morphology studies will inform and 
guide individually tailored treatment (Figure 10.3)   
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Diagnostic evaluation and management of PoTS 
 
ADDITIONAL 
CARDIOVASCULAR 
AUTONOMIC TESTING  
Liquid meal  
challenge test 
Modified 
exercise test 
STANDARD AUTONOMIC 
FUNCTION TEST 
AFT  
SENSORY 
TESTS AND 
SKIN BIOPSY 
+ 
Splanchnic 
hyperemia 
- 
low BP profile 
+ - 
+ 
Deconditioning  
- 
Normal/high 
BP profile 
Non- Pharma 
+ - 
Fludro 
 Bisoprolol/
Propanolol
/Clonidine/
Ivabradine
l 
Midodrine 
+  
Neuropathic 
PoTS +/- 
collagen IV 
pathology 
- 
Non 
Neuropathic 
Allied tests to 
exclude 
secondary 
pathology 
+ - 
+ - + - 
Liquid meal  
challenge test 
+/- Octreotide 
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Figure 10.3 Diagnostic evaluation and management of PoTS including the standard 
autonomic evaluation (Head up tilt and standing tests), allied investigation to exclude 
secondary pathology, (Mathias et al., 2012), and skin biopsy to define the Neuropathic 
phenotype and the collagene pathology (Jacob et al., 2000). Patients who are negative on 
standard autonomic investigation are investigated with liquid meal and exercise challenge 
tests, which are also informative in terms of pathophysiology, indicating predominant 
splanchnic hyperemia and pooling in the muscle vascular beds after exercise. The 
autonomic cardiovascular investigation is crucial in tailoring the patients management. 
Patients who do not response to first and second line treatment and with evidence of 
splanchnic hyperemia (liquid meal challenge test with and without octreotide) can benefit 
from octreotide. 
 Abbrevations: Non- Pharma, non pharmacological measures; Fludro, fludrocortisone 
 
Studies in PoTS are continuously reshaping the current treatment of these patients with a 
particular focus on patients resistant to currently available drugs. This has been addressed 
in this thesis in Chapter 9 by evaluating the pre- and post-prandial cardiovascular autonomic 
function responses to the acute use of the somatostatin analogue, Octreotide, in PoTS 
patients resistant to current medications. Octreotide was effective in reducing orthostatic 
tachycardia and improving symptoms of orthostatic intolerance in PoTS in both pre- and 
post-prandial phases. This emphasized the crucial role played by the regulation of the 
splanchnic circulation in these patients and that a targeted approach of reducing excessive 
blood pooling in the splanchnic vascular bed could provide a promising treatment in PoTS 
patients. The protocol used (liquid meal challenge with and without Octreotide) also provided 
a means of both objectively and subjectively determining the potential benefits of Octreotide 
both pre- and post-prandially (Figure 10.3).  
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Appendix 1. AUTONOMIC and musculoskeletal QUESTIONNAIRE AND QUALITY OF 
LIFE SCOREs (AQQoL) 
Date
Surname First name
Date of Birth
MEDICATION
Name of medication Dosage
Neurovascular & Autonomic Medicine Unit
AUTONOMIC SYMPTOMS AND QUALITY OF LIFE SCORE
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NO
less than 
once a 
month
1-4 
times a 
month
More 
than once 
a week
Daily No 
impact 
on my 
daily life 
Mild-moderate 
impact. It limits 
less than 50% 
of my daily 
activities
Severe impact. 
It limits most of 
my daily 
activities
1) Do you feel dizzy or lightheaded? a a a a a a a a
2) Have you ever passed out/lost consciousness? a a a a a a a a
3) Have you ever nearly fainted/swooned (not 
unconscious but blacked out or fell down from 
dizziness)?
a a a a a a a a
4) If you have fainted, nearly fainted, or been 
frequently dizzy is this related to: 
a) Early morning a a a a a
b) After eating a meal
a a a a a
c) After standing for a long time a a a a a
d) After physical acitivity or exercise a a a a a
e) After hot bath,hot shower, jacuzzi,or sauna
a a a a a
f) While urinating a a a a a
g) While coughing a a a a a
h) While pressing on side of neck or moving your 
head
a a a a a
YES IMPACT ON YOUR DAILY LIFE
Please tick one box for each question. If your answer is YES please 
tick also one box about the IMPACT ON YOUR DAILY LIFE
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Please tick one box for each question. If your 
answer is YES please tick also one box about 
the IMPACT ON YOUR DAILY LIFE
NO
less 
than 
once a 
month
1-4 
times 
a 
month
More 
than 
once a 
week
Daily No impact on 
my daily life 
Mild-moderate 
impact. It limits less 
than 50% of my 
daily activities
Severe impact. It 
limits most of my 
daily activities
5) If you have fainted, nearly fainted, or been 
frequently dizzy, does it occur when you are:
a) standing a a a a a a a a
b) sitting a a a a a a a a
c) lying down
a a a a a a a a
6) If you have fainted, nearly fainted, or been 
frequently dizzy does it get worse with:
a) being upset or scared a a a a a a a a
b) alcohol a a a a a a a a
c) menstrual cycle
a a a a a a a a
d) hot weather/ hot bath a a a a a a a a
7) If you have fainted, nearly fainted, or been 
frequently dizzy, Does it get better when you lie 
down?
a a a a a a a a
8) Have you had any seizures or convulsions?
a a a a a a a a
IMPACT ON YOUR DAILY LIFEYES
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Please tick one box for each question. If your 
answer is YES please tick also one box about 
the IMPACT ON YOUR DAILY LIFE
NO
9) Do you have any of the following symptoms? less 
than 
once a 
month
1-4 
times a 
month
More 
than 
once a 
week
Daily No impact 
on my daily 
life 
Mild-
moderate 
impact. It 
limits less 
than 50% of 
my daily 
activities
Severe impact. It 
limits most of my 
daily activities
a) Palpitations or racing heart a a a a a a a a
b) Chest pain a a a a a a a a
c) Headache a a a a a a a a
d) Blurred Vision a a a a a a a a
e) Weakness in your arm and legs a a a a a a a a
f) Shortness of breath a a a a a a a a
g) Fatigue/needing to lie down a a a a a a a a
h) Vertigo a a a a a a a a
i) Difficulty thinking or concentrating a a a a a a a a
j) pain centered in the neck and shoulders a a a a a a a a
YES IMPACT ON YOUR DAILY LIFE
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Please tick one box for each question. If your 
answer is YES please tick also one box about 
the IMPACT ON YOUR DAILY LIFE
NO
less 
than 
once a 
month
1-4 
times a 
month
More 
than 
once a 
week
Daily No impact 
on my daily 
life 
Mild-
moderate 
impact. It 
limits less 
than 50% of 
my daily 
activities
Severe impact. It 
limits most of my 
daily activities
10) Do you have any of the following symptoms?
a) Nausea/feeling queasy a a a a a a a a
b) Abdominal pain/ stomach ache a a a a a a a a
c) Diarrhoea a a a a a a a a
d) Constipation a a a a a a a a
e) Vomiting after a meal a a a a a a a a
f) Feeling excessively full  after a small meal a a a a a a a a
g) Loss of appetite a a a a a a a a
h) Bloating a a a a a a a a
11) Have you had gained weight? a Date/amount of weight change
12) Have you had lost weight? a Date/amount of weight change
13) Do you have any difficulty in swallowing? a a a a a a a a
YES IMPACT ON YOUR DAILY LIFE
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Please tick one box for each question. If 
your answer is YES please tick also one box 
about the IMPACT ON YOUR DAILY LIFE
NO
less 
than 
once a 
month
1-4 
times a 
month
More 
than 
once a 
week
Daily No impact 
on my daily 
life 
Mild-
moderate 
impact. It 
limits less 
than 50% of 
my daily 
activities
Severe 
impact. It 
limits most 
of my daily 
activities
a) Leaked urine a a a a a a a a
b) Difficulty passing urine a a a a a a a a
c) Frequency and urgency a a a a a a a a tick the box if drug are 
required
a
d) Not completely emptying your bladder a a a a a a a a tick the box if intermittent 
catheritation is required
a
e) Urinary incontinence a a a a a a a a tick the box if indwelling 
catheter is needed
a
f) Recurrent urinary infection a a a a a a a a
a a a a a a a a15) Do you need to get up in the night to urinate?
YES IMPACT ON YOUR DAILY LIFE
14) Do you have any problem with control of your 
bladder?
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Please tick one box for each question. If your answer is YES please tick 
also one box about the IMPACT ON YOUR DAILY LIFE
NO
less than 
once a 
month
1-4 times 
a month
More 
than once 
a week
Daily No impact on 
my daily life 
Mild-moderate 
impact. It limits 
less than 50% 
of my daily 
activities
Severe impact. 
It limits most of 
my daily 
activities
16) Do you have any of the following symptoms?
a) Dry mouth a a a a a a a a
b) Dry eyes a a a a a a a a
17) Do you have any color changes in your skin e.g discolored hands or feet 
when upright?
a a a a a a a a
18) Do you have facial flushing a a a a a a a a
19) Have there been any changes with your sweating?
a) Widespread reduction of sweating a a a a a a a a
b) Reduced sweating on your feet a a a a a a a a
c) Increased sweating under your armpits a a a a a a a a
d) Increased sweating on the palms of your hand a a a a a a a a
e) Increased sweating over your feet a a a a a a a a
f) Facial sweating a a a a a a a a
g) Reduced tolerance to hot environments a a a a a a a a
h) Increased sweating all over your body a a a a a a a a
20) If you have increased sweating does it get worse or is this related to:
a) Food intake *1 a a a a a a a a
b) physical activity/Exercise a a a a a a a a
21) Do you have night sweat a a a a a a a a
*1 specify kind of food and where you get increased sweanting following food intake
YES IMPACT ON YOUR DAILY LIFE
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Please tick one box for each question. If your answer is YES please tick 
also one box about the IMPACT ON YOUR DAILY LIFE
No impact 
on my daily 
life 
Mild-moderate 
impact. It 
limits less than 
50% of my 
daily activities
Severe 
impact. It 
limits most 
of my daily 
activities
NO
27) Do you have any of the following symptoms? for longer 
than 3 
months 
not longer 
than 3 
months 
a) Pains in the knees a a a a a a
b) Pains in the fingers a a a a a a
c) Pains in the hips a a a a a a
d) Pains in the elbows a a a a a a
e) Back pain a a a a a a
NO YES
28) Do you have pain in your hands or feet? a a a a a
29) Do you have pain in your legs? a a a a a
30) Does the pain tend to be worse with activity or at the end of the day? a a a a a
31) Does the pain get better with rest? a a a a a
32) Do you need medication for pain? *2 a a a a a
33) Have you ever had any fractures? a a a a a
34) Have you ever had any joint dislocation? a a a a a
35) Have you ever had a hernia? a a a a a
36) Do you have a uterine/rectal prolapse? a a a a a
37) Have you ever noted easy bruising? a a a a a
38) Do you have any scars?/scarring? a a a a a
39) Does the scar tissue remain thin and paper-like? a a a a a
40) Do any of your joints click? a a a a a
*2  list here medication for pain
YES
IMPACT ON YOUR DAILY LIFE
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PLEASE INDICATE HERE IF YOU HAVE ANY RELATIVES WHO 
HAVE THE FOLLOWING SYMPTOMS: 
NO YES
1) dizzy or lightheaded/ fainting when upright a a _______________________             
2) increased sweating a a _______________________             
3) Hypermobile/double jointed a a _______________________             
PLEASE LIST BELOW ANY OTHER SYMPTOMS SIMILAR TO THE 
ONES YOU ARE EXPERIENCING WHICH ARE NOT INCLUDED IN 
THE PREVIOUS QUESTION:
Relationship                               Symptom
_______________________
_______________________ _______________________
_______________________ _______________________
_______________________ _______________________
_______________________ _______________________
_______________________ _______________________
_______________________ _______________________
_______________________ _______________________
_______________________ _______________________
Relationship (brother, sister, parents, 
children, grandparents)                                 
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Please tick one box for each question. If your answer is YES please tick 
also one box about the IMPACT ON YOUR DAILY LIFE
NO YES
No impact on 
my daily life 
Mild-moderate impact. It 
limits less than 50% of my 
daily activities
Severe impact. 
It limits most 
of my daily 
activities
41) Are you sleepy or feel tired during the day even though you slept through the 
night?
a a a a a
42) Have you even been told that you snore loudly even when sleeping on your 
side?
a a a a a
43) Does your snoring disturb other people? a a a a a
44) Have you even been told, that you "stop breathing" when sleeping? a a a a a
45) Do you wake up "gasping" or "short of breath"? a a a a a
NO YES
No impact on 
my daily life 
Mild-moderate impact Severe impact
For men only
46) Are you able to have an erection? a a a a a
47) Are you able to ejaculate? a a a a a
48) Is your ability to have an erection/ ejaculate changed compared past year?*3 a a a a a
*3 list here if drugs are needed
IMPACT ON YOUR DAILY LIFE
IMPACT ON YOUR DAILY LIFE
 
 
 
 
